



EMORY UNIVERSITY

Independent Auditors' Reports as Required by Uniform Guidance and
State of Georgia and Related Information

Year ended August 31, 2017

EMORY UNIVERSITY

Independent Auditors' Reports as Required by Uniform Guidance and State of Georgia and Related Information

Year ended August 31, 2017

Table of Contents

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements and Supplementary Schedules – Years ended August 31, 2017 and 2016	3–51
Supplementary Schedule of Expenditures of Federal Awards – Year ended August 31, 2017	52–74
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards – Year ended August 31, 2017	75
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	76–77
Independent Auditors' Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	78–79
Independent Auditors' Report on Compliance for Each Major Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	80–82
Schedule of Findings and Questioned Costs	83



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees
Emory University:

We have audited the accompanying consolidated financial statements of Emory University and subsidiaries (Emory University), which comprise the consolidated statements of financial position as of August 31, 2017 and 2016, the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Emory University and subsidiaries as of August 31, 2017 and 2016, and the changes in their net assets and their cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.



Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary information included in schedules 1 through 3 is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated December 19, 2017 on our consideration of Emory University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Emory University's internal control over financial reporting and compliance.

KPMG LLP

December 19, 2017

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
August 31, 2017 and August 31, 2016
(Dollars in thousands)

	<u>August 31, 2017</u>	<u>August 31, 2016</u>
ASSETS:		
Cash and cash equivalents	\$ 51,113	\$ 492,549
Patient accounts receivable, net	364,376	375,966
Student accounts receivable, net	57,713	47,972
Loans receivable, net	24,921	26,672
Contributions receivable, net	80,407	99,674
Other receivables, net	246,286	239,858
Prepaid expenses, deferred charges and other assets	310,799	348,058
Investments	8,043,880	6,917,239
Interests in perpetual funds held by others	1,244,906	1,170,348
Property and equipment, net	3,102,848	3,009,906
Total assets	<u>\$ 13,527,249</u>	<u>\$ 12,728,242</u>
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 595,228	\$ 538,509
Deferred tuition and other revenue	431,735	468,813
Interest payable	29,271	28,307
Liability for derivative instruments	188,612	268,735
Bonds and notes payable	1,992,454	1,862,330
Accrued liabilities for benefit obligations and professional liabilities	565,699	595,466
Funds held in trust for others	747,109	665,215
Annuities payable	14,921	15,579
Government advances for federal loan programs	18,721	18,724
Total liabilities	<u>4,583,750</u>	<u>4,461,678</u>
Unrestricted net assets:		
Net assets controlled by Emory	3,960,429	3,537,370
Net assets related to noncontrolling interests	96,633	81,273
Total unrestricted net assets	<u>4,057,062</u>	<u>3,618,643</u>
Temporarily restricted net assets	2,722,596	2,602,814
Permanently restricted net assets	2,163,841	2,045,107
Total net assets	<u>8,943,499</u>	<u>8,266,564</u>
Total liabilities and net assets	<u>\$ 13,527,249</u>	<u>\$ 12,728,242</u>

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY
CONSOLIDATED STATEMENT OF ACTIVITIES
Year Ended August 31, 2017 (with summarized financial information for the year ended 2016)
(Dollars in thousands)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2017	Total August 31, 2016
OPERATING REVENUES AND OTHER SUPPORT:					
Tuition and fees	\$ 675,179	-	-	\$ 675,179	\$ 640,025
Less: Scholarship allowances	(253,897)	-	-	(253,897)	(232,208)
Net tuition and fees	421,282	-	-	421,282	407,817
Endowment spending distribution	179,696	-	-	179,696	172,261
Distribution from perpetual funds	34,873	-	-	34,873	33,199
Other investment income designated for current operations	72,622	-	-	72,622	57,499
Gifts and contributions	44,550	-	-	44,550	51,849
Grants and contracts	470,375	-	-	470,375	400,030
Indirect cost recoveries	131,012	-	-	131,012	122,148
Net patient service revenue	3,174,419	-	-	3,174,419	2,935,464
Medical services	301,404	-	-	301,404	273,896
Sales and services of auxiliary enterprises	74,464	-	-	74,464	72,688
Independent operations	23,097	-	-	23,097	23,440
Other revenue	163,133	-	-	163,133	153,580
Net assets released from restrictions	44,477	(15,093)	-	29,384	31,395
Total operating revenues and other support	5,135,404	(15,093)	-	5,120,311	4,735,266
OPERATING EXPENSES:					
Salaries and fringe benefits	3,055,127	-	-	3,055,127	2,875,003
Student financial aid	13,159	-	-	13,159	14,774
Professional fees and purchased services	503,309	-	-	503,309	463,513
Supplies and pharmaceuticals	757,407	-	-	757,407	712,016
Other operating expenses	341,749	-	-	341,749	285,720
Interest on indebtedness	81,476	-	-	81,476	78,487
Depreciation	247,302	-	-	247,302	237,857
Total operating expenses	4,999,529	-	-	4,999,529	4,667,370
NET OPERATING ACTIVITIES:	135,875	(15,093)	-	120,782	67,896
NONOPERATING ACTIVITIES, NET:					
Investment return in excess of (less than) spending distribution for current operations	179,573	177,417	3,123	360,113	(37,709)
Change in undistributed income from perpetual funds held by others	-	-	74,558	74,558	98,817
Gifts and contributions	5,964	25,465	41,335	72,764	87,210
Loss on disposal of property and equipment	(11,494)	-	-	(11,494)	(3,678)
Loss on defeasance of debt	(8,659)	-	-	(8,659)	-
Change in fair value of derivative instruments	80,123	-	-	80,123	(91,944)
Pension and postretirement benefit plans	23,017	-	-	23,017	(45,712)
Other nonoperating items, net	(7,174)	2,571	(282)	(4,885)	7,819
Net assets released from restrictions	41,194	(70,578)	-	(29,384)	(31,395)
Total nonoperating activities, net	302,544	134,875	118,734	556,153	(16,592)
CHANGE IN NET ASSETS	438,419	119,782	118,734	676,935	51,304
Less change in net assets related to noncontrolling interests	15,360	-	-	15,360	2,929
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ 423,059	\$ 119,782	\$ 118,734	\$ 661,575	\$ 48,375

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY
CONSOLIDATED STATEMENT OF ACTIVITIES
Year ended August 31, 2016
(Dollars in thousands)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2016
OPERATING REVENUES AND OTHER SUPPORT:				
Tuition and fees	\$ 640,025	-	-	\$ 640,025
Less: Scholarship allowances	(232,208)	-	-	(232,208)
Net tuition and fees	407,817	-	-	407,817
Endowment spending distribution	172,261	-	-	172,261
Distribution from perpetual funds	33,199	-	-	33,199
Other investment income designated for current operations	57,499	-	-	57,499
Gifts and contributions	51,849	-	-	51,849
Grants and contracts	400,030	-	-	400,030
Indirect cost recoveries	122,148	-	-	122,148
Net patient service revenue	2,935,464	-	-	2,935,464
Medical services	273,896	-	-	273,896
Sales and services of auxiliary enterprises	72,688	-	-	72,688
Independent operations	23,440	-	-	23,440
Other revenue	153,580	-	-	153,580
Net assets released from restrictions	39,469	(8,074)	-	31,395
Total operating revenues and other support	4,743,340	(8,074)	-	4,735,266
OPERATING EXPENSES:				
Salaries and fringe benefits	2,875,003	-	-	2,875,003
Student financial aid	14,774	-	-	14,774
Professional fees and purchased services	463,513	-	-	463,513
Supplies and pharmaceuticals	712,016	-	-	712,016
Other operating expenses	285,720	-	-	285,720
Interest on indebtedness	78,487	-	-	78,487
Depreciation	237,857	-	-	237,857
Total operating expenses	4,667,370	-	-	4,667,370
NET OPERATING ACTIVITIES:	75,970	(8,074)	-	67,896
NONOPERATING ACTIVITIES, NET:				
Investment return (less than) in excess of spending distribution for current operations	50,785	(89,420)	926	(37,709)
Change in undistributed income from perpetual funds held by others	-	-	98,817	98,817
Gifts and contributions	2,098	40,862	44,250	87,210
Loss on disposal of property and equipment	(3,678)	-	-	(3,678)
Change in fair value of derivative instruments	(91,944)	-	-	(91,944)
Pension and postretirement benefit plans	(45,712)	-	-	(45,712)
Other nonoperating items, net	7,290	592	(63)	7,819
Net assets released from restrictions	117,127	(148,522)	-	(31,395)
Total nonoperating activities, net	35,966	(196,488)	143,930	(16,592)
CHANGE IN NET ASSETS	111,936	(204,562)	143,930	51,304
Less change in net assets related to noncontrolling interests	2,929	-	-	2,929
CHANGE IN NET ASSETS CONTROLLED BY EMORY	\$ 109,007	\$ (204,562)	\$ 143,930	\$ 48,375

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended August 31, 2017 and 2016

(Dollars in thousands)

	<u>2017</u>	<u>2016</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ 676,935	\$ 51,304
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Capital contributions from noncontrolling interests	802	3,587
Contributions for endowment and capital projects	(17,000)	(29,902)
Net realized gains on sale of investments	(351,422)	(101,009)
Net unrealized gains on investments	(228,118)	(20,769)
Loss on disposal of property and equipment	11,494	3,678
Interests in perpetual funds held by others	(74,558)	(98,817)
Loss on defeasance of debt	8,659	-
Depreciation and amortization	247,302	237,857
Provision for uncollectible patients accounts receivable	196,904	183,518
Accretion/amortization of bond discounts/premiums and issuance costs	(2,627)	(1,798)
Actuarial adjustments for retiree pension and benefit plans	(23,017)	45,712
Change in fair value of derivative instruments	(80,123)	91,944
Decrease (increase) in operating assets:		
Accounts and other receivables, net	(201,483)	(191,527)
Contributions receivable for operations, net	20,334	10,600
Prepaid expenses, deferred charges and other assets	(29,243)	(24,326)
Increase (decrease) in operating liabilities:		
Accounts payable, accrued liabilities and interest payable	53,090	48,374
Accrued liabilities for benefit obligations and professional liabilities	(6,750)	34,129
Deferred tuition and other revenue	(37,078)	28,541
Net cash provided by operating activities	<u>164,101</u>	<u>271,096</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Disbursements for loans to students	(2,933)	(3,226)
Repayment of loans from students	4,684	4,965
Proceeds from sales and maturities of investments	13,016,971	8,900,249
Purchases of investments	(13,564,072)	(8,853,527)
Purchases of property, plant and equipment	(347,145)	(351,730)
Increase in funds held in trust for others	81,894	19,219
Net cash used in investing activities	<u>(810,601)</u>	<u>(284,050)</u>

(Continued)

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

Years Ended August 31, 2017 and 2016

(Dollars in thousands)

	<u>2017</u>	<u>2016</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds received from contributions for endowment and capital projects	15,933	12,352
Proceeds from bonds payable	491,171	-
Principal repayments of bonds payable	(365,776)	(42,249)
Required refund (posting) of collateral for debt-related derivatives	66,502	(67,572)
Decrease in annuities payable	(658)	(1,494)
(Decrease) increase in government advances for federal loan programs	(3)	890
Bond issuance costs	(1,303)	-
Capital distributions to noncontrolling interests	(802)	(3,587)
	<u>205,064</u>	<u>(101,660)</u>
Net cash provided (used in) by financing activities		
	<u>205,064</u>	<u>(101,660)</u>
Net decrease in cash and cash equivalents	(441,436)	(114,614)
Cash and cash equivalents at beginning of year	492,549	607,163
	<u>492,549</u>	<u>607,163</u>
Cash and cash equivalents at end of year	\$ 51,113	\$ 492,549
	<u>\$ 51,113</u>	<u>\$ 492,549</u>
 Supplemental disclosure:		
Cash paid for interest	\$ 83,455	\$ 81,799
Change in accrued liabilities attributable to property, plant and equipment purchases	10,477	16,299
Income taxes (refunded) paid, net	(235)	1,760
Pledge payments received in form of securities and immediately sold	34,452	33,756

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research and healthcare facilities to support its mission. Emory provides educational services to approximately 7,900 undergraduate students and 7,300 graduate and professional students within its nine schools and colleges. Included within the University is the Emory Healthcare system, Emory Medical Care Foundation (EMCF) and Emory Innovations, LLC.

The Emory Healthcare system (Emory Healthcare) consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Saint Joseph's Hospital (ESJH), Saint Joseph's Translational Research Institute (SJTRI) d/b/a T3 Laboratories (T3) (sold in 2016), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates – Joint Operating Company (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), Emory Rehabilitation Hospital (ERH) and Clifton Casualty Insurance Company, Ltd. (CCIC).

The consolidated financial statements include the University and all other entities in which Emory has significant financial interest and control. All significant inter-entity accounts and transactions have been eliminated in consolidation.

EUH, EUHM, EJCH and ESJH are sometimes referred to herein, collectively, as “the Hospitals.”

(2) Summary of Significant Accounting Policies

The following significant accounting policies are used in the preparation of the accompanying consolidated financial statements:

The consolidated financial statements have been prepared on the accrual basis in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenues, gains and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

Unrestricted Net Assets – Net assets that are not subject to donor-imposed stipulations. Certain unrestricted net assets are designated for specific purposes or uses under various internal operating and administrative arrangements of the University.

Temporarily Restricted Net Assets – Net assets that are subject to donor-imposed stipulations that will be met either by actions of the University and/or the passage of time.

Permanently Restricted Net Assets – Net assets that are subject to donor-imposed restrictions that the University maintains permanently (see note 7). Generally, the donors of these assets permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes.

Revenues are reported as increases in unrestricted net assets unless their use is limited by donor-imposed restrictions. Expenses are reported as decreases in unrestricted net assets. Gains and losses on investments

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

and other assets or liabilities are reported as increases or decreases in unrestricted net assets unless their use is restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications between the applicable classes of net assets.

Income and realized and unrealized gains on investments of permanently donor-restricted endowment net assets are reported as follows:

- As increases in permanently restricted net assets if the terms of the gift require that they be added to the principal of a permanent endowment fund.
- As increases in temporarily restricted net assets until appropriated for expenditure by the University and/or donor restrictions are met.

Revenues earned, expenses incurred, and returns made available for the University's operating purposes of teaching, research, patient care, and other programs and services are components of the net operating revenues/expenses presented in the consolidated statement of activities. The University considers the following items to be nonoperating: gifts and contributions for capital and long-term investment and the related net assets released from restriction, investment return in excess of or less than spending distribution for current operations, actuarial gain or loss on annuity obligations, gain or loss on disposal of property and equipment, loss of defeasance of debt, change in fair value of derivative instruments, pension and postretirement related changes other than net periodic cost, gain or loss from affiliates (equity method), and other, net.

(a) Cash Equivalents

Cash equivalents consist primarily of short-term money market mutual funds and treasury bills with original maturities of 90 days or less that are not invested as part of the long-term investment assets. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes.

(b) Contributions Receivable

Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift. Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at a credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is provided based upon management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

(c) Loans Receivable, Net

Emory-funded loans to students are carried at estimated net realizable value. Loans receivable from students under certain governmental loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to Federal Direct Loans (which are not reported in the financial statements), loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing and Health Professions Student Loan Programs.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(d) Other Receivables, Net

Other receivables are recorded at net realizable value and include receivables under grants and contracts, medical services provided to other organizations and losses recoverable from reinsurers.

(e) Investments

Investments are reported at fair value.

Investments in securities include U.S. and non-U.S. equities and fixed income instruments, both publicly traded and privately held. Fair value for these investments is measured based upon quoted prices in active markets, if available. If the market is inactive, fair value is determined by underlying managers and reviewed by the University after considering various sources of information. Due to variations in trading volumes and the lack of quoted market prices for fixed income, the fair value of fixed income is normally derived through recent reported trades for identical or similar securities, making adjustments through the reporting date based upon available market observable data described above.

Investments in funds primarily include investments in commingled equity and fixed income funds and other investments in funds (hedged strategies, private market investments, real estate partnerships and natural resources) and are reported at fair value as determined by the University in accordance with the University's valuation policies and procedures. The University has estimated the fair value of the majority of its investments in investment funds on the basis of the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if a) the underlying investment manager's calculation of NAV is fair value based, and b) the NAV has been calculated by the fund manager or fund administrator as of the University's fiscal year end date. If the reported NAV is not as of the University's fiscal year end date or is not fair value based, the University will adjust the NAV, if deemed necessary. If the University determines it is not practicable to calculate an adjusted NAV as of the University's fiscal year end date, the practical expedient will not be utilized and other valuation methodologies will be used. Typically, real estate partnerships and similar funds are valued based on appraisals of underlying properties held and conducted by third-party appraisers retained by the general partner or investment manager. General partners of oil and gas partnerships also use third-party appraisers to value properties. Valuations provided by the general partners and investment managers are evaluated by the Emory Investment Management Office and are believed to present reasonable estimates of fair value at August 31, 2017 and 2016.

The University's investments in investment funds are subject to the terms of the respective funds' agreements, private placement memoranda, and other governing agreements of such funds. These terms are typical for hedge fund and private equity arrangements. The University's investments are also subject to management and performance fees as specified in such funds' agreements. Additionally, such funds in which the University invests may restrict both the transferability of the University's interest and the University's ability to withdraw. In light of such restrictions imposed, an investment in these funds is illiquid and subject to liquidity risk.

Investment transactions are accounted for on the trade date basis. Dividend income is recognized on the ex-dividend date and interest income is recognized on the accrual basis. Realized gains and losses are determined by the specific identification method for investments in investment funds and average

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

cost for investments in securities. Additionally, gains and losses from realized and unrealized changes in the fair value of investments are reported in the consolidated statements of activities as increases or decreases in unrestricted net assets, if there are no donor restrictions, or in temporarily restricted net assets, until amounts have been appropriated and the donor-imposed time restrictions have elapsed. Changes in the fair value of these instruments are recognized as nonoperating investment gains or losses in the consolidated statements of activities.

(f) ***Fair Value Measurements***

Fair value measurements reflected in the consolidated financial statements conceptually represent the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. GAAP provides a hierarchy that prioritizes the inputs to fair value measurements based on the extent to which inputs to valuation techniques are observable in the marketplace. The hierarchy assigns a higher priority to observable inputs that reflect verifiable information obtained from independent sources, and a lower priority to unobservable inputs that would reflect the University's assumptions about how market participants would value an asset or liability based on the best information available. Fair value measurements must maximize the use of observable inputs and minimize the use of unobservable inputs.

Assets and liabilities measured and reported at fair value are classified and disclosed within one of the following categories:

Level 1 – Valuations for assets and liabilities traded in active exchange markets as of the reporting date. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities.

Level 2 – Valuations are determined through direct or indirect observations other than quoted market prices. The type of investments in Level 2 also includes certain positions in which the University is a unit of account holder within a fund or account that holds underlying assets that are traded in active exchange markets with readily available pricing.

Level 3 – Valuations for assets and liabilities that are unobservable and derived from other valuation methodologies including discounted cash flow models and similar techniques, and not based on market exchange, dealer, or broker-traded transactions. Level 3 valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities.

The majority of the University's investments are held through limited partnerships and commingled funds, for which fair value is estimated using the NAVs reported by the investment managers as a practical expedient. Such investments have not been categorized within the fair value hierarchy.

(g) ***Split-Interest Agreements***

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenues are recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

(h) *Interests in Perpetual Funds Held by Others*

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in beneficial interest in perpetual funds and as contribution revenue at the date such funds are established. The largest fund of this type consists primarily of shares of common stock of The Coca-Cola Company. The carrying value of Emory's interest is adjusted annually for changes in fair value. The fair value of these perpetual funds is recorded in the consolidated statements of financial position on August 31, 2017 and 2016 at \$1,244.9 million and \$1,170.3 million, respectively.

(i) *Property and Equipment*

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years; land improvements and infrastructure – 5 to 40 years; moveable equipment – 3 to 20 years; fixed equipment – 3 to 30 years; software and enterprise systems – 3 to 10 years; leasehold improvements – term of the lease; and library books – 10 years. Certain assets totaling \$99.0 million and \$93.1 million, such as art, museum assets and rare books, are included in property and equipment on August 31, 2017 and August 31, 2016, respectively, but are not depreciated.

(j) *Tuition and Fees*

Tuition and fee revenues are recognized in the fiscal year during which the academic services are rendered. Student tuition and fees received in advance of services to be rendered are reported as deferred revenue. Student aid provided by the University for tuition and fees is reflected as a reduction of gross tuition and fee revenue.

(k) *Contributions Revenue*

Contributions, including unconditional promises to give, are recognized as revenues in the period received. Contributions restricted for capital projects, endowment funds, and contributions under split-interest agreements or perpetual funds held by others are reported as nonoperating revenue. All other contributions are recorded as operating revenues. Unconditional promises to give, with payments due in future periods, are recorded as increases in temporarily or permanently restricted assets at the estimated present value of future cash flows, net of an allowance for uncollectible pledges.

Donor-restricted contributions are reported as temporarily restricted or permanently restricted revenue that increases those net asset classes. Expirations of temporary restrictions on net assets, such as the donor stipulation being met or the passage of time, are reported as net assets released from restrictions and reflect reclassifications from temporarily restricted net assets to unrestricted net assets. If the donor stipulation for a temporarily restricted contribution is met in the year of the gift, the contribution is reflected in the unrestricted net asset class. Temporary restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

not recognized until they become unconditional; that is, when the conditions on which they depend are met.

(l) *Grants and Contracts Revenue and Indirect Cost Recoveries*

Indirect cost recoveries and grants and contracts revenue are reported at the estimated net realizable amounts due from sponsoring agencies. These grants and contract awards generally specify the purpose for which the funds are to be used. Revenues from sponsored grants and contracts are recognized when allowable expenditures are incurred under such agreements. These revenues, primarily from the federal government, are recorded as unrestricted support. Amounts recorded in grants and contracts receivable are for grant expenditures incurred in advance of the receipt of funds.

Indirect cost recoveries are based on negotiated rates and represent recoveries of facilities and administrative costs incurred under grants and contracts agreements.

(m) *Net Patient Service Revenue*

Net patient service revenue is reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenues on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations. Emory Healthcare's estimates in this area may differ from actual experience, and those differences may be material.

(n) *Auxiliary Enterprises and Independent Operations*

Auxiliary enterprises include residence halls, food service, bookstore and parking operations which provide services to students, faculty and staff. Fee charges are directly related to the costs of services provided. Independent operations include an externally managed conference center, hotel, and a fitness center. Fee charges are based on market rates for the services provided.

(o) *Income Taxes*

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code (the Code) and is generally exempt from the federal income taxes on related income pursuant to Section 501(a) of the Code. Accordingly, no provision for income taxes is made in the consolidated financial statements. Unrelated business income of the University is reported on Form 990-T. As of August 31, 2017 and 2016, there were no material uncertain tax positions.

(p) *Derivative Instruments*

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments in order to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value. Changes in the fair value of these instruments are recognized as nonoperating investment gains or losses in the consolidated statements of activities.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The University will from time to time utilize interest rate swap agreements to hedge interest rate market exposure of variable rate debt. The University uses the accrual method to account for the interest rate swap agreements in connection with the underlying bonds. The difference between amounts paid and received under such agreements is reported in interest expense in the consolidated statements of activities. Changes in the fair value of these swap agreements are recognized as nonoperating changes in net assets in the consolidated statements of activities.

(q) Pension and Postretirement Benefits

The University recognizes the funded status of its defined benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in unrestricted net assets.

(r) New Accounting Pronouncements

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, *Revenue from Contracts with Customers* (ASU 2014-09), which requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. An entity also should disclose sufficient quantitative and qualitative information to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective for the University for fiscal years beginning after December 15, 2017 (as amended in August 2015 by ASU No. 2015-14, *Deferral of Effective Date*). The University has not yet completed its assessment of the impact of the new guidance on its consolidated financial statements.

In February 2016, the FASB issued ASU No. 2016-02, *Leases* (Topic 842) (ASU 2016-02). The amendments in ASU 2016-02 create FASB ASC Topic 842, *Leases*, and supersede the requirements in ASC Topic 840, *Leases*. ASU 2016-02 requires the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under ASC Topic 840. Under the guidance of ASU 2016-02, a lessee should recognize in the balance sheet a liability to make lease payments (lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. The accounting applied by a lessor under ASU 2016-02 is largely unchanged from that applied under ASC Topic 840. The ASU is effective for all business entities for fiscal years beginning after December 15, 2018. The University has not yet determined the impact of the new standard on its current policies for lessee accounting.

In August 2016, the FASB issued ASU No. 2016-14, *Presentation of Financial Statements of Non-for-Profit Entities* (ASU 2016-14). ASU 2016-14 (1) reduces the number of net asset classes presented from three to two; (2) requires the presentation of expenses by functional and natural classification in one location; and (3) requires quantitative and qualitative disclosures about liquidity and availability of financial assets. The ASU is effective for annual financial statements issued for fiscal years beginning after December 15, 2017. The University is in the process of assessing the impact of the new guidance on its consolidated financial statements.

In January 2017, the FASB issued ASU No. 2017-02, *Not-for-Profit Entities - Consolidation* (Subtopic 958-810) which provides further guidance around when a not-for-profit entity that is a general partner

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

or a limited partner should consolidate a for-profit partnership or similar legal entity once the amendments in Accounting Standards Update 2015-02, *Consolidation* (Topic 810): Amendments to the Consolidation Analysis, become effective. It also clarifies that the amendments in the new guidance on classifying and measuring financial instruments in ASU 2016-01 were not intended to affect the ability of not-for-profit entities with investments in certain for-profit entities to elect to measure those investments at fair value. The new standard is effective for the University for fiscal years beginning after December 15, 2017. The University is in the process of assessing the impact of the new guidance on its consolidated financial statements.

In March 2017, the FASB issued ASU No. 2017-07, *Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost*, which requires companies to present the service cost component of net benefit cost in the income statement line items where they report compensation cost, and all other components of net benefit cost in the income statement separately from the service cost component and outside of operating income, if this subtotal is presented. Additionally, the service cost component will be the only component that can be capitalized. The new standard is effective for fiscal years beginning after December 15, 2018. It also requires retrospective application for the amendments related to the presentation of the service cost component and other components of net benefit cost, and prospective application for the amendments related to the capitalization requirements for the service cost components of net benefit cost. The University is in the process of assessing the impact of the new guidance on its consolidated financial statements.

(s) ***Use of Estimates***

The preparation of the consolidated financial statements in conformity with GAAP requires that management make estimates and assumptions affecting the reported amounts of assets, liabilities, revenues, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for uncollectible accounts and contractual adjustments, reserves for employee healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities related to the University's pension and other postretirement benefit plans. Depreciation expense is based on the estimated useful lives of the related assets.

(t) ***Conflict of Interest Policies***

University trustees, directors, principal officers and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members. When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. Written conflict of interest policies for the University require, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest. Each board member is required to certify compliance with the conflict of interest policy on an annual basis and indicate

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

whether the University does business with an entity in which that member (or an immediate family member) has a material financial interest or is employed or serves as a director or officer. When such relationships exist, measures are taken to mitigate any actual or perceived conflict, including requiring that such transactions be conducted at arm's length, for good and sufficient consideration, based on terms that are fair and reasonable to the University, and in accordance with applicable conflict of interest laws.

(3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	<u>2017</u>	<u>2016</u>
Unconditional promises expected to be collected in:		
Less than one year	\$ 35,953	58,900
One year to five years	52,171	42,473
Over five years	<u>3,671</u>	<u>9,610</u>
Gross contributions receivable	91,795	110,983
Less:		
Allowance for uncollectible amounts	(2,516)	(3,101)
Discount to present value	<u>(8,872)</u>	<u>(8,208)</u>
Contributions receivable, net	<u>\$ 80,407</u>	<u>99,674</u>

At August 31, 2017 and 2016, the five largest outstanding donor pledge balances represented 42.0% and 50.0%, respectively, of Emory's gross contributions receivable. Contributions receivable are discounted at rates ranging from 1.79% to 9.25%.

As of August 31, 2017, the University had received bequest intentions and conditional promises of approximately \$22.0 million. These intentions to give are not recognized as assets or revenues and, if received, will generally be restricted for purposes stipulated by the donor.

(4) Business and Credit Concentrations

Emory Healthcare grants credit to patients, substantially all of whom reside in the service areas. Emory Healthcare generally does not require collateral or other security in extending credit to patients; however, it routinely obtains assignment of (or is otherwise entitled to receive) patients' benefits payable under their health insurance programs, plans, or policies (e.g., Medicare, Medicaid, Managed Care, capitated, and other

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

preferred provider arrangements and commercial insurance policies). The composition of net receivables from patients and third-party payors follows:

	2017	2016
Managed care and other third-party payors	54%	53%
Medicare	38	37
Patients	4	5
Medicaid	4	5
	100%	100%

(5) Net Patient Service Revenue

Emory Healthcare has agreements with governmental and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates. Contractual adjustments under third-party reimbursement programs represent the difference between Emory Healthcare's billings at established rates for services and amounts reimbursed by third-party payors. A summary of the basis of reimbursement with major third-party payors follows:

- Medicare – Substantially all acute care and professional services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to patient classification systems that are based on clinical, diagnostic, and other factors. Revenue from the Medicare program accounted for approximately 41% of Emory Healthcare's net patient service revenue for both years ended August 31, 2017 and 2016.
- Medicaid – Inpatient and professional services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Outpatient services are generally paid based upon cost reimbursement methodologies. Emory Healthcare's cost reports have been audited and substantially settled for all fiscal years through August 31, 2013. Revenue from the Medicaid program accounted for approximately 4% of Emory Healthcare's net patient service revenue for both years ended August 31, 2017 and 2016.

Emory Healthcare has also entered into other reimbursement arrangements providing for payment methodologies which include prospectively determined rates per discharge, discounts from established charges, and prospectively determined per diem rates.

The composition of net patient service revenue (excluding charity care) follows (in thousands):

	2017	2016
Gross patient service revenue	\$ 9,106,824	8,343,096
Less provisions for contractual and other adjustments	(5,735,501)	(5,224,114)
Less provisions for uncollectible accounts	(196,904)	(183,518)
Net patient service revenue	\$ 3,174,419	2,935,464

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Emory Healthcare recognizes patient service revenue associated with services provided to patients with third-party payor coverage on the basis of contractual rates for the services rendered. For uninsured patients who do not qualify for financial assistance in accordance with Emory Healthcare's established charity/indigent care policy, Emory Healthcare recognizes revenue on the basis of its discounted rates for services provided. On the basis of historical experience, a significant portion of Emory Healthcare's uninsured patients are unable or unwilling to pay for the services provided. Thus, Emory Healthcare records a significant provision for uncollectible accounts related to uninsured patients in the period the services are provided.

Patient service revenue, net of contractual allowances and discounts (but before the provision for uncollectible accounts), recognized during the years ended August 31, 2017 and 2016 from these major payor sources is as follows (in thousands):

	<u>2017</u>	<u>2016</u>
Third-party payors	\$ 3,173,150	2,988,727
Self-pay	198,173	130,255
Total	<u>\$ 3,371,323</u>	<u>3,118,982</u>

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(6) Investments

The following table summarizes the fair value of investments as of August 31 (in thousands):

	2017	2016
Short-term investments and cash equivalents ^(a)	\$ 427,137	341,498
Investments in securities:		
Global equity securities		
U.S. equity securities	437,527	361,078
Non-U.S. equity securities	141,152	173,445
Fixed income securities		
U.S. government securities	897,719	491,649
Domestic bonds and long-term notes ^(b)	431,770	122,384
International bonds and long-term notes ^(c)	174,647	21,485
Investments in private securities ^(d)	16,287	14,765
Commingled funds - equity ^(e)	762,567	656,602
Commingled funds - fixed income ^(e)	442,598	673,550
Investments in funds:		
Hedged strategies ^(f)	2,251,918	2,177,099
Private market investments ^(g)	1,261,446	1,083,857
Natural resources ^(h)	518,985	457,842
Real estate partnerships ⁽ⁱ⁾	281,497	326,869
Derivatives ^(j)	(9,572)	192
Marketable real estate investments ^(k)	1,881	1,928
Oil and gas properties	680	680
Miscellaneous investments ^(l)	—	7
	8,038,239	6,904,930
Joint ventures (equity method)	5,641	12,309
	\$ 8,043,880	6,917,239

^(a) Includes short-term U.S. Treasury securities with maturities of less than one year, as well as funds that invest in these types of investments. At August 31, 2017 and 2016, \$24.2 million and \$25.3 million, respectively, was posted as collateral (primarily related to derivatives' trading agreements) and thus not readily available for use.

^(b) Includes investments in non-government debt securities. Investments consist primarily of credit-oriented securities including U.S. investment-grade and below investment-grade debt securities. Other investments include mortgage-backed securities, asset-backed securities, repurchase agreements, senior loans, and bank loans.

^(c) Includes fixed income investments in non-U.S. debt securities such as government bonds, corporate bonds, bank loans, and asset backed securities.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

- (d) Includes investments in private securities not held through a traditional fund or commingled vehicle.
- (e) Includes professionally managed pooled investment funds registered with the Securities and Exchange Commission or the Comptroller of the Currency (i.e., mutual funds and collective trusts).
- (f) Includes investments in fund structures that pursue multiple strategies to diversify risks and reduce volatility. Fund managers have the ability to shift investments across a wide variety of sectors, geographies, and strategies and from a net long position to a net short position. Certain investments in hedged strategies may be subject to restrictions that limit the University's ability to withdraw capital until i) a certain "lock-up period" has expired or ii) until certain underlying investments designated as "illiquid" in "side pockets" are sold. In addition, this class includes investments that may be subject to restrictions that limit the amount that the University is able to withdraw as of a given redemption date.
- (g) Includes illiquid investments in venture capital, growth equity, buyout, mezzanine, distressed debt and reinsurance held in commingled vehicles in which Emory is typically a limited partner or shareholder. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds. As of August 31, 2017, it is estimated that underlying assets of the funds will be liquidated over the next 12 years.
- (h) Includes investments in timber, mining, energy, farmland, commodities and related services businesses held through liquid and illiquid fund structures. The nature of the investments in this category is largely such that distributions are received through liquidation of the underlying assets of the funds. As of August 31, 2017, it is estimated that the underlying assets of the funds will be liquidated over the next 8 years.
- (i) Includes illiquid investments in real estate assets, projects, or land held in commingled funds. The fair value of these investments is calculated from the net asset value of Emory's ownership interests in these funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds. As of August 31, 2017, it is estimated that the underlying assets of the funds will be liquidated over the next 9 years.
- (j) Includes investments in derivative instruments including both exchange traded and over the counter futures, forwards, swaps, options, rights and warrants valued at the fair market value of each underlying instrument.
- (k) Includes miscellaneous investments in real estate such as land gifts.
- (l) Includes other investments in mutual funds not included in the endowment and other similar funds.

At August 31, 2017 and 2016, cash equivalents of \$427.1 million and \$341.5 million, respectively, are included in investments and restricted for investment activity within the investment portfolio. The Investment Policy for the long-term asset portfolio contains an allocation to cash equivalents with a range of 0.0% to 6.0%.

The University's investment policy allows fund managers to use foreign exchange contracts, currency hedges, and other derivative transactions to reduce volatility and manage market risk in investment portfolios. These financial instruments are included in investments at fair value in the accompanying consolidated statements of financial position with the related gain or loss recognized as investment income and gains (losses) in excess of spending distributions for current operations in the accompanying consolidated statements of activities.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The University may hold investments denominated in currencies other than the U.S. dollar. Thus, there is exposure to currency risk because the value of the investments denominated in other currencies may fluctuate due to changes in currency exchange rates, and this can have an effect on the reported value of these investments.

The value of securities held by the University may decline in response to certain economic events, including those events impacting entities whose securities are owned and included in the investment portfolio. Those events impacting valuation may include (but are not limited to) economic changes, market fluctuations, regulatory changes, global and political instability, and currency, interest rate, and commodity price fluctuations. The University attempts to manage this risk through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions.

As of August 31, 2017, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	Unfunded commitments	Redemption frequency (if currently eligible)	Redemption notice period
Hedged strategies	\$ 40,000	30 days - over 2 years	3 - 306 days
Private market investments	1,027,760	not eligible	not eligible
Real estate partnerships	324,869	not eligible	not eligible
Natural resources	118,010	30 days or not eligible	30-90 days or not eligible
	<u>\$ 1,510,639</u>		

Unfunded commitments are expected to be called by funds within five years of fund inception.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Investment return as reflected in the accompanying consolidated statements of activities for August 31 is as follows (in thousands):

	<u>2017</u>	<u>2016</u>
Investment income, net	\$ 32,891	70,273
Realized and unrealized gains, net	<u>579,540</u>	<u>121,778</u>
Total investment return	<u>612,431</u>	<u>192,051</u>
Operating		
Endowment spending distribution	179,696	172,261
Other investment income designated for current operations	<u>72,622</u>	<u>57,499</u>
Total operating return	252,318	229,760
Nonoperating		
Investment return in excess of (less than) spending distribution for current operations	<u>360,113</u>	<u>(37,709)</u>
Total investment return	<u>\$ 612,431</u>	<u>192,051</u>

The University employs an internal core group of investment professionals dedicated to the management of Emory's investments and external investment managers.

(7) Endowment Net Assets

The University's Endowment (Endowment) consists of over 1,900 individual funds established for a variety of purposes including both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The Board of Trustees of the University has approved the University's adoption of the State of Georgia Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as permanently restricted net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund that is not classified in permanently restricted net assets is classified as temporarily restricted net assets until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

prescribed by UPMIFA. In accordance with UPMIFA, the University considers several factors in making a determination to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University and the investment policies of the University.

The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, and deposits held in custody and miscellaneous investments. As of August 31, 2017, approximately 62.4% of the investments described in note 6 are classified as endowed net assets. Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2017			2016		
	Donor- Restricted	Board- Designated	Total	Donor- Restricted	Board- Designated	Total
Unrestricted	\$ (7,779)	1,498,575	1,490,796	(19,893)	1,398,999	1,379,106
Temporarily restricted	2,642,490	—	2,642,490	2,467,363	—	2,467,363
Permanently restricted	881,625	—	881,625	837,814	—	837,814
Total endowment funds	\$ 3,516,336	1,498,575	5,014,911	3,285,284	1,398,999	4,684,283

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>Permanently Restricted</u>	<u>Total</u>
Balance as of August 31, 2015	\$ 1,404,065	2,557,777	806,288	4,768,130
Investment return:				
Investment income	10,122	29,302	—	39,424
Realized and unrealized gain, net	23,200	24,351	—	47,551
Total investment return	<u>33,322</u>	<u>53,653</u>	<u>—</u>	<u>86,975</u>
Cash contributions	369	2	29,701	30,072
Transfers of institutional funds for quasi endowments	28,423	—	—	28,423
Withdrawal of board-designated funds for strategic initiatives	(3,666)	—	—	(3,666)
Appropriations for expenditure	(74,791)	(130,002)	—	(204,793)
Appropriations for capital purposes	(7,096)	(13,762)	—	(20,858)
Other	<u>(1,520)</u>	<u>(305)</u>	<u>1,825</u>	<u>—</u>
Balance as of August 31, 2016	\$ 1,379,106	2,467,363	837,814	4,684,283
Investment return:				
Investment income	2,807	16,021	—	18,828
Realized and unrealized gain, net	134,226	350,647	—	484,873
Total investment return	<u>137,033</u>	<u>366,668</u>	<u>—</u>	<u>503,701</u>
Cash contributions	1,100	—	41,206	42,306
Additions of funds for endowments	—	—	2,647	2,647
Transfers of institutional funds for quasi endowments	23,747	(258)	—	23,489
Withdrawal of board-designated funds for strategic initiatives	(5,555)	—	—	(5,555)
Appropriations for expenditure	(51,147)	(162,998)	—	(214,145)
Appropriations for capital purposes	(6,421)	(15,394)	—	(21,815)
Other	<u>12,933</u>	<u>(12,891)</u>	<u>(42)</u>	<u>—</u>
Balance as of August 31, 2017	\$ <u>1,490,796</u>	<u>2,642,490</u>	<u>881,625</u>	<u>5,014,911</u>

(b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature that are reported in unrestricted net assets were \$7.8 million and \$19.9 million as of August 31, 2017 and 2016, respectively. Subsequent gains that restore the fair value of the assets of the endowment fund to book value will be classified as an increase in unrestricted net assets.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(c) ***Return Objectives and Risk Parameters***

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under this policy, as approved by the Board of Trustees, the endowment assets are invested within risk tolerances of the University to provide an expected total return in excess of spending and inflation over the long-term.

(d) ***Strategies Employed for Achieving Objectives***

To satisfy its long-term rate-of-return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across global equities, fixed income, marketable alternatives, and private investments to achieve its long-term return objectives within prudent risk constraints. The Endowment's long-term target asset allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

(e) ***Relationship between Investment Objectives and Spending Policy***

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs. The distribution of endowment income in 2017 and 2016 was based on 4.75% of the average fair value of the endowment over the previous 12 months ending on December 31. The University considers the expected return on its endowment, including the effect of inflation in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

(8) Derivative Instruments and Hedging Activities

Investments

The University has executed derivative financial instruments in the normal course of its business. Investment strategies employed by Emory and investment managers retained by Emory may incorporate the use of various derivative financial instruments with valuation risk. Emory uses these instruments for a number of investment purposes, including hedging or altering exposure to certain asset classes and cost-effectively adding exposures to portions of the portfolio. Futures, options, swaps and other derivative instruments are used to adjust elements of investment exposures to various securities, markets and currencies without actually taking a position in the underlying asset.

These instruments expose Emory to risk of an unexpected movement in the fair value of the underlying security, a counterparty failing to meet its obligations, and, in certain circumstances, not being able to unwind a position at current fair value due to market illiquidity. Emory has established procedures to monitor and manage these risks. The purchase and sale of exchange traded derivatives require collateral deposits with a Futures Commission Merchant (FCM). In the event of an FCM's insolvency, recovery may be limited to

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Emory's pro rata share of segregated customer funds available. It is possible that the recovery amount could be less than the total of cash and other equity deposited. Management does not consider the underlying counterparty risk from these arrangements to have a material impact on the financial position of the University.

Emory's net investment related derivative exposures, categorized by primary underlying risk, as of August 31, 2017 (in thousands):

	Gross Notional Amount ⁽¹⁾	Derivative Assets ⁽²⁾	Derivative Liabilities ⁽²⁾	Gains (Losses) ⁽³⁾
Interest-rate contracts	\$ 1,103,290	1,087	(1,017)	6,492
Foreign exchange contracts	511,563	814	(2,260)	(2,637)
Equity contracts	883,547	5,464	(16,513)	31,649
Credit contracts	142,905	2,947	(94)	1,763
Total	\$ 2,641,305	10,312	(19,884)	37,267

Emory's net investment related derivative exposures, categorized by primary underlying risk, as of August 31, 2016 (in thousands):

	Gross Notional Amount ⁽¹⁾	Derivative Assets ⁽²⁾	Derivative Liabilities ⁽²⁾	Gains (Losses) ⁽³⁾
Interest-rate contracts	\$ 45,753	88	(112)	3,734
Foreign exchange contracts	26,920	64	(254)	(2,301)
Equity contracts	119,444	559	(106)	(5,664)
Credit contracts	890	—	(47)	39
Total	\$ 193,007	711	(519)	(4,192)

- (1) The notional amount is representative of the absolute value of the open contracts on August 31, 2017 and 2016.
- (2) Derivative assets less derivative liabilities for investment-related activities are presented as net in Note 6.
- (3) Gains (losses) on derivatives are included in the Statements of Activities in "investment return in excess of (less than) spending distribution for current operations" in "nonoperating activities".

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Emory's investment related derivative assets and liabilities at August 31, 2017, by counterparty, are as follows (in thousands):

	Assets	Liabilities	Cash Collateral Held (Pledged)
Counterparty A	\$ 9,403	(17,590)	(71,536)
Counterparty B	310	(138)	246
Counterparty C	221	(339)	(150)
Counterparty D	146	(1,012)	(856)
Counterparty E	72	(69)	—
All other	160	(736)	36
Total	\$ 10,312	(19,884)	(72,260)

Emory's investment related derivative assets and liabilities at August 31, 2016, by counterparty, are as follows (in thousands):

	Assets	Liabilities	Cash Collateral Held (Pledged)
Counterparty A	\$ 565	(116)	(25,103)
Counterparty B	50	(237)	—
Counterparty C	50	—	—
Counterparty D	36	(121)	(82)
Counterparty E	7	(6)	—
All other	3	(39)	(120)
Total	\$ 711	(519)	(25,305)

Debt

As a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by factors influencing the spread between the taxable and tax-exempt market interest rates on its basis exchange. Certain University derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivatives in net liability positions. At August 31, 2017, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2017, Emory had nine interest rate swap agreements expiring on various dates ranging from November 15, 2028 through December 1, 2042. These agreements require Emory to pay fixed interest rates

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

to the counterparties varying from 3.328% to 4.388% in exchange for variable rate payments from the counterparties based on a percentage of the three month London Interbank Offered Rate (LIBOR).

Net settlement transactions related to the agreements described above resulted in interest expense totaling \$17.4 million and \$19.6 million during 2017 and 2016, respectively. The fair value of each exchange agreement is estimated based on pricing models that utilize significant observable inputs, such as relevant current interest rates, that reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

The aggregate fair value of all derivative instruments with credit-risk related contingent features that are in a liability position was \$188.6 million and \$268.7 million on August 31, 2017 and 2016, respectively, for which Emory University had a requirement to post collateral in the amount of \$7.8 million and \$74.3 million for 2017 and 2016, respectively. Collateral postings are reported in prepaid expenses, deferred charges and other assets in the consolidated statements of financial position.

The following table summarizes the debt-related derivatives as of August 31 (in thousands):

Interest Rate Swaps		2017		2016	
Inception	Maturity	Liability Fair Value	Unrealized Gain (Loss)	Liability Fair Value	Unrealized Gain (Loss)
August 4, 2005	September 1, 2035	\$ (30,551)	13,442	(43,993)	(15,305)
August 25, 2005	September 1, 2035	(10,177)	4,593	(14,770)	(5,194)
April 19, 2007	November 15, 2028	(1,569)	505	(2,074)	(279)
December 1, 2007	September 1, 2035	(22,462)	9,084	(31,546)	(9,930)
May 1, 2008	September 1, 2038	(25,976)	10,624	(36,600)	(11,854)
December 1, 2008	December 1, 2042	(33,031)	15,983	(49,014)	(18,919)
December 1, 2009	September 1, 2035	(22,841)	9,133	(31,974)	(9,961)
June 23, 2015	September 1, 2035	(31,492)	12,502	(43,994)	(15,305)
June 23, 2015	September 1, 2035	(10,513)	4,257	(14,770)	(5,197)
	Total	\$ <u>(188,612)</u>	<u>80,123</u>	<u>(268,735)</u>	<u>(91,944)</u>

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and, therefore, potentially impact the value of the instruments on Emory's consolidated statement of financial position. Emory management, with consultation from third-party financial advisors, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed. Emory has additional counterparty arrangements managed by funds in which Emory invests, which are included in the general investment and fund manager monitoring activities for the funds.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Emory's debt-related derivative liabilities at August 31, 2017, by counterparty, are as follows (in thousands):

	Liabilities	Cash Collateral Held (Pledged)
Counterparty A	\$ (22,462)	—
Counterparty B	(33,031)	—
Counterparty C	(40,728)	—
Counterparty D	(48,817)	(6,500)
Counterparty E	(42,005)	(1,270)
All other	(1,569)	—
Total	\$ (188,612)	(7,770)

Emory's debt-related derivative liabilities at August 31, 2016, by counterparty, are as follows (in thousands):

	Liabilities	Cash Collateral Held (Pledged)
Counterparty A	\$ (31,546)	—
Counterparty B	(49,014)	(7,500)
Counterparty C	(58,763)	(17,392)
Counterparty D	(68,574)	(28,800)
Counterparty E	(58,764)	(20,580)
All other	(2,074)	—
Total	\$ (268,735)	(74,272)

(9) Fair Values of Assets and Liabilities

The carrying values for cash and cash equivalents, patient receivables, short-term receivables, and short-term payables approximate fair value because of the terms and relative short maturity of these financial instruments. Current year additions to contributions receivable and annuity and other split-interest obligations carrying amounts approximate fair value because these instruments are recorded at estimated net present value and are categorized as Level 3 assets. Long-term investments and funds held in trust for others are reflected in the accompanying consolidated financial statements at fair value. It is not practicable to determine the fair value of loans receivable, comprised primarily of federally sponsored student loans, and government advances for federal loan programs, due to significant government restrictions as to marketability, interest rates, and repayment terms of these loans.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2017 (in thousands):

	Total fair value	Investments measured at NAV ⁽³⁾	Fair value hierarchy		
			Level 1	Level 2	Level 3
Financial assets:					
Short-term investments and cash equivalents	\$ 427,137	—	389,429	37,708	—
Investments in securities:					
Global equity securities					
U.S. equity securities	437,527	—	437,362	137	28
Non-U.S. equity securities	141,152	—	140,831	321	—
Fixed income securities:					
U.S. government securities	897,719	—	163	897,556	—
Domestic bonds and long-term notes	431,770	—	1,628	429,020	1,122
International bonds and long-term notes	174,647	—	37	174,610	—
Investments in private securities	16,287	—	—	—	16,287
Commingled funds - equity	762,567	366,617	133,757	262,193	—
Commingled funds - fixed income	442,598	—	293,450	149,148	—
Investments in funds:					
Hedged strategies	2,251,918	2,251,918	—	—	—
Private market investments	1,261,446	1,260,729	—	—	717
Natural resources	518,985	518,985	—	—	—
Real estate partnerships	281,497	281,497	—	—	—
Derivatives	(9,572)	—	4,806	(14,378)	—
Marketable real estate investments	1,881	—	207	1,674	—
Oil and gas properties	680	—	—	—	680
Total investments ⁽¹⁾	8,038,239	4,679,746	1,401,670	1,937,989	18,834
Interest in perpetual funds held by others ⁽²⁾	1,244,906	—	—	—	1,244,906
Total assets at fair value	\$ 9,283,145	4,679,746	1,401,670	1,937,989	1,263,740
Financial liabilities:					
Derivative instruments - interest rate swaps	(188,612)	—	—	(188,612)	—
Funds held in trust for others	(747,109)	—	—	(747,109)	—
Total liabilities at fair value	\$ (935,721)	—	—	(935,721)	—

(1) Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above (see note 6).

(2) Primarily invested in The Coca-Cola Company.

(3) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the statement of financial position.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2016 (in thousands):

	Total fair value	Investments measured at NAV ⁽³⁾	Fair value hierarchy		
			Level 1	Level 2	Level 3
Financial assets:					
Short-term investments and cash equivalents	\$ 341,498	—	340,194	1,304	—
Investments in securities:					
Global equity securities					
U.S. equity securities	361,078	—	360,766	309	3
Non-U.S. equity securities	173,445	—	167,103	5,835	507
Fixed income securities:					
U.S. government securities	491,649	—	163	491,486	—
Domestic bonds and long-term notes	122,384	—	1,626	119,646	1,112
International bonds and long-term notes	21,485	—	39	21,446	—
Investments in private securities	14,765	—	—	—	14,765
Commingled funds - equity	656,602	319,668	78,092	258,842	—
Commingled funds - fixed income	673,550	—	452,715	220,835	—
Investments in funds:					
Hedged strategies	2,177,099	2,177,099	—	—	—
Private market investments	1,083,857	1,083,199	—	—	658
Natural resources	457,842	457,842	—	—	—
Real estate partnerships	326,869	326,869	—	—	—
Derivatives	192	—	266	(74)	—
Marketable real estate investments	1,928	—	254	1,674	—
Oil and gas properties	680	—	—	—	680
Miscellaneous investments	7	—	7	—	—
Total investments ⁽¹⁾	<u>6,904,930</u>	<u>4,364,677</u>	<u>1,401,225</u>	<u>1,121,303</u>	<u>17,725</u>
Interest in perpetual funds held by others ⁽²⁾	<u>1,170,348</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>1,170,348</u>
Total assets at fair value	<u>\$ 8,075,278</u>	<u>4,364,677</u>	<u>1,401,225</u>	<u>1,121,303</u>	<u>1,188,073</u>
Financial liabilities:					
Derivative instruments - interest rate swaps	(268,735)	—	—	(268,735)	—
Funds held in trust for others	<u>(665,215)</u>	<u>—</u>	<u>—</u>	<u>(665,215)</u>	<u>—</u>
Total liabilities at fair value	<u>\$ (933,950)</u>	<u>—</u>	<u>—</u>	<u>(933,950)</u>	<u>—</u>

(1) Certain investments in joint ventures carried under the equity method of accounting are not reported at fair value and thus not included in the table above (see note 6).

(2) Primarily invested in The Coca-Cola Company.

(3) Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the statement of financial position.

Investments made directly by the University whose values are based on quoted market prices in active markets, and are therefore classified within Level 1, include actively traded common and preferred stock,

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

U.S. government fixed income instruments and non-U.S. government fixed income instruments. Level 1 investments may also include commingled funds such as listed mutual funds, futures contracts, and exchange traded funds (ETFs).

Investments that trade in markets that are considered to be active, but are based on dealer quotations or alternative pricing sources supported by observable inputs or investments that trade in markets that are not considered to be active, but are valued based on quoted market prices, dealer quotations or alternative pricing sources supported by observable inputs are classified within Level 2. Alternative pricing sources include quotations from market participants and pricing models which are based on accepted industry modeling techniques. These investments include U.S. investment-grade and below investment-grade debt securities, international corporate bonds, mortgage-backed securities, asset-backed securities, money market funds, senior loans and bank loans, most derivative contracts other than futures, and commingled structures with quoted market prices.

Investments that do not trade in active markets and for which values are instead derived from significant unobservable inputs are classified within Level 3. However, as of August 31, 2017 and August 31, 2016, approximately \$4.7 billion and \$4.4 billion, respectively, of the University's investments are held through limited partnerships and commingled vehicles for which fair value is estimated using NAVs reported by the fund managers as a practical expedient, and thus are not categorized in the fair value hierarchy.

Typically, such funds are structured as limited partnership or limited liability vehicles. Funds with hedged strategies generally offer redemption terms and often hold marketable securities in addition to certain illiquid investments. The determination of NAV by managers of private market, real estate and natural resources funds, which generally do not have redemption terms, requires the use of significant unobservable inputs because the underlying investments trade infrequently or not at all. Such investments may include, for example, private placements, distressed securities, and properties and other real interests. Inputs used by the fund managers may include the original transaction price, recent transactions in the same or similar market, completed or pending third-party transactions in the underlying investment or comparable issuers, and subsequent rounds of financing. When observable prices are not available these investments are valued using one or more valuation techniques described below.

- **Market Approach:** This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.
- **Income Approach:** This approach determines a valuation by discounting future cash flows.
- **Cost Approach:** This approach is based on the principle of substitution and the concept that a market participant would not pay more than the amount that would currently be required to replace the asset.

Due to inherent uncertainty of fair value, such estimates of fair value may differ from values that would have been applied had a readily available market existed and those differences could be material. Although a secondary market exists for these investments, the market is not active and individual transactions are typically not observable. When transactions do occur in this limited secondary market, they may occur at discounts to the reported net asset value. It is therefore reasonably possible that if the University were to sell

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

these investments in the secondary market, a buyer may require a discount to the reported net asset value, and that discount could be significant.

The categorization or omission of an investment within the hierarchy does not necessarily correspond to the perceived risk of that investment. The funds and the University use inputs in applying various valuation techniques that are assumptions which market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, operating statistics, specific and broad credit data, liquidity statistics, recent transactions, earnings forecasts, future cash flows, market multiples, discount rates and other factors.

The following tables summarize the University's Level 3 reconciliation as of August 31, 2017 and 2016 (in thousands):

	Balance as of August 31, 2016	Net gains (losses)	Purchases	Sales	Transfer in (out) of Level 3	Balance as of August 31, 2017
Investments in U.S. equity securities	\$ 3	(46)	72	(1)	—	28
Non-U.S. equity securities	507	113	—	(620)	—	—
Domestic bonds & long-term notes	1,112	17	—	(7)	—	1,122
Investments in private securities	14,765	18,574	—	(17,052)	—	16,287
Investment in funds:						
Private market investments	658	15	31	(92)	105	717
Oil and gas properties	680	—	—	—	—	680
Total investments	17,725	18,673	103	(17,772)	105	18,834
Interest in perpetual funds held by others	1,170,348	74,558	—	—	—	1,244,906
Total assets	\$ 1,188,073	93,231	103	(17,772)	105	1,263,740

	Balance as of August 31, 2015	Net gains (losses)	Purchases	Sales	Transfer in (out) of Level 3	Balance as of August 31, 2016
Investments in U.S. equity securities	\$ 3	—	—	—	—	3
Non-U.S. equity securities	—	(24)	531	—	—	507
Domestic bonds & long-term notes	400	(6)	—	(8)	726	1,112
International bonds & long terms notes	785	(287)	74	(572)	—	—
Investments in private securities	14,257	—	508	—	—	14,765
Investment in funds:						
Private market investments	679	(61)	40	—	—	658
Oil and gas properties	2,255	(1,575)	—	—	—	680
Total investments	18,379	(1,953)	1,153	(580)	726	17,725
Interest in perpetual funds held by others	1,071,531	98,817	—	—	—	1,170,348
Total assets	\$ 1,089,910	96,864	1,153	(580)	726	1,188,073

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(10) Property and Equipment

Property and equipment at August 31 is summarized as follows (in thousands):

	<u>2017</u>	<u>2016</u>
Land and land improvements	\$ 201,696	201,898
Buildings and improvements	3,376,910	3,164,393
Equipment	2,308,381	2,171,703
Library and museum assets	414,132	392,350
Construction in progress	214,071	265,145
	<u>6,515,190</u>	<u>6,195,489</u>
Less accumulated depreciation	<u>(3,412,342)</u>	<u>(3,185,583)</u>
	<u>\$ 3,102,848</u>	<u>3,009,906</u>

Property and equipment is reviewed for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss shall be recognized only if the carrying amount of a long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. There were no asset impairments for fiscal year 2017 and 2016.

The University has identified asset retirement obligations primarily from commitments to remove asbestos and lead paint in University facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.00% and discount rate of 4.74%. The liability for asset retirement obligations at August 31, 2017 and 2016 is \$63.0 million and \$59.9 million, respectively, and is included in accounts payable and accrued liabilities in the accompanying consolidated statements of financial position.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(11) Long-Term Debt

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs consisted of the following at August 31 (dollars in thousands):

	<u>Average interest rate</u>	<u>Final maturity</u>	<u>Outstanding principal</u>	
			<u>2017</u>	<u>2016</u>
Tax-exempt fixed-rate revenue bonds:				
2016 Series A	4.62%	October 1, 2046	\$ 130,030	—
2016 Series B	4.17	October 1, 2043	221,710	—
2013 Series A	4.95	October 1, 2043	191,415	195,735
2011 Series A	4.95	September 1, 2041	121,500	213,650
2009 Series B ⁽¹⁾	4.79	September 1, 2035	200,530	205,290
2009 Series C	4.93	September 1, 2039	95,060	96,505
2008 Series C ⁽²⁾	4.96	September 1, 2038	—	122,460
2005 Series A ⁽²⁾	4.15	September 1, 2025	—	33,835
Total tax-exempt fixed-rate revenue bonds			<u>960,245</u>	<u>867,475</u>
Tax-exempt variable-rate revenue bonds:				
2013 Series B ⁽³⁾	1.01	October 1, 2039	135,100	135,100
2013 Series C ⁽³⁾	1.38	October 1, 2039	57,865	57,865
2007 Series A	1.47	November 15, 2028	9,770	9,800
2005 Series B	0.71	September 1, 2035	250,000	250,000
2005 Series C	0.71	September 1, 2036	124,150	124,150
Total tax-exempt variable-rate revenue bonds			<u>576,885</u>	<u>576,915</u>
Taxable fixed-rate revenue bonds:				
2009 Series A	5.63	September 1, 2019	250,000	250,000
1994 Series C	8.00	October 1, 2024	5,080	5,515
Series 1991	8.85	April 1, 2022	243	306
Total taxable fixed-rate revenue bonds			<u>255,323</u>	<u>255,821</u>
Taxable variable-rate revenue bonds:				
1999 Series B	0.87	November 1, 2029	9,085	9,535
1995 Series B	0.87	November 1, 2025	2,115	2,280
1994 Series B	0.79	October 1, 2024	7,970	8,690
Total taxable variable-rate revenue bonds			<u>19,170</u>	<u>20,505</u>
Commercial paper:				
2010 Program 1 - Tax-exempt	0.81	August 1, 2050	2,834	2,834
2008 Program 1 - Taxable	0.84	April 1, 2047	108,394	112,278
Total commercial paper			<u>111,228</u>	<u>115,112</u>
Other long-term debt ⁽⁴⁾	Various		379	630
Unamortized bond premiums			80,642	36,310
Unamortized bond discounts			(2,325)	(2,647)
Bond issuance costs			(9,093)	(7,791)
Total bonds and notes payable			<u>\$ 1,992,454</u>	<u>1,862,330</u>

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

- (1) Included in the 2009 Series Bonds is a medium-term maturity of \$43.0 million due on September 1, 2019 at an average interest rate of 4.68%.
- (2) Series 2008C and 2005A bonds were refunded with proceeds from the University's issuance of 2016B Series bonds.
- (3) Series 2013B and 2013C bonds are floating rate notes and interest rates are based on a spread to one month LIBOR and SIFMA, respectively.
- (4) Included in other long-term debt are the St. Joseph's capital leases.

The University incurred interest expense of \$81.5 million and \$78.5 million in 2017 and 2016, respectively, net of capitalized interest of \$0.8 million and \$0.7 million in 2017 and 2016. During 2017, the average interest rate on University tax-exempt and taxable variable rate demand bonds (VRDB) was 0.71% and 0.87%, respectively. Related indices for this period were 0.74% for tax-exempt debt (The Securities Industry and Financial Markets Association Index – SIFMA) and 0.87% for taxable debt (London Interbank Offered Rate – LIBOR).

During 2017, the University refunded its 2008C and 2005A Series Bonds totaling \$147.2 million with proceeds from the University's issuance of 2016B Series Bonds. The University incurred an accounting loss of \$8.7 million on the refunding of the extinguishment of the 2008C and 2005A Series Bonds which is included in the nonoperating activities in the accompanying 2017 consolidated statement of activities.

At August 31, 2017 the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

Payable in fiscal year:		
2018	\$	22,247
2019		21,873
2020		302,418
2021		18,614
2022		13,461
Thereafter		<u>1,544,617</u>
		1,923,230
Unamortized net premium		78,317
Unamortized net bond issuance costs		<u>(9,093)</u>
	\$	<u><u>1,992,454</u></u>

In 2010, the University established a \$400.0 million tax-exempt Commercial Paper program. The primary purpose of the program is to meet interim financing needs related to capital projects. As of August 31, 2017 and 2016, the University had outstanding balances of \$2.8 million under this program.

In 2008, the University established a \$100.0 million taxable Commercial Paper program for general financial needs. In 2014, the University increased the program to \$150.0 million. As of August 31, 2017 and 2016, the University had an outstanding balance of \$108.4 million and \$112.3 million, respectively, under this program.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The University has a standby credit facility to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. Currently, it has one diversified facility totaling \$150.0 million that is committed for this sole purpose and cannot be used for operating needs of the University. There were no draws against this line of credit in 2017 and 2016.

The University also has a \$75.0 million line of credit at August 31, 2017. There was no balance outstanding as of August 31, 2017. There were no draws on either line of credit in 2017 or 2016.

The University has two letters of credit with a commercial bank totaling \$1.7 million. There were no draws against these letters of credit as of August 31, 2017 and 2016.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements. At August 31, 2017 and 2016, the University was in compliance with these covenants.

(12) Temporarily and Permanently Restricted Net Assets

Temporarily restricted net assets consist of the following as of August 31 (in thousands):

	<u>2017</u>	<u>2016</u>
Appreciation on endowments restricted until appropriated	\$ 2,517,580	2,342,332
Term endowments	124,910	125,031
Contributions receivable, time and purpose restricted	48,447	67,983
Restricted for capital projects and other donor purposes	24,518	60,230
Annuity and life income agreements	7,141	7,238
	<u>\$ 2,722,596</u>	<u>2,602,814</u>

Permanently restricted net assets include endowment funds subject to UPMIFA (note 7) as well as perpetual trusts and endowments held by others. Permanently restricted net assets consist of the following as of August 31 (in thousands):

	<u>2017</u>	<u>2016</u>
Donor-restricted endowments	\$ 881,625	837,814
Interests in perpetual funds held by others	1,244,906	1,170,348
Contributions receivable, restricted for endowment	31,961	31,691
Annuity and life income agreements	2,081	2,019
Split-interest trusts	3,268	3,235
	<u>\$ 2,163,841</u>	<u>2,045,107</u>

Generally, the donors of these restricted gifts permit the University to use all or part of the income earned and net appreciation on related investments for general or specific purposes, such as scholarships, faculty salaries or other operational and administrative support.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(13) Retirement and Deferred Compensation Plans

The University has a defined contribution plan under Internal Revenue Code (IRC) Section 403(b) covering certain employees and teaching staff. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Emory Healthcare sponsors a retirement plan, covering most full time employees, under which annuities are purchased with contributions by Emory Healthcare and its employees. The benefits are vested only to the extent of the annuities purchased. The Emory Clinic (TEC) sponsors The Emory Clinic, Inc. Retirement Savings Plan (the Plan), covering all its employees, except those considered leased employees or those covered under collective bargaining agreements, as defined. The Plan provides for employees to make salary reduction contributions and for TEC to make discretionary contributions for employees who have attained the age of 21 and are employees at the date the contribution is made. The Plan provides for contributions at an annual determined percentage of compensation and employees cliff vest in employer contributions after three years of service. Retirement expense totaled \$131.6 million and \$129.8 million during 2017 and 2016, respectively, and is included in operating expense in the accompanying consolidated statements of activities.

The University sponsors an IRC Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the point of termination of employment from the University. As of August 31, 2017 and 2016, respectively, the University held other assets of \$115.7 million and \$98.9 million under the plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which \$106.0 million and \$90.0 million are classified as Level 1 as of August 31, 2017 and 2016, respectively, \$3.0 million and \$2.9 million are classified as Level 2 as of August 31, 2017 and 2016, respectively, and \$6.7 million and \$6.3 million are classified as Level 3 as of August 31, 2017 and 2016. Associated liabilities for the obligations of \$115.7 million and \$98.9 million as of August 31, 2017 and 2016, respectively, are included in accrued liabilities for benefit obligations and professional liabilities.

(14) Pension Plan

Emory Healthcare sponsors a defined benefit pension plan (the Plan). The Plan was curtailed, effective December 31, 2011. The terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

The JOC assumed certain defined benefit pension liabilities covering certain employees of the entities contributed to the JOC by SJHS (SJHS Pension Plan). The Plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal year 2015, subject to certain terms and conditions.

At the time of the formation of the JOC and assumption of control over the JOC by Emory Healthcare, Emory Healthcare recognized as part of the business combination a liability representing the unfunded status of the SJHS Pension Plan, in accordance with FASB ASC 805-20, *Business Combinations – Identifiable Assets*,

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Liabilities, and Any Noncontrolling Interest. The SJHS Pension Plan is accounted for by Emory Healthcare as a multiple-employer plan in accordance with FASB ASC 715-30, *Defined Benefit Plans – Pension*.

The changes in the projected benefit obligations as of August 31 follow (in thousands):

	2017		2016	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Projected benefit obligation, beginning of year	\$ 324,577	160,393	286,388	140,067
Interest cost	10,605	6,042	13,221	6,358
Actuarial (gain) loss	(1,131)	(6,498)	31,502	18,401
Benefits paid	(7,176)	(5,247)	(6,534)	(4,433)
Projected benefit obligation, end of year	<u>\$ 326,875</u>	<u>154,690</u>	<u>324,577</u>	<u>160,393</u>

Given the fiscal year 2012 curtailment of the plans, the accumulated benefit obligations at August 31, 2017 and 2016 are the same as the projected benefit obligations.

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of August 31 follow (in thousands):

	2017		2016	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Fair value of plan assets, beginning of year	\$ 213,181	99,096	192,506	88,931
Actual return on plan assets	19,666	10,197	21,514	8,908
Employer contributions	9,447	6,270	5,695	5,690
Benefits paid	(7,176)	(5,247)	(6,534)	(4,433)
Fair value of plan assets, end of year	<u>\$ 235,118</u>	<u>110,316</u>	<u>213,181</u>	<u>99,096</u>
Funded status - accrued pension cost recognized in the consolidated statements of financial position	<u>\$ (91,757)</u>	<u>(44,374)</u>	<u>(111,396)</u>	<u>61,297</u>

The components of net periodic pension cost as of August 31 follow (in thousands):

	2017		2016	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Interest cost	\$ 10,605	6,042	13,221	6,358
Expected return on plan assets	(17,156)	(6,971)	(15,657)	(6,254)
Amortization of prior service cost	3,061	(438)	2,503	(438)
Recognized actuarial loss	2,576	2,196	6,270	1,756
Net periodic pension cost	<u>\$ (914)</u>	<u>829</u>	<u>6,337</u>	<u>1,422</u>

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The amounts accumulated in unrestricted net assets for net unrecognized actuarial loss totaled \$92.5 million and \$101.8 million as of August 31, 2017 and 2016, respectively, for Emory Healthcare and \$56.2 million and \$67.7 million as of August 31, 2017 and 2016, respectively, for SJHS Pension Plan.

Emory Healthcare's net loss of \$2.3 million and SJHS Pension Plan's net loss of \$1.4 million are expected to be amortized from unrestricted net assets into net periodic pension cost in fiscal year 2018.

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position for 2017 and 2016 follow:

	2017		2016	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Discount rate	4.07%	4.07%	3.83%	3.83%
Expected long-term rate of return on plan assets	8.00	7.00	8.00	7.00

Weighted average assumptions used to determine net periodic pension cost for 2017 and 2016 follow:

	2017		2016	
	Emory Healthcare	SJHS Pension Plan	Emory Healthcare	SJHS Pension Plan
Discount rate	3.83%	3.83%	4.67%	4.62%
Expected return on plan assets	8.00	7.00	8.00	7.00

Emory Healthcare Plan Assets

The Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the Plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the Plan's investment objectives.

The Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan's target asset allocation.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The following table summarizes the Plan's assets which are recorded at fair value as of August 31 (in thousands):

		2017				
		Total fair value	Fair value hierarchy		Target allocation	Total asset allocation
			Level 1	Level 2		
Investments:						
Short-term investments and cash equivalents	\$	354	(332)	686	—%	—%
Commingled funds - equity		163,270	—	163,270	70	70
Commingled funds - fixed income		71,494	—	71,494	30	30
Total investments	\$	<u>235,118</u>	<u>(332)</u>	<u>235,450</u>	<u>100%</u>	<u>100%</u>
		2016				
		Total fair value	Fair value hierarchy		Target allocation	Total asset allocation
			Level 1	Level 2		
Investments:						
Short-term investments and cash equivalents	\$	384	(267)	651	—%	—%
Commingled funds - equity		148,103	—	148,103	70	70
Commingled funds - fixed income		64,694	—	64,694	30	30
Total investments	\$	<u>213,181</u>	<u>(267)</u>	<u>213,448</u>	<u>100%</u>	<u>100%</u>

SJHS Pension Plan Assets

Under the terms of the agreement forming the JOC, the assets of the SJHS Pension Plan formally remain assets of SJHS and the plan assets remain invested in the CHE Trinity Health Pension Investment Program. Accordingly, neither the JOC nor Emory Healthcare has discretion over the management of the plan assets. However, the plan assets related to the entities contributed to the JOC (and certain other employees leased to the JOC) are contractually required to be clearly separated from the plan assets of the other entities participating in the CHE Trinity Health Employee Pension Program. The SJHS Pension Plan's investment objectives are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the framework of the plan's investment policy. Asset allocation strategies and investment management structure are designed to meet the plan's investment objectives.

The SJHS Pension Plan's expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the plan's target asset allocation.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The following table summarizes the Plan's assets which are recorded at fair value as of August 31 (in thousands):

	2017				
	Total fair value	Fair value hierarchy		Target allocation	Total asset allocation
		Level 1	Level 2		
Investments:					
Short-term investments and cash equivalents	\$ 3,990	1,868	2,122	—%	4%
Commingled funds - equity	54,671	23,190	31,481	50	49
Commingled funds - fixed income	35,868	—	35,868	40	33
Managed funds	15,787	—	15,787	10	14
Total investments	<u>\$ 110,316</u>	<u>25,058</u>	<u>85,258</u>	<u>100%</u>	<u>100%</u>
	2016				
	Total fair value	Fair value hierarchy		Target allocation	Total asset allocation
		Level 1	Level 2		
Investments:					
Short-term investments and cash equivalents	\$ 4,523	1,850	2,673	—%	4%
Commingled funds - equity	48,830	16,790	32,040	50	49
Commingled funds - fixed income	32,315	—	32,315	40	33
Managed funds	13,428	—	13,428	10	14
Total investments	<u>\$ 99,096</u>	<u>18,640</u>	<u>80,456</u>	<u>100%</u>	<u>100%</u>

Cash Flows

Emory Healthcare expects to contribute \$6.0 million to the Emory Healthcare Pension Plan in fiscal year 2018 and expects to contribute \$0.2 million to the SJHS Pension Plan in fiscal year 2018.

Expected Future Benefit Payments

Emory Healthcare annual future benefit payments, excluding lump sum settlements, are expected to range from \$8.1 million to \$13.2 million for the next five years. SJHS Pension Plan annual future benefit payments, excluding lump sum settlements, are expected to range from \$5.7 million to \$7.1 million for the next five years.

Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

(15) **Postretirement Healthcare and Life Insurance Benefits**

The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	2017			2016
	Emory University	Emory Healthcare	Total	Total
APBO, beginning of year	\$ 103,184	57,932	161,116	131,294
Service cost	1,644	664	2,308	1,984
Interest cost	3,326	1,855	5,181	6,018
Actuarial (gain) loss	(2,130)	(472)	(2,602)	26,677
Benefits paid	(3,393)	(1,378)	(4,771)	(4,857)
APBO, end of year	<u>\$ 102,631</u>	<u>58,601</u>	<u>161,232</u>	<u>161,116</u>

The changes in the fair value of plan assets, funded status of the plan and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of August 31 are as follows (in thousands):

	2017			2016
	Emory University	Emory Healthcare	Total	Total
Fair value of plan assets, beginning of year	\$ 60,916	19,500	80,416	78,592
Actual return on plan assets	7,293	2,330	9,623	3,556
Benefits paid by Emory	—	(1,378)	(1,378)	(1,732)
Fair value of plan assets, end of year	<u>\$ 68,209</u>	<u>20,452</u>	<u>88,661</u>	<u>80,416</u>
Funded status - accrued postretirement benefit cost recognized in the consolidated statements of financial position	<u>\$ (34,422)</u>	<u>(38,149)</u>	<u>(72,571)</u>	<u>(80,700)</u>

Actuarial assumptions used to determine the values of the APBO and the benefit costs for years ended August 31, 2017 and 2016 included a discount rate of 4.11% and 3.85%, respectively. Since the plan was amended on April 11, 2002 to limit the University's liability for future medical care cost increases to 4.00%, the per capita cost increase of healthcare benefits is capped at 4.00%. The estimated long-term rate of return on plan assets was 8.00% for the University and Emory Healthcare for both years ended August 31, 2017 and 2016. During fiscal year 2014, the University's Health Plan Steering Committee approved a change in the postretirement benefits plan whereby it converted to a Medicare exchange model. The model uses a concierge service to assist participants with plan selection and includes a Health Reimbursement Account (HRA) of \$100 per month for each participant to help pay for the coverage. It also provides coverage of drug costs for participants in a Part D drug plan who have catastrophic, as defined, expenses. The effective date for this change was September 1, 2014.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The components of net periodic postretirement benefit cost for years ended August 31 were as follows (in thousands):

	2017			2016
	Emory University	Emory Healthcare	Total	Total
Service cost of benefits earned	\$ 1,644	664	2,308	1,984
Interest cost on APBO	3,326	1,855	5,181	6,018
Expected return on plan assets	(4,738)	(1,480)	(6,218)	(6,093)
Recognized net actuarial loss	3,392	2,734	6,126	3,778
Net periodic postretirement benefit cost	\$ 3,624	3,773	7,397	5,687

The amounts accumulated in unrestricted net assets follow (in thousands):

	2017			2016
	Emory University	Emory Healthcare	Total	Total
Net unrecognized actuarial loss	\$ 43,957	24,297	68,254	79,703
Prior service cost	(176)	222	46	118
Total	43,781	24,519	68,300	79,821

In fiscal year 2018, net unrecognized actuarial losses of \$2.2 million for Emory University and \$2.2 million for Emory Healthcare are expected to be amortized from unrestricted net assets into net periodic postretirement benefit cost.

Plan Assets

The Investment Committee of the Emory University Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans. The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations. The secondary objective is to meet or exceed the plans' actuarial assumed rate of return over time, without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

The following tables summarize the University's VEBA Trust assets as of August 31 (in thousands):

		2017						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity	\$	52,714	15,026	13,656	24,032	75%	77%	
Commingled funds - fixed income		15,495	—	8,968	6,527	25	23	
Total investments	\$	<u>68,209</u>	<u>15,026</u>	<u>22,624</u>	<u>30,559</u>	100%	100%	
		2016						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity		45,717	13,059	12,071	20,587	75%	75%	
Commingled funds - fixed income		15,199	—	8,731	6,468	25	25	
Total investments	\$	<u>60,916</u>	<u>13,059</u>	<u>20,802</u>	<u>27,055</u>	100%	100%	

The following tables summarize Emory Healthcare's VEBA Trust assets as of August 31 (in thousands):

		2017						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity	\$	15,377	—	4,563	10,814	75%	75%	
Commingled funds - fixed income		5,075	—	3,067	2,008	25	25	
Total investments	\$	<u>20,452</u>	<u>—</u>	<u>7,630</u>	<u>12,822</u>	100%	100%	
		2016						
		Total fair value	NAV	Fair value hierarchy		Target allocation	Total asset allocation	
				Level 1	Level 2			
Investments:								
Commingled funds - equity	\$	14,653	—	4,031	10,622	75%	75%	
Commingled funds - fixed income		4,847	—	2,990	1,857	25	25	
Total investments	\$	<u>19,500</u>	<u>—</u>	<u>7,021</u>	<u>12,479</u>	100%	100%	

Cash Flows

Emory Healthcare plans to fund future retiree claims from VEBA Trust assets.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$3.1 million to \$4.3 million for Emory University and from \$1.9 million to \$2.7 million for Emory Healthcare, for the next five years.

(16) Charity Care and Community Benefits

Emory Healthcare provides care to patients who meet certain criteria under their charity care policies without charge or at amounts less than their established rates. Because such operating companies do not pursue collection of amounts determined to qualify as charity care, such amounts are not included in net patient service revenue.

Records are maintained to identify and monitor the level of charity care provided. These records include the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies. The cost of charity care provided totaled approximately \$74.7 million and \$72.8 million for the years ended August 31, 2017 and 2016, respectively. Emory Healthcare estimated these costs by applying a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

(17) Functional Expenses

The Consolidated Statements of Activities include the following functional expenses for the years ended August 31 (in thousands):

	<u>2017</u>	<u>2016</u>
Instruction	\$ 454,276	448,333
Research	490,306	443,787
Public service	102,796	96,409
Academic support	162,308	155,049
Student services	95,017	88,081
Institutional support	199,057	217,710
Scholarships and fellowships	17,668	18,764
Medical services	263,842	214,817
Healthcare services	3,145,643	2,919,448
Auxiliary enterprises	46,554	43,100
Independent operations	<u>22,062</u>	<u>21,872</u>
Total operating expenses	<u>\$ 4,999,529</u>	<u>4,667,370</u>

Costs related to the University's operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the space study, conducted the second half of calendar year 2014, and debt financing records. Total amounts allocated in 2017 and 2016 were \$192.0 million and \$182.4 million, respectively. Fundraising costs were approximately \$34.1 million and \$30.9 million in 2017 and 2016, respectively.

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

(18) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare's wholly owned off-shore captive insurer, provides claims-made primary medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2017 and 2016, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$121.5 million (discounted at 2%) and \$131.0 million (discounted at 2%), respectively.

Emory has purchased layered excess and umbrella insurance and reinsurance coverage beyond the amounts retained by CCIC, through various carriers, for a total of \$128.0 million per claim and in the aggregate.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims and the wide range of potential outcomes complicate the estimation. University management believes adequate provision has been made for the related risk.

(19) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit organization founded by former United States President Jimmy Carter and Rosalynn Carter which sponsors various domestic and international programs. The Board of Trustees of CCI is comprised of 16 to 28 members, including its founders, and others as elected half by the University, including the University President, and half by the Carter Center class trustees. The University's Board of Trustees has the authority to approve amendments to CCI's articles of incorporation and bylaws.

Funds held in trust for others include \$708.4 million and \$628.8 million representing CCI's investment in the University's long-term investment portfolio of August 31, 2017 and 2016, respectively.

(20) Commitments and Contingencies

The University is in the process of constructing, renovating and equipping certain facilities for which the outstanding commitments at August 31, 2017 totaled \$68.2 million.

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures, which may be disallowed by the granting agencies cannot be determined at this time, although management expects they will not have a material effect on the University's consolidated financial statements.

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel review. In addition, the University is subject to many federal and state regulations and, as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of many of these actions is not presently determinable, it is the opinion of management that any

EMORY UNIVERSITY

Notes to Consolidated Financial Statements

August 31, 2017 and 2016

resulting liability from these actions will not have a material adverse effect on the consolidated financial position or operating results of the University. The University also has a comprehensive program of primary and excess insurance; however if a final judgment were entered in any action in excess of its insurance coverage, the University would be liable for the excess. Management of the University believes any current pending lawsuit subjecting the University to liability would not have a materially adverse effect on the University's consolidated financial position.

(21) Subsequent Events

Emory has evaluated subsequent events after the consolidated statement of financial position date of August 31, 2017 through December 19, 2017, the date the consolidated financial statements were issued. No additional matters were identified for recognition or disclosure.

SUPPLEMENTARY INFORMATION

EMORY UNIVERSITY (excluding Emory Healthcare)
STATEMENTS OF FINANCIAL POSITION - SUPPLEMENTARY INFORMATION
August 31, 2017 and August 31, 2016
(Dollars in thousands)

Schedule 1

	<u>August 31, 2017</u>	<u>August 31, 2016</u>
ASSETS:		
Cash and cash equivalents	\$ (341,279)	\$ 186,065
Student accounts receivable, net	57,713	47,972
Loans receivable, net	24,921	26,672
Contributions receivable, net	80,407	99,674
Other receivables, net	142,864	125,790
Prepaid expenses, deferred charges and other assets	230,259	275,214
Investments	7,698,190	6,594,513
Interests in perpetual funds held by others	1,244,906	1,170,348
Property and equipment, net	1,953,229	1,962,513
Due from affiliates	487,291	388,647
Total assets	<u>\$ 11,578,501</u>	<u>\$ 10,877,408</u>
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 200,502	\$ 185,932
Deferred tuition and other revenue	429,085	466,869
Interest payable	29,145	28,182
Liability for derivative instruments	187,042	266,661
Bonds and notes payable	1,984,348	1,854,126
Accrued liabilities for benefit obligations and professional liabilities	151,075	145,907
Funds held in trust for others	747,109	665,215
Annuities payable	14,921	15,579
Government advances for federal loan programs	18,721	18,724
Total liabilities	<u>3,761,948</u>	<u>3,647,195</u>
Unrestricted net assets	2,952,126	2,643,649
Temporarily restricted net assets	2,704,860	2,545,560
Permanently restricted net assets	2,159,567	2,041,004
Total net assets	<u>7,816,553</u>	<u>7,230,213</u>
Total liabilities and net assets	<u>\$ 11,578,501</u>	<u>\$ 10,877,408</u>

See accompanying independent auditors' report.

EMORY UNIVERSITY (excluding Emory Healthcare)
Schedule 2
STATEMENT OF ACTIVITIES - SUPPLEMENTARY INFORMATION
Year ended August 31, 2017 (with summarized financial information for the year ended 2016)
(Dollars in thousands)

	Unrestricted	Temporarily Restricted	Permanently Restricted	Total August 31, 2017	Total August 31, 2016
OPERATING REVENUES AND OTHER SUPPORT:					
Tuition and fees	\$ 675,179	-	-	\$ 675,179	\$ 640,025
Less: Scholarship allowances	(253,897)	-	-	(253,897)	(232,208)
Net tuition and fees	421,282	-	-	421,282	407,817
Endowment spending distribution	179,696	-	-	179,696	172,261
Distributions from perpetual funds	34,873	-	-	34,873	33,199
Other investment income designated for current operations	65,138	-	-	65,138	55,120
Gifts and contributions	44,285	-	-	44,285	32,042
Grants and contracts	470,375	-	-	470,375	400,030
Indirect cost recoveries	131,012	-	-	131,012	122,148
Medical services	301,404	-	-	301,404	273,896
Sales and services of auxiliary enterprises	74,464	-	-	74,464	72,688
Independent operations	23,097	-	-	23,097	23,440
Other revenue	56,620	-	-	56,620	52,632
Net assets released from restrictions	44,477	(15,093)	-	29,384	31,395
Total operating revenues and other support	1,846,723	(15,093)	-	1,831,630	1,676,668
OPERATING EXPENSES:					
Salaries and fringe benefits	1,312,353	-	-	1,312,353	1,242,738
Student financial aid	13,159	-	-	13,159	14,774
Other operating expenses	364,020	-	-	364,020	303,725
Interest on indebtedness	59,887	-	-	59,887	56,933
Depreciation	133,516	-	-	133,516	129,752
Total operating expenses	1,882,935	-	-	1,882,935	1,747,922
NET OPERATING ACTIVITIES:	(36,212)	(15,093)	-	(51,305)	(71,254)
NONOPERATING ACTIVITIES, NET:					
Investment return in excess of (less than) spending distribution for current operations	164,916	177,355	2,952	345,223	(51,164)
Change in undistributed income from perpetual funds held by others	-	-	74,558	74,558	98,817
Gifts and contributions	3,050	25,527	41,335	69,912	84,298
Loss on disposal of property and equipment	(11,510)	-	-	(11,510)	(6,932)
Loss on defeasance of debt	(8,659)	-	-	(8,659)	-
Change in fair value of derivative instruments	79,619	-	-	79,619	(91,666)
Pension and postretirement benefit plans	5,523	-	-	5,523	(12,517)
Other nonoperating items, net	(5,696)	(2,422)	(282)	(8,400)	10,552
Net assets released from restrictions	(3,317)	(26,067)	-	(29,384)	(31,395)
Total nonoperating activities, net	223,926	174,393	118,563	516,882	(7)
Net transfers from affiliates	120,763	-	-	120,763	63,519
CHANGE IN NET ASSETS	308,477	159,300	118,563	586,340	(7,742)
BEGINNING NET ASSETS	2,643,649	2,545,560	2,041,004	7,230,213	7,237,955
ENDING NET ASSETS	\$ 2,952,126	\$ 2,704,860	\$ 2,159,567	\$ 7,816,553	\$ 7,230,213

See accompanying independent auditors' report.

STATEMENTS OF CASH FLOWS - SUPPLEMENTARY INFORMATION

Years Ended August 31, 2017 and 2016

(Dollars in thousands)

	<u>2017</u>	<u>2016</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ 586,340	\$ (7,742)
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Contributions for endowment and capital projects	(17,000)	(29,902)
Net realized gain on sale of investments	(348,883)	(86,234)
Net unrealized gain on investments	(219,897)	(25,905)
Loss on disposal of property and equipment	11,510	6,932
Interests in perpetual funds held by others	(74,558)	(98,817)
Loss on defeasance of debt	8,659	-
Depreciation and amortization	133,516	129,752
Accretion/amortization of bond discounts/premiums and issuance costs	(2,809)	(1,980)
Change in fair value of derivative instruments	(79,619)	91,665
Decrease (increase) in:		
Accounts and other receivables, net	(26,815)	29,415
Contributions receivable for operations, net	20,334	10,600
Prepaid expenses, deferred charges and other assets	(21,547)	(15,749)
(Decrease) increase in:		
Accounts payable, accrued liabilities and interest payable	10,940	(9,231)
Accrued liabilities for benefit obligations and professional liabilities	5,168	23,636
Deferred tuition and other revenue	(37,784)	28,435
Net cash (used in) provided by operating activities	<u>(52,445)</u>	<u>44,875</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Disbursements of loans to students	(2,933)	(3,226)
Repayment of loans from students	4,684	4,965
Proceeds from sales and maturities of investments	12,993,489	8,866,599
Purchases of investments	(13,528,386)	(8,814,194)
Purchases of property, plant and equipment	(131,149)	(163,366)
Increase in funds held in trust for others	81,894	19,219
Increase in investments held for affiliate	170	601
Net cash used in investing activities	<u>(582,231)</u>	<u>(89,402)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds received from contributions for endowment and capital projects	15,933	12,352
Proceeds from bonds payable	491,171	-
Principal repayments of bonds payable	(365,496)	(42,251)
Disbursements to affiliate for capital projects	(44,511)	(92,915)
(Increase) decrease in affiliate debt, net	(54,303)	20,414
Required refund (posting) of collateral for debt related derivatives	66,502	(67,572)
Decrease in annuities payable	(658)	(1,494)
(Decrease) increase in government advances for federal loan programs	(3)	890
Bond issuance costs	(1,303)	-
Net cash provided by (used in) financing activities	<u>107,332</u>	<u>(170,576)</u>
Net decrease in cash and cash equivalents	<u>(527,344)</u>	<u>(215,103)</u>
Cash and cash equivalents at beginning of year	<u>186,065</u>	<u>401,168</u>
Cash and cash equivalents at end of year	<u>\$ (341,279)</u>	<u>\$ 186,065</u>
Supplemental disclosure:		
Cash paid for interest	\$ 61,865	\$ 60,244
Accounts payable attributable to property, plant and equipment purchases	10,477	15,070
Income taxes (refunded) paid, net	(235)	1,760
Pledge payments received in form of securities and immediately sold	34,452	33,756

See accompanying independent auditors' report.

**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL
AWARDS**

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Research and Development Cluster:				
U.S. Department of Agriculture:				
Sustainable Agriculture Research and Education:				
Pass-through University of Minnesota	H004403736	10.215	\$ —	637
Total CFDA No. 10.215			—	637
U.S. Department of Agriculture:				
Agriculture and Food Research Initiative (AFRI)	2013-67011-21133	10.310	—	(439)
Agriculture and Food Research Initiative (AFRI)	2015-67017-23080	10.310	—	150,591
Pass-through North Carolina A and T State University	2011-0494-12	10.310	—	139,444
Pass-through University of Florida	UF12245	10.310	—	612
Total CFDA No. 10.310			—	290,208
U.S. Department of Agriculture Total			—	290,845
U.S. Department of Commerce:				
Sea Grant Support:				
Pass-through Georgia Sea Grant, University of Georgia	RR746-075/4945466	11.417	—	2,418
Pass-through Georgia Sea Grant, University of Georgia	RR746-076/S001049	11.417	—	2,228
Total CFDA No. 11.417			—	4,646
Fisheries Development and Utilization Research and Development Grants and Cooperative Agreements	NA15NMF4270347	11.427	41,898	91,536
Total CFDA No. 11.427			41,898	91,536
Climate and Atmospheric Research	NA13OAR4310059 – Amend	11.431	—	17,667
Total CFDA No. 11.431			—	17,667
U.S. Department of Commerce Total			41,898	113,849
U.S. Department of Defense:				
Basic and Applied Scientific Research	N00014-09-1-0912	12.300	—	(695)
Basic and Applied Scientific Research	N00014-13-1-0253	13.300	—	471
Basic and Applied Scientific Research	N00014-16-1-2276	12.300	17,477	207,536
Pass-through Brown University	00000922	12.300	—	156,719
Total CFDA No. 12.300			17,477	364,031
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA1-15-C-0075	12.351	256,962	1,734,444
Basic Scientific Research – Combating Weapons of Mass Destruction	HDTRA-1-16-1-0029	12.351	—	198,425
Basic Scientific Research – Combating Weapons of Mass Destruction	35000	12.351	—	7,552
Total CFDA No. 12.351			256,962	1,940,421
Military Medical Research and Development	W81XWH-12-0255	12.420	—	152,700
Military Medical Research and Development	W81XWH-12-1-0436	12.420	—	49,919
Military Medical Research and Development	W81XWH-14-1-0616	12.420	—	226,292
Military Medical Research and Development	W81XWH-15-1-0132	12.420	—	157,182
Military Medical Research and Development	W81XWH-15-1-0154	12.420	169,725	250,708
Military Medical Research and Development	W81XWH-15-1-0545	12.420	—	643,805
Military Medical Research and Development	W81XWH-15-1-0676	12.420	—	416,741
Military Medical Research and Development	W81XWH-15-2-0045	12.420	175,153	311,480
Military Medical Research and Development	W81XWH-16-1-0535	12.420	—	159,724
Military Medical Research and Development	W81XWH-16-1-0584	12.420	18,171	84,311
Military Medical Research and Development	W81XWH-16-1-0744	12.420	119,293	262,300
Military Medical Research and Development	W81XWH-17-1-0104	12.420	—	17,429
Military Medical Research and Development	W81XWH1710187	12.420	—	55,771
Pass-through Dana Farber Cancer Institute	3,078,403	12.420	—	171,942
Pass-through Henry M Jackson Foundation	3,269	12.420	—	163,201
Pass-through Natl Trauma Institute	NTI-NTRR15-02	12.420	—	47,082
Pass-through University of California San Francisco	8599sc	12.420	—	26,573
Pass-through University of Texas San Antonio	159424/155536	12.420	—	33,536
Pass-through Veterans Medical Research Foundation	08409004-315804	12.420	—	2,840
Total CFDA No. 12.420			482,342	3,233,536
Basic Scientific Research	W911NF-13-1-0100P005	12.431	—	29,024
Basic Scientific Research	W911NF-14-1-0208 P00	12.431	—	111,385
Basic Scientific Research	W911NF-16-1-0028	12.431	—	22,524
Pass-through U.S. Army	W911NF-17-1-0382	12.431	—	11,563
Pass-through University of California Los Angeles	1000GSA786	12.431	—	359,885
Pass-through Virginia Tech	450378-19554-02	12.431	—	167,551
Total CFDA No. 12.431			—	701,932
Basic, Applied, and Advanced Research in Science and Engineering	FA9550-13-1-0002	12.630	—	136
Total CFDA No. 12.630			—	136
Uniformed Services University Medical Research Projects:				
Pass-through Duke University	3834189	12.750	—	1,199,214
Pass-through Geneva Foundation	S-1263-01	12.750	—	33,089
Pass-through Geneva Foundation	S-1348-01	12.750	—	34,851
Pass-through Henry M Jackson Foundation	2490 – PO# 825668	12.750	751	172,808
Pass-through Henry M Jackson Foundation	3434 PO#882221	12.750	—	71,933
Pass-through Henry M Jackson Foundation	PO 830097/2604	12.750	—	633,113
Total CFDA No. 12.750			751	2,145,008
Air Force Defense Research Sciences Program:	FA9550-17-1-0006	12.800	—	117,102
Passed-through Yale University	C17L12686(L00137)	12.800	—	99,740
Total CFDA No. 12.800			—	216,842
Research and Technology Development	HR0011-16-2-0011	12.910	—	349,072
Research and Technology Development	N66001-16-2-4054	12.910	103,107	566,850
Research and Technology Development	W31P4Q-14-1-0010	12.910	3,410,401	4,660,554
Pass-through University of Pennsylvania	569456	12.910	—	228,491
See accomps Total CFDA No. 12.910			3,513,508	5,804,967

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Contract	W911NF-16-C-0008	12.RD	\$ 685,170	2,367,541
Contract	W81XWH-13-1-0246	12.RD	—	74,759
Contract	W81XWH-16-1-0644	12.RD	—	154,649
Contract	W81XWH-16-1-0721	12.RD	—	10,895
Pass-through University of Michigan	Subaward #3004116108	12.RD	—	190,662
Pass-through University of Southern California	57417972	12.RD	—	26,365
Pass-through University of Southern California	PO# 57169635	12.RD	—	378,378
Total CFDA No. 12.RD			<u>685,170</u>	<u>3,203,249</u>
U.S. Department of Defense Total			<u>4,956,210</u>	<u>17,610,122</u>
U.S. Department of State:				
Academic Exchange Programs – Humphrey Fellowship Program:				
Pass-through Institute Of International Education	66469933	19.010	—	517
Pass-through Institute Of International Education	3223_Eemory_7.1.1.16	19.010	—	19,243
Total CFDA No. 19.010			<u>—</u>	<u>19,760</u>
U.S. Department of State Total			<u>—</u>	<u>19,760</u>
U.S. Department of Transportation:				
National Highway Traffic Safety Administration (NHTSA) Discretionary Safety Grants				
Total CFDA No. 20.614			<u>—</u>	<u>566</u>
U.S. Department of Transportation Total			<u>—</u>	<u>566</u>
National Aeronautics and Space Administration:				
Science	NNX11A153G S08	43.001	14,661	202,270
Science	NNX14AG01G	43.001	95,668	337,271
Science	NNX15AH74G-001	43.001	—	117,481
Science	NNX16AE49A	43.001	—	10,738
Science	NNX16AQ28G 000001	43.001	3,588	73,105
Science	NNX17AE72G	43.001	—	33,556
Pass-through Massachusetts Institute of Technology	5710004161	43.001	—	37,843
Pass-through University Of Georgia	RR185-474/S001129	43.001	—	16,354
Pass-through University Of Iowa	W000921108/PO 100174	43.001	—	6,996
Pass-through University Of Nebraska	25-0514-0171-002	43.001	—	(9,015)
Total CFDA No. 43.001			<u>113,917</u>	<u>826,599</u>
Aeronautics:				
Passed-through California Institute Of Technology	1363692	43.002	—	40,373
Total CFDA No. 43.002			<u>—</u>	<u>40,373</u>
Exploration				
Exploration	NNX11AC30G (S18&S19)	43.003	—	70
Exploration	NNX15AD63G S07	43.003	—	464,844
Pass-through Georgia Institute of Technology	RH412-G2 A1	43.003	—	16,262
Total CFDA No. 43.003			<u>—</u>	<u>481,176</u>
Contract				
Pass-through California Institute of Technology	1558091	43.RD	—	58,956
Total CFDA No. 43.007			<u>—</u>	<u>58,956</u>
National Aeronautics and Space Administration Total			<u>113,917</u>	<u>1,407,104</u>
National Endowment for the Humanities:				
Promotion of the Arts, Grants to Organizations and Individuals				
Pass-through Arizona State University	16-998	45.024	—	4,522
Total CFDA No. 45.024			<u>—</u>	<u>4,522</u>
Promotion of the Humanities, Research				
Pass-through Arizona State University	RZ – 230579-15	45.161	—	29,378
Total CFDA No. 45.161			<u>—</u>	<u>29,378</u>
National Endowment for the Humanities Total			<u>—</u>	<u>33,900</u>
National Science Foundation:				
Engineering Grants	1609831	47.041	—	45,988
Engineering Grants	1640848	47.041	—	35,935
Engineering Grants	CBET 1546790	47.041	—	4,004
Engineering Grants	CBET-1150235	47.041	9,134	52,627
Engineering Grants	CBET-1336401	47.041	—	(41)
Engineering Grants	CBET-1512626	47.041	—	139,057
Engineering Grants	CBET1706891	47.041	—	24,358
Engineering Grants	CMMI-1250235	47.041	—	(275)
Engineering Grants	ECCS 1503878	47.041	—	131,819
Engineering Grants	EFRI-1137229	47.041	174,476	198,789
Engineering Grants	IIP-1619679	47.041	—	8,765
Engineering Grants	PHY1740578	47.041	—	9,386
Pass-through American Statistical Association	1560332	47.041	—	34,185
Total CFDA No. 47.041			<u>183,610</u>	<u>683,597</u>
Mathematical and Physical Sciences				
Mathematical and Physical Sciences	1557712	47.049	—	(510)
Mathematical and Physical Sciences	1610377	47.049	—	170,260
Mathematical and Physical Sciences	1709132	47.049	—	24,227
Mathematical and Physical Sciences	1710225	47.049	—	18,117
Mathematical and Physical Sciences	66469933	47.049	—	32,309
Mathematical and Physical Sciences	CHE-1362249	47.049	—	36,625
Mathematical and Physical Sciences	CHE-1145227	47.049	—	696
Mathematical and Physical Sciences	CHE-1150492	47.049	—	17,762
Mathematical and Physical Sciences	CHE-1205646	47.049	2,513,985	4,439,159
Mathematical and Physical Sciences	CHE-1213904	47.049	—	14
Mathematical and Physical Sciences	CHE-1265586	47.049	—	(3,606)
Mathematical and Physical Sciences	CHE-1309817	47.049	—	(2,166)
Mathematical and Physical Sciences	CHE-1352040	47.049	—	95,586
Mathematical and Physical Sciences	CHE-1362113	47.049	—	37
Mathematical and Physical Sciences	CHE-1362281	47.049	—	72,462
Mathematical and Physical Sciences	CHE-1362502	47.049	—	142,301
Mathematical and Physical Sciences	CHE-1412590	47.049	—	69,564
Mathematical and Physical Sciences	CHE-1455211	47.049	—	75,487
Mathematical and Physical Sciences	CHE-1463552-002	47.049	—	145,710
Mathematical and Physical Sciences	CHE-1465189	47.049	—	127,268
Mathematical and Physical Sciences	CHE-1506405	47.049	—	235,388

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Mathematical and Physical Sciences	CHE-1507932	47.049	\$ —	113,342
Mathematical and Physical Sciences	CHE-1531620	47.049	—	90,524
Mathematical and Physical Sciences	CHE1565912	47.049	—	327,648
Mathematical and Physical Sciences	CHE1611102	47.049	—	183,976
Mathematical and Physical Sciences	CHE1626172	47.049	—	322,000
Mathematical and Physical Sciences	DMR-1151646	47.049	—	47,587
Mathematical and Physical Sciences	DMR-1207431-002	47.049	—	87
Mathematical and Physical Sciences	DMR-1409851	47.049	—	65,294
Mathematical and Physical Sciences	DMR-1455086	47.049	—	138,508
Mathematical and Physical Sciences	DMR-1504449	47.049	—	121,724
Mathematical and Physical Sciences	DMR-1506446	47.049	—	85,975
Mathematical and Physical Sciences	DMR-1534317	47.049	—	249,707
Mathematical and Physical Sciences	DMR1609763	47.049	—	105,048
Mathematical and Physical Sciences	DMS 1522599	47.049	—	52,715
Mathematical and Physical Sciences	DMS-1620406	47.049	—	49,692
Mathematical and Physical Sciences	DMS-1201542	47.049	—	20,909
Mathematical and Physical Sciences	DMS-1301698	47.049	—	67,218
Mathematical and Physical Sciences	DMS-1401319	47.049	—	34,129
Mathematical and Physical Sciences	DMS-1412973	47.049	—	50,886
Mathematical and Physical Sciences	DMS-1418889	47.049	—	74,900
Mathematical and Physical Sciences	DMS-1419060	47.049	—	45,515
Mathematical and Physical Sciences	DMS-1463882	47.049	—	145,890
Mathematical and Physical Sciences	DMS-1522760	47.049	—	106,501
Mathematical and Physical Sciences	DMS-1555048	47.049	—	74,162
Mathematical and Physical Sciences	DMS1557960	47.049	—	89,511
Mathematical and Physical Sciences	DMS-1601306	47.049	—	42,726
Mathematical and Physical Sciences	DMS1606418	47.049	—	15,080
Mathematical and Physical Sciences	DMS-1712970	47.049	—	9,994
Mathematical and Physical Sciences	PHY1719578	47.049	—	32,267
Mathematical and Physical Sciences	PHY-1410978	47.049	—	87,674
Total CFDA No. 47.049			<u>2,513,985</u>	<u>8,547,879</u>
Geosciences	AGS-1350021	47.050	—	5,862
Pass-through University of California Berkeley	00009258/BB00797482	47.050	—	36,854
Total CFDA No. 47.050			<u>—</u>	<u>42,716</u>
Computer and Information Science and Engineering	1350885	47.070	—	234
Computer and Information Science and Engineering	1618932	47.070	—	37,570
Computer and Information Science and Engineering	1636933	47.070	41,451	263,915
Computer and Information Science and Engineering	CNS1553579-001	47.070	—	93,499
Total CFDA No. 47.070			<u>41,451</u>	<u>395,218</u>
Biological Sciences	1354829	47.074	—	129,144
Biological Sciences	1359575	47.074	—	72,866
Biological Sciences	1456912	47.074	—	207,775
Biological Sciences	1457291	47.074	78,840	257,036
Biological Sciences	1553344	47.074	—	107,002
Biological Sciences	1557724	47.074	64,006	265,443
Biological Sciences	1624104	47.074	—	48,507
Biological Sciences	1655163	47.074	—	32,666
Biological Sciences	1146316005	47.074	—	35,080
Biological Sciences	1120572 AM 6	47.074	—	850
Biological Sciences	DBI-1344203	47.074	—	111,340
Biological Sciences	DBI-1346549	47.074	—	45,556
Biological Sciences	DBI-1353939	47.074	—	145,247
Biological Sciences	DEB-1257160	47.074	—	136
Biological Sciences	DEB-1601520	47.074	—	9,747
Biological Sciences	DEB1640698	47.074	59,949	159,300
Biological Sciences	IOS-1149829	47.074	—	115,990
Biological Sciences	IOS-1354998	47.074	12,838	172,845
Biological Sciences	IOS1656247	47.074	—	77,772
Biological Sciences	MCB-1350829	47.074	—	153,723
Biological Sciences	MCB-1413062	47.074	—	230,166
Biological Sciences	215001-03	47.074	—	8,264
Biological Sciences	S-000585	47.074	—	201,758
Pass-through Longwood University				
Pass-through University Of California Riverside				
Total CFDA No. 47.074			<u>215,633</u>	<u>2,588,193</u>
Social, Behavioral, and Economic Sciences	1533260	47.075	122,616	233,521
Social, Behavioral, and Economic Sciences	1560674	47.075	—	17,697
Social, Behavioral, and Economic Sciences	1613577	47.075	—	10,243
Social, Behavioral, and Economic Sciences	1632477	47.075	—	158,185
Social, Behavioral, and Economic Sciences	1632660	47.075	—	169,687
Social, Behavioral, and Economic Sciences	1125756 AMD 02	47.075	—	2,620
Social, Behavioral, and Economic Sciences	1634001-001	47.075	5,760	23,830
Social, Behavioral, and Economic Sciences	BCS-1430403	47.075	—	7,817
Social, Behavioral, and Economic Sciences	BCS-1528091	47.075	—	57,374
Social, Behavioral, and Economic Sciences	BCS-1560458	47.075	—	30,544
Social, Behavioral, and Economic Sciences	BCS-1658234	47.075	—	2,621
Social, Behavioral, and Economic Sciences	SES-1127665	47.075	—	1,695
Pass-through Auburn University	16-CLA-200590-EU	47.075	—	2,846
Pass-through Columbia University	SES-0951516	47.075	—	6,091
Pass-through Smith Kettlewell Eye Research Institute	8201101-EU	47.075	—	3,640
Total CFDA No. 47.075			<u>128,376</u>	<u>728,511</u>
Education and Human Resources	DGE1444932	47.076	—	1,800,470
Education and Human Resources	DUE-1068238	47.076	—	22,590
Pass-through Georgia Institute Of Technology	R5702G3 Amend 10	47.076	—	14
Pass-through Georgia Institute Of Technology	RG083-G1	47.076	—	28,931
Pass-through Georgia Institute Of Technology	SP00012566-01	47.076	—	212,572
Total CFDA No. 47.076			<u>—</u>	<u>2,064,577</u>
National Science Foundation Total			<u>3,083,055</u>	<u>15,050,691</u>
U.S. Department of Veterans Affairs:				
Veterans State Hospital Care	508-14-2-4103-0116	64.016	—	4,774
Total CFDA No. 64.016			<u>—</u>	<u>4,774</u>
Contract:				
U.S. Dept Of Veteran Affairs	PO# 508D35025	64.RD	—	5,827
Total CFDA No. 64.RD			<u>—</u>	<u>5,827</u>
U.S. Department of Veterans Affairs Total			<u>—</u>	<u>10,601</u>

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
U.S. Environmental Protection Agency:				
Environmental Protection Consolidated Research: Pass-through Georgia Institute Of Technology	RD557-G1	66.500	\$ —	12,817
Total CFDA No. 66.500			—	12,817
Science to Achieve Results (STAR) Research Program	83479901	66.509	253,117	504,338
Science to Achieve Results (STAR) Research Program	83586901	66.509	20,989	120,948
Science to Achieve Results (STAR) Research Program	a83615301	66.509	—	411,529
Pass-through Dartmouth College	R904	66.509	—	70,269
Pass-through Harvard University	112514-5080711	66.509	—	109,963
Pass-through Rutgers University	8195 Mod 3	66.509	—	93,644
Total CFDA No. 66.509			274,106	1,310,691
Office of Research and Development Consolidated Research/Training/Fellowships: Pass-through Health Effects Institute	4942-RFA13-1/14-3	66.511	120,504	126,342
Total CFDA No. 66.511			120,504	126,342
U.S. Environmental Protection Agency Total			394,610	1,449,850
U.S. Department of Energy:				
Office of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	—	37,783
Office of Science Financial Assistance Program	DE-FG02-01ER15153-00	81.049	—	96,652
Office of Science Financial Assistance Program	DE-FG02-02ER15377	81.049	—	9,588
Office of Science Financial Assistance Program	DE-FG02-07ER15906/9	81.049	—	409,924
Office of Science Financial Assistance Program	DE-FG02-97ER14782	81.049	—	544
Office of Science Financial Assistance Program	DE-SC0008798-0007	81.049	—	290,569
Office of Science Financial Assistance Program	DE-SC0016004 MOD 000	81.049	—	166,105
Total CFDA No. 81.049			—	1,011,265
U.S. Department of Energy Total			—	1,011,265
U.S. Department of Education:				
Overseas Programs – Doctoral Dissertation Research Abroad	P022A150016	84.022	—	76,090
Overseas Programs – Doctoral Dissertation Research Abroad	PO22A160058	84.022	—	51,414
Total CFDA No. 84.022			—	127,504
Education Research, Development, and Dissemination	R305A160240-17	84.305	—	390,741
Total CFDA No. 84.305			—	390,741
U.S. Department of Education Total			—	518,245
U.S. Department of Health and Human Services:				
Innovations in Applied Public Health Research	5P01TP000300-05 REVI	93.061	—	3,260
Total CFDA No. 93.061			—	3,260
Global AIDS	5 NU14GH001237-04-00	93.067	1,413,615	2,532,884
Total CFDA No. 93.067			1,413,615	2,532,884
Chronic Diseases: Research, Control, and Prevention: Pass-through American College of Rheumatology	6NU58DP006138	93.068	—	47,263
Total CFDA No. 93.068			—	47,263
Family Smoking Prevention and Tobacco Control Act Regulatory Research	5R01CA179422-03	93.077	75,905	81,214
Family Smoking Prevention and Tobacco Control Act Regulatory Research	5R01CA179422-05	93.077	2,643	484,063
Total CFDA No. 93.077			78,548	565,277
Food and Drug Administration, Research	5R01FD003527-02 REVI	93.103	—	(646)
Food and Drug Administration, Research	5R01FD004814-03	93.103	15,065	334,910
Pass-through Duke University	2034640	93.103	—	267,361
Pass-through Georgia Institute of Technology	RG219-G/AMND 2	93.103	—	149,291
Pass-through Seattle Children's Research Institute	11389SUB	93.103	—	76,913
Total CFDA No. 93.103			15,065	827,829
Maternal and Child Health Federal Consolidated Programs	5 T03MC07651--12--00	93.110	—	30,238
Maternal and Child Health Federal Consolidated Programs	5 T76MC28446-03-00	93.110	57,547	310,156
Total CFDA No. 93.110			57,547	340,394
Environmental Health	1R01ES027859-01	93.113	—	175,865
Environmental Health	1R01ES027892-01	93.113	—	62,676
Environmental Health	2P30ES019776-05	93.113	—	158,109
Environmental Health	3R01ES023839-03S1	93.113	—	301,496
Environmental Health	3R21ES025632-02S1	93.113	—	199,370
Environmental Health	4P30RD019776-04	93.113	69,137	860,472
Environmental Health	4R01ES022223-04	93.113	433,990	657,487
Environmental Health	5 R21 ES022795-02REV	93.113	20,080	35,821
Environmental Health	5K01ES025445-03	93.113	—	206,145
Environmental Health	5K22ES025418-02	93.113	—	(18)
Environmental Health	5K99ES024570-02	93.113	—	158
Environmental Health	5P30ES019776-03REVIS	93.113	—	(513)
Environmental Health	5P50ES026071-03	93.113	—	975,132
Environmental Health	5R01ES024790-03	93.113	—	269,022
Environmental Health	5R01ES025145-03	93.113	25,644	228,020
Environmental Health	5R01ES025775-02	93.113	35,772	531,006
Environmental Health	5R01ES026082-02	93.113	—	106,514
Environmental Health	5R21ES023927-02	93.113	—	111,051
Environmental Health	5T32ES012160-10	93.113	—	(230)
Environmental Health	5T32ES012870-14	93.113	—	398,869
Environmental Health	5R01ES023485-04	93.113	—	333,015
Pass-through Dartmouth College	R905	93.113	—	59,097
Pass-through University Of California Los Angeles	1935 G TA389	93.113	—	109,209
Pass-through University Of North Carolina Chapel Hill	R01ES021777	93.113	—	4,377
Total CFDA No. 93.113			584,623	5,782,140
Oral Diseases and Disorders Research	5R01DE026333-02 REVI	93.121	60,306	816,973
Oral Diseases and Disorders Research	7R01DE025837-02	93.121	—	8,195
Pass-through Johns Hopkins University	2002808810	93.121	—	34,997
Total CFDA No. 93.121			60,306	860,165
Grants to Increase Organ Donations	5R39OT269910300	93.134	—	342,414
Total CFDA No. 93.134			—	342,414

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Centers for Research and Demonstration for Health Promotion and Disease Prevention:				
Pass-through Dartmouth College	1612R196	93.135	\$ —	7,441
Pass-through Morehouse School of Medicine	002-EMORY-260056-03	93.135	—	101,525
Pass-through New York University	14-A0-00-002153-01	93.135	—	12,174
Pass-through University Of Washington	UWSC7246	93.135	—	46,900
Total CFDA No. 93.135			—	168,040
Injury Prevention and Control Research and State and Community Based Programs	5R49CE001494-05	93.136	—	(15,099)
Total CFDA No. 93.136			—	(15,099)
NIHES Hazardous Waste Worker Health and Safety Training			27,888	321,021
Total CFDA No. 93.142		93.142	27,888	321,021
NIHES Superfund Hazardous Substances_Basic Research and Education			—	167,050
Pass-through Michigan State University	RC105856Emory	93.143	—	167,050
Total CFDA No. 93.143			—	167,050
AIDS Education and Training Centers	6 H4HA00067-13-09	93.145	—	235,108
Total CFDA No. 93.145			—	235,108
Human Genome Research	5R01HG007508-03	93.172	90,363	209,307
Pass-through University of Chicago	FP061089B	93.172	—	116,724
Pass-through University of Iowa	PO# 1001531479	93.172	—	105,040
Total CFDA No. 93.172			90,363	431,071
Research Related to Deafness and Communication Disorders	5F31DC015395-02 Revi	93.173	—	32,277
Research Related to Deafness and Communication Disorders	5R01DC006483-10	93.173	—	91,631
Research Related to Deafness and Communication Disorders	5R01DC008343-10	93.173	2,805	80,281
Research Related to Deafness and Communication Disorders	5R01DC014496-02 REVI	93.173	—	431,944
Research Related to Deafness and Communication Disorders	5R03DC015302-02	93.173	2,607	61,833
Pass-through University of Memphis	5-40456/AMND02	93.173	14,118	103,483
Total CFDA No. 93.173			19,530	801,449
Nursing Workforce Diversity	5D19HP269730300	93.178	—	211,042
Total CFDA No. 93.178			—	211,042
Telehealth Programs:			—	55,799
Pass-through University of Arizona	297824	93.211	—	3,055
Pass-through University of Arizona	G22RH30360	93.211	—	52,744
Total CFDA No. 93.211			—	55,799
Research and Training in Complementary and Alternative Medicine	4R01AT007052-05	93.213	226,500	392,677
Research and Training in Complementary and Alternative Medicine	5UG3AT008857-02 REVI	93.213	755,734	1,168,149
Pass-through University of Illinois	16043	93.213	—	15,172
Total CFDA No. 93.213			982,234	1,575,998
Research on Healthcare Costs, Quality and Outcomes	1R01HS024712-01A1		—	56,156
Research on Healthcare Costs, Quality and Outcomes	1R03HS024613-01 REVI	93.226	—	66,516
Research on Healthcare Costs, Quality and Outcomes	1R03HS024809-01	93.226	—	81,303
Research on Healthcare Costs, Quality and Outcomes	1R13HS025102-01	93.226	27,816	30,011
Research on Healthcare Costs, Quality and Outcomes	1R18HS024499-01	93.226	170,228	402,706
Research on Healthcare Costs, Quality and Outcomes	1R36HS022206-01	93.226	—	(638)
Research on Healthcare Costs, Quality and Outcomes	1R36HS024655-01A1	93.226	—	33,084
Research on Healthcare Costs, Quality and Outcomes	1R36HS024845-01 REVI	93.226	—	25,762
Research on Healthcare Costs, Quality and Outcomes	5R00HS022431-05	93.226	—	64,995
Research on Healthcare Costs, Quality and Outcomes	5R01HS024530-02	93.226	—	204,868
Research on Healthcare Costs, Quality and Outcomes	5R03 HS025018-02	93.226	—	48,500
Research on Healthcare Costs, Quality and Outcomes	4R24HS022059-03	93.226	—	221,801
Pass-through Cincinnati Childrens Hospital	136514/ PO 310049988	93.226	—	27,225
Pass-through Georgia State University	SP00011579-02	93.226	—	(1,570)
Pass-through Vanderbilt University	VUMC 57339	93.226	—	16,262
Pass-through Vanderbilt University Medical Center	VUMC57339	93.226	—	33,415
Total CFDA No. 93.226			198,044	1,310,396
Mental Health Research Grants	1R21MH106716-01	93.242	—	1,964
Mental Health Research Grants	4R01MH095503-05	93.242	46,179	95,427
Mental Health Research Grants	5R01MH078100-05	93.242	—	40,654
Mental Health Research Grants	5R01MH090584-05	93.242	—	288,315
Mental Health Research Grants	5R01MH092284-05	93.242	382	137,105
Mental Health Research Grants	5R01MH100318-03 REV	93.242	—	307,878
Mental Health Research Grants	5R01MH102690-04	93.242	67,502	663,784
Mental Health Research Grants	5R01MH108826-02	93.242	117,106	488,456
Mental Health Research Grants	5R21MH103187-02	93.242	36,242	108,014
Mental Health Research Grants	1F31MH111224-01A1 Re	93.242	—	9,140
Mental Health Research Grants	1K18MH105098-01	93.242	—	62
Mental Health Research Grants	1R01MH107033-02	93.242	—	440,968
Mental Health Research Grants	1R01MH110701-01A1REV	93.242	—	140,007
Mental Health Research Grants	1R01MH112076-02	93.242	—	211,666
Mental Health Research Grants	1R21MH112449-01	93.242	2,492	76,331
Mental Health Research Grants	2P50MH100029-05	93.242	—	224,954
Mental Health Research Grants	2R01MH082833-05	93.242	—	4,121
Mental Health Research Grants	3R01MH110364-02S1	93.242	50,559	484,852
Mental Health Research Grants	4K01MH095823-05	93.242	—	122,931
Mental Health Research Grants	4P50MH100029-05REVIS	93.242	873,473	1,575,952
Mental Health Research Grants	4R01MH079448-07	93.242	—	286,934
Mental Health Research Grants	4R01MH094757-05	93.242	—	505,659
Mental Health Research Grants	4R01MH096893-05	93.242	—	329,822
Mental Health Research Grants	4R01MH101477-05	93.242	—	507,018
Mental Health Research Grants	4U01MH101720-04	93.242	291,615	1,076,697
Mental Health Research Grants	5F30MH108276-02	93.242	—	25,933
Mental Health Research Grants	5F31MH102956-02	93.242	—	1,250
Mental Health Research Grants	5F31MH105237-03	93.242	—	23,591
Mental Health Research Grants	5F31MH106298-03	93.242	—	30,982
Mental Health Research Grants	5F31MH109208-02 REVI	93.242	—	38,332
Mental Health Research Grants	5F32MH101976-03	93.242	—	1,639
Mental Health Research Grants	5F32MH102890-02	93.242	—	18
Mental Health Research Grants	5K01MH107320-02	93.242	—	105,659
Mental Health Research Grants	5K01MH108741-02	93.242	43,934	175,034
Mental Health Research Grants	5K08MH105754-03 REVI	93.242	—	164,755
Mental Health Research Grants	5K23MH095679-05	93.242	—	194,808
Mental Health Research Grants	5K23MH096042-04	93.242	—	9,631
Mental Health Research Grants	5K23MH101380-04	93.242	—	170,551

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	5K24MH075867-08	93.242	\$ —	45,405
Mental Health Research Grants	5P50MH100023-03S1	93.242	—	320
Mental Health Research Grants	5P50MH100023-05	93.242	259,624	1,990,676
Mental Health Research Grants	5P50MH100029-04REVIS	93.242	40,182	39,008
Mental Health Research Grants	5R00MH102355-05 REVI	93.242	—	275,712
Mental Health Research Grants	5R01MH058846-16REVIS	93.242	—	1,043
Mental Health Research Grants	5R01MH069852-12S1	93.242	—	839,771
Mental Health Research Grants	5R01MH072908-12 Revi	93.242	64,479	428,102
Mental Health Research Grants	5R01MH073719-08 REVI	93.242	—	734,403
Mental Health Research Grants	5R01MH079448-06 REVI	93.242	—	(1,686)
Mental Health Research Grants	5R01MH099021-04/REVI	93.242	320,220	539,544
Mental Health Research Grants	5R01MH099211-05 REVI	93.242	66,777	375,964
Mental Health Research Grants	5R01MH100122-05 REVI	93.242	—	259,552
Mental Health Research Grants	5R01MH100390-02REVIS	93.242	68,562	68,562
Mental Health Research Grants	5R01MH100390-05	93.242	310,052	506,888
Mental Health Research Grants	5R01MH100467-05	93.242	43,592	526,129
Mental Health Research Grants	5R01MH100917-04REVIS	93.242	—	389,981
Mental Health Research Grants	5R01MH100999-05 REVI	93.242	—	1,033,528
Mental Health Research Grants	5R01MH101477-03	93.242	—	(379)
Mental Health Research Grants	5R01MH104534-03 REVI	93.242	42,322	836,162
Mental Health Research Grants	5R01MH104632-02	93.242	—	390,672
Mental Health Research Grants	5R01MH105561-04	93.242	68,972	355,870
Mental Health Research Grants	5R01MH107305-03S1	93.242	—	402,642
Mental Health Research Grants	5R01MH108605-02 REVI	93.242	—	320,350
Mental Health Research Grants	5R01MH109026-02REVIS	93.242	—	519,563
Mental Health Research Grants	5R01MH109637-02	93.242	—	400,635
Mental Health Research Grants	5R01MH111416-02	93.242	—	216,944
Mental Health Research Grants	5R01MH111682-02	93.242	91,088	521,507
Mental Health Research Grants	5R21MH098212-02	93.242	—	(1,600)
Mental Health Research Grants	5R21MH100670-02REV	93.242	—	94,362
Mental Health Research Grants	5R21MH102677-02S1	93.242	30,532	72,674
Mental Health Research Grants	5R21MH105353-02	93.242	17,608	25,625
Mental Health Research Grants	5R21MH105811-02 REVI	93.242	—	153,800
Mental Health Research Grants	5R21MH105816-02	93.242	14,498	122,289
Mental Health Research Grants	5R21MH105897-02Revis	93.242	—	68,247
Mental Health Research Grants	5R21MH106902-02	93.242	—	169,921
Mental Health Research Grants	5R21MH106904-02	93.242	—	135,351
Mental Health Research Grants	5R21MH108025-02	93.242	—	185,380
Mental Health Research Grants	5R21MH108873-02 REVI	93.242	103,698	149,957
Mental Health Research Grants	5R21MH108928-02 REVI	93.242	—	191,591
Mental Health Research Grants	5R25MH101079-04	93.242	—	148,127
Mental Health Research Grants	5R34MH106368-03 REVI	93.242	12,131	245,029
Mental Health Research Grants	5U01MH081988-09	93.242	—	574,334
Mental Health Research Grants	5U01MH101720-03	93.242	26,041	25,663
Pass-through Boston Children's Hospital	RSTFD00001137206	93.242	—	99,262
Pass-through Boston College	4500002127	93.242	—	47,149
Pass-through Bowdoin College	2011_003	93.242	—	15,838
Pass-through Butler Hospital	9225-5345	93.242	—	33,738
Pass-through Case Western Reserve University	RESS09294	93.242	—	196,271
Pass-through Case Western Reserve University	RESS09490 AM 3	93.242	—	122,633
Pass-through Cincinnati Children's Hospital	134471	93.242	—	16,019
Pass-through Columbia University	1(GG009422)Amend 2	93.242	—	99,155
Pass-through Columbia University	1(GG012007-01)	93.242	—	15,408
Pass-through Columbia University	4(GG010260)	93.242	—	8,392
Pass-through Dartmouth College	R882/AMND 4	93.242	—	115,024
Pass-through Duke University	2035613	93.242	—	151,257
Pass-through Feinstein Institute for Medical Research	507010EU	93.242	—	11,288
Pass-through Florida State University	R01789 AMEND 1	93.242	—	(12,170)
Pass-through Florida State University	R01842	93.242	—	93,803
Pass-through Georgia Institute of Technology	RF655-G1	93.242	—	176,841
Pass-through Georgia State University	SP00011261-02 Am 3	93.242	—	13,823
Pass-through Georgia State University	SP000112851-01	93.242	—	29,636
Pass-through Georgia State University	SP00012441-01	93.242	—	301,344
Pass-through Georgia State University	SP00012851-02	93.242	—	27,518
Pass-through Public Health Foundation Enterprises	349.0102	93.242	—	134,859
Pass-through Rhode Island Hospital	7137207	93.242	—	27,211
Pass-through State University of New York	1129280-72487	93.242	—	164,904
Pass-through University of Alabama Birmingham	000506211-004	93.242	—	40,644
Pass-through University of Arkansas	50613	93.242	—	12,800
Pass-through University of California Irvine	2015-3229	93.242	—	45,608
Pass-through University of California Los Angeles	2000 G RJ488	93.242	259,909	345,043
Pass-through University of Iowa	1001469951/AMND 02	93.242	—	64,863
Pass-through University of North Carolina	5106111	93.242	—	171,413
Pass-through University of Pittsburgh	0032045 (126571-1)	93.242	—	2,386
Pass-through University of Pittsburgh	0052887(129409-2)	93.242	—	2,760
Pass-through University of South Carolina	17-3193	93.242	—	201,699
Pass-through University of South Carolina	17-3333	93.242	—	13,244
Pass-through University of South Florida	6144-1113-00-A	93.242	—	28,973
Pass-through University of Washington	UWSC7311	93.242	—	21,252
Pass-through University of Wisconsin-Madison	409K065	93.242	—	15,012
Total CFDA No. 93.242			<u>3,369,771</u>	<u>26,303,312</u>
Public Health Training Centers Grant Program	6UB6HP27875--03--01	93.249	<u>310,628</u>	<u>949,489</u>
Total CFDA No. 93.249			<u>310,628</u>	<u>949,489</u>
Occupational Safety and Health Program	5R01OH010745-03	93.262	129,859	279,903
Occupational Safety and Health Program	5R01OH10657-03	93.262	179,476	461,216
Occupational Safety and Health Program	5T03OH008609-12	93.262	—	55,644
Total CFDA No. 93.262			<u>309,335</u>	<u>796,763</u>
Complex Humanitarian Emergency and War-Related Injury Public Health Activities	5NT01GH001185-05-00	93.269	—	<u>87,111</u>
Total CFDA No. 93.269			—	<u>87,111</u>
Adult Viral Hepatitis Prevention and Control	1U51PS003909-01S1	93.270	—	—
Total CFDA No. 93.270			—	—
Alcohol Research Programs	4K08AA021404-05	93.273	—	182,254
Alcohol Research Programs	5K08AA021404-04	93.273	—	(5,829)
Alcohol Research Programs	5R01AA021411-03	93.273	—	21
Alcohol Research Programs	1U01AA026108-01	93.273	—	9,142
Alcohol Research Programs	5R01AA018096-05	93.273	25,161	32,334
Alcohol Research Programs	7K01AA021113-06	93.273	—	127,961
Alcohol Research Programs	1R01AA025854-01	93.273	—	202,787

EMORY UNIVERSITY
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2017

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Alcohol Research Programs	4K05AA021143-05	93.273	\$ —	186,915
Alcohol Research Programs	5F31AA024960-02 REVI	93.273	—	34,878
Alcohol Research Programs	5R00AA021803-04	93.273	—	234,745
Alcohol Research Programs	5R01AA022601-06	93.273	18,754	424,713
Alcohol Research Programs	5R01AA023826-02 REV	93.273	—	227,146
Alcohol Research Programs	5R01AA025857-02	93.273	—	170,109
Alcohol Research Programs	7R01AA020695-06	93.273	127,225	388,303
Pass-through Childrens Hospital of Los Angeles	P2013-0010/AMD #5	93.273	—	27,095
Pass-through Pacific Institute for Res and Evaluation	P60AA006282	93.273	—	17,445
Pass-through San Diego State University Research Fdn	53311N P1650 7802 21	93.273	—	86,268
Pass-through University of California San Diego	79573871	93.273	—	27,492
Pass-through University of California San Diego	PO# 10313752-005	93.273	—	1,990
Pass-through University of California San Diego	PO# S9000068/AMND#4	93.273	—	68,459
Pass-through Wayne State University	WSU17049	93.273	—	33,500
Total CFDA No. 93.273			<u>171,140</u>	<u>2,477,728</u>
Drug Abuse and Addiction Research Programs	5R03CA183016-02	93.279	20,365	38,169
Drug Abuse and Addiction Research Programs	5K24A1114444-04	93.279	—	239,843
Drug Abuse and Addiction Research Programs	5R01DA035101-05 REVI	93.279	162,460	410,119
Drug Abuse and Addiction Research Programs	5R01DA038453-03 REVI	93.279	113,379	275,566
Drug Abuse and Addiction Research Programs	1K99DA039991-01A1	93.279	—	104,864
Drug Abuse and Addiction Research Programs	3R90DA033462-05S1	93.279	—	15,792
Drug Abuse and Addiction Research Programs	4K05DA031246-05	93.279	—	90,906
Drug Abuse and Addiction Research Programs	5F31DA036316-03	93.279	—	22,023
Drug Abuse and Addiction Research Programs	5R01DA030996-05 REV	93.279	—	(4,474)
Drug Abuse and Addiction Research Programs	5R01DA037568-04 REVI	93.279	451,560	767,362
Drug Abuse and Addiction Research Programs	5R01DA038196-04	93.279	—	918,405
Drug Abuse and Addiction Research Programs	5R01DA038588-04	93.279	—	768,157
Drug Abuse and Addiction Research Programs	5R03DA039797-02 REVI	93.279	1,424	2,222
Drug Abuse and Addiction Research Programs	5R03DA042358-02	93.279	—	84,085
Drug Abuse and Addiction Research Programs	5R21DA034808-02 REV	93.279	—	(1,018)
Drug Abuse and Addiction Research Programs	5R21DA040788-02	93.279	—	258,723
Drug Abuse and Addiction Research Programs	5R21DA042727-02	93.279	71,177	175,582
Drug Abuse and Addiction Research Programs	5R34DA035728-03	93.279	—	40,497
Drug Abuse and Addiction Research Programs	5R37DA0110344-19	93.279	—	311,702
Drug Abuse and Addiction Research Programs	5T90DA032466-05REVIS	93.279	—	2,512
Drug Abuse and Addiction Research Programs	5U01DA036233-05	93.279	104,130	564,188
Pass-through Boston Medical Center	356301	93.279	—	311,745
Pass-through Case Western Reserve University	RES511882/AMND 1	93.279	—	82,712
Pass-through Columbia University	1(GG008261-01)	93.279	—	372
Pass-through Mount Sinai School of Medicine	0255-0671-4609	93.279	—	39,470
Pass-through Mount Sinai School of Medicine	0255-0781-4609	93.279	—	55,936
Pass-through Northwestern University	60032445 EU	93.279	—	27,052
Pass-through Northwestern University	60044002 EU/AMND A01	93.279	—	12,625
Pass-through Northwestern University	60044679 EU	93.279	—	39,260
Pass-through St Lukes Roosevelt Institute for Health	0255-0781-4609	93.279	—	(19,749)
Pass-through University of Georgia	RR376-419/4945356	93.279	—	28,591
Pass-through University of Georgia	RR540-160/4941946	93.279	—	55,947
Pass-through University of Georgia	RR793-094/S001437	93.279	—	18,082
Pass-through University of Miami	667618	93.279	—	212,641
Pass-through University of Michigan	3003998630	93.279	—	15,564
Total CFDA No. 93.279			<u>924,495</u>	<u>5,965,473</u>
Mental Health National Research Service Awards for Research Training	5T32MH073525-05	93.282	—	1,111
Total CFDA No. 93.282			<u>—</u>	<u>1,111</u>
Centers for Disease Control and Prevention_ Investigations and Technical Assistance	200-2016-M-89045	93.283	—	9,874
Centers for Disease Control and Prevention_ Investigations and Technical Assistance	5U01DP005119-04 REVI	93.283	—	945,338
Pass-through Atlanta Research and Education Fdn	2016 EIP	93.283	—	767,842
Pass-through Atlanta Research and Education Fdn	40500-036-16130867	93.283	32,136	58,906
Pass-through Atlanta Research and Education Fdn	40500-036-17130867	93.283	—	227,877
Pass-through Georgia Dept of Public Health	40500-036-16161891	93.283	—	21,619
Pass-through Georgia Dept of Public Health	40500-036-18161799	93.283	—	700,084
Pass-through Georgia State University	SP00012872-01	93.283	—	5,874
Total CFDA No. 93.283			<u>32,136</u>	<u>2,737,414</u>
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB004987-09 REVI	93.286	126,411	309,061
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB020008-03	93.286	192,881	603,080
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB022872-02	93.286	—	335,615
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R03EB018918-02REVIS	93.286	—	16,015
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB016662-02	93.286	6,998	5,449
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB019068-02	93.286	17,300	53,072
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R21EB022828-02	93.286	—	201,054
Discovery and Applied Research for Technological Innovations to Improve Human Health	5R01EB014266-04	93.286	—	(6,141)
Pass-through Georgia Institute of Technology	RB224-G1	93.286	—	54,178
Pass-through Georgia Institute of Technology	RB224-S4	93.286	—	39,335
Pass-through Georgia Institute of Technology	RF188-G1	93.286	—	26,593
Pass-through Georgia Institute of Technology	RF636-G2	93.286	—	36,734
Pass-through Georgia Institute of Technology	RF773-G1	93.286	—	79,887
Pass-through Georgia Institute of Technology	RF990-G1/AMEND1	93.286	—	20,471
Pass-through Georgia Institute of Technology	RG538-G1	93.286	—	5,141
Pass-through Georgia Institute of Technology	RH376-G1	93.286	—	37,178
Pass-through Georgia State University	SP00013490	93.286	—	35,162
Pass-through University of California San Francisco	Subaward 8354sc	93.286	—	129,814
Total CFDA No. 93.286			<u>343,590</u>	<u>1,981,698</u>
Minority Health and Health Disparities Research	3U01MD010611-02S1 R	93.307	86,106	575,563
Minority Health and Health Disparities Research	5R01MD009064-04 REV	93.307	—	357,948
Minority Health and Health Disparities Research	5R01MD009746-03 REVI	93.307	—	582,102
Minority Health and Health Disparities Research	5R01MD010241-04	93.307	158,589	384,844
Minority Health and Health Disparities Research	5R01MD010290-03 REVI	93.307	27,493	392,344
Minority Health and Health Disparities Research	5R01MD010455-02 REV	93.307	—	371,959
Minority Health and Health Disparities Research	5R24MD008077-03REVIS	93.307	(28,000)	63,523
Minority Health and Health Disparities Research	5R01MD008966-04 REVI	93.307	—	437,617
Pass-through Morehouse School of Medicine	TCCPP009	93.307	—	10,000
Pass-through Nova Southeastern University	331500	93.307	—	28,350
Pass-through University of Pennsylvania	571099	93.307	—	242,730
Pass-through Wake Forest University	WFUHS 551279	93.307	—	23,907
Total CFDA No. 93.307			<u>244,188</u>	<u>3,470,887</u>
Trans-NIH Research Support	5R21CA185932-02	93.310	—	39,086
Trans-NIH Research Support	10P2AI112242-01 REVI	93.310	—	207,464
Trans-NIH Research Support	5DP5OD019892-04	93.310	—	481,573

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Trans-NIH Research Support	1U24DK112341-01	93.310	\$ —	30,274
Trans-NIH Research Support	1U2CES026560-01	93.310	40,551	1,888,693
Trans-NIH Research Support	5R21GM122632-02	93.310	—	286,133
Trans-NIH Research Support	5U01GM116254-03	93.310	166,580	527,915
Trans-NIH Research Support	5DP5OD012198-04REV	93.310	—	51,356
Trans-NIH Research Support	5DP7OD018424-03REVIS	93.310	—	(11,673)
Trans-NIH Research Support	5DP7OD018424-05	93.310	28,055	399,595
Trans-NIH Research Support	5R01CA163256-05REVIS	93.310	32,649	259,914
Trans-NIH Research Support	5K01OD023039-02	93.310	—	271,818
Pass-through Broad Institute	5230123-5500000603	93.310	—	5,983
Pass-through Duke University	203-5654	93.310	—	55,148
Pass-through George Washington University	15-M31	93.310	—	113
Pass-through Research Foundation for Mental Hygiene	1013335	93.310	—	24,999
Pass-through Univ of Texas Health Sciences Ctr	159763/159042	93.310	—	(3,091)
Pass-through University of Michigan	3003774756	93.310	—	42,788
Pass-through University of North Carolina	5106189	93.310	—	6,245
Pass-through Women & Infants Hospital of Rhode Island	9519	93.310	—	37,152
Pass-through Women & Infants Hospital of Rhode Island	9525	93.310	—	102,556
Total CFDA No. 93.310			267,835	4,704,041
Rare Disorders: Research, Surveillance, Health Promotion, and Education:				
Pass-through Research Foundation for Mental Hygiene	PO#127027	93.315	—	20,768
Total CFDA No. 93.315			—	20,768
Research, Monitoring and Outcomes Definitions for Vaccine Safety	6 VSRNV000003-01-01	93.344	—	55,729
Total CFDA No. 93.344			—	55,729
National Center for Advancing Translational Sciences	5TL1TR000456-09	93.350	—	2,583
National Center for Advancing Translational Sciences	5UL1TR000454-10	93.350	787	(68,933)
National Center for Advancing Translational Sciences	4KL2TR000455-10 REVI	93.350	137,252	501,145
National Center for Advancing Translational Sciences	4TL1TR000456-10REVIS	93.350	39,722	143,804
National Center for Advancing Translational Sciences	4UL1TR000454-10REVIS	93.350	1,178,145	3,901,957
National Center for Advancing Translational Sciences	5U54TR001456-08	93.350	601,995	1,008,752
Pass-through Lena Biosciences, Inc.	1R43TR001286-01A1	93.350	—	12,004
Pass-through University of Pittsburgh	9010570	93.350	—	1,148
Pass-through University of Pittsburgh	0055353 (128885-6)	93.350	17,599	38,661
Total CFDA No. 93.350			1,975,500	5,541,121
Research Infrastructure Programs	3U24OD011023-14S1	93.351	—	1,262,737
Research Infrastructure Programs	4R24OD010445-04	93.351	77,888	223,335
Research Infrastructure Programs	5P1OD011132-57S2	93.351	—	10,771,234
Research Infrastructure Programs	5R21OD020182-02	93.351	31,877	224,012
Research Infrastructure Programs	5R24OD010930-12S1 RE	93.351	—	1,143,463
Research Infrastructure Programs	5R24OD020174-02 REVI	93.351	159,309	391,634
Research Infrastructure Programs	5R24OD020349-02 REVI	93.351	18,030	546,537
Research Infrastructure Programs	5R25OD020234-02	93.351	—	162,140
Research Infrastructure Programs	5U24OD011023-13	93.351	—	738
Research Infrastructure Programs	1S10OD021773-01A1	93.351	—	39,578
Pass-through University of Nebraska	34-5150-2058-001	93.351	—	96,720
Total CFDA No. 93.351			287,104	14,862,128
Construction Support	1C06OD018248-01Revis	93.352	—	12
Total CFDA No. 93.352			—	12
Nurse Education, Practice and Retention Grants	6 UDYHP26046-02-01	93.359	—	(186)
Nurse Education, Practice and Retention Grants	6UD7HP26046-02-02	93.359	—	(69,910)
Total CFDA No. 93.359			—	(70,096)
Nursing Research	5R00NR014587-05	93.361	—	190,263
Nursing Research	5R00NR014675-06	93.361	—	73,609
Nursing Research	5R01NR012021-05	93.361	—	(2,531)
Nursing Research	5R01NR014054-4REV	93.361	—	(4,602)
Nursing Research	5T32NR012715-04	93.361	—	(40,482)
Nursing Research	1F31NR015010-02	93.361	—	611
Nursing Research	1F31NR015722-02 REVI	93.361	—	25,454
Nursing Research	1F31NR015975-02 REVI	93.361	—	37,815
Nursing Research	1K01NR016984-01	93.361	—	36,920
Nursing Research	1R01NR017018-01	93.361	—	67,225
Nursing Research	3P30NR014134-04S1	93.361	—	160
Nursing Research	3R01NR014800-03S1	93.361	—	(1,720)
Nursing Research	4F31NR014611-03	93.361	—	36,014
Nursing Research	4P30NR014134-05	93.361	—	299,979
Nursing Research	4R01NR014054-05	93.361	—	324,880
Nursing Research	4R01NR014800-05	93.361	—	563,404
Nursing Research	4R32NR012715-05	93.361	—	235,548
Nursing Research	5F31NR014609-02REVIS	93.361	—	(1,128)
Nursing Research	5F31NR014611-02REVIS	93.361	—	(757)
Nursing Research	5F31NR015400-02	93.361	—	27,944
Nursing Research	5K01NR014673-03	93.361	—	167
Nursing Research	5K01NR015733-03	93.361	—	92,898
Nursing Research	5R01NR013700-05 REVI	93.361	311,345	509,795
Nursing Research	5R01NR014886-02	93.361	—	(913)
Nursing Research	5R01NR014973-03 REVI	93.361	—	820,488
Nursing Research	5R01NR015783-02	93.361	—	320,570
Nursing Research	5R0NR012923-04	93.361	—	276,647
Nursing Research	5R21NR014544-02	93.361	93,364	292,079
Pass-through Dana Farber Cancer Institute	1215008	93.361	—	5,328
Pass-through Northwestern University	60044948 EU	93.361	—	25,900
Pass-through University of Alabama	UA15-058	93.361	—	103,124
Pass-through Virginia Commonwealth University	FP00001797- SA001	93.361	—	106,182
Pass-through Yale University	M15A11961 (CON-80000)	93.361	—	102,794
Total CFDA No. 93.361			404,709	4,523,665
National Center for Research Resources	5P51OD011132-55REV	93.389	—	(529)
Total CFDA No. 93.389			—	(529)

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cancer Cause and Prevention Research	1R01CA208758-01A1	93.393	\$ —	40,260
Cancer Cause and Prevention Research	4R01CA077337-15	93.393	—	133,707
Cancer Cause and Prevention Research	5 R03 CA183006-02REV	93.393	—	14,074
Cancer Cause and Prevention Research	5R01CA095318-13	93.393	—	385,064
Cancer Cause and Prevention Research	5R01CA166825-05 REVI	93.393	218,926	440,963
Cancer Cause and Prevention Research	5R01CA178999-05	93.393	—	234,101
Cancer Cause and Prevention Research	5R01CA179424-04	93.393	—	392,126
Cancer Cause and Prevention Research	5R21CA182752-02	93.393	—	52,975
Cancer Cause and Prevention Research	5R21CA198455-02	93.393	—	138,800
Cancer Cause and Prevention Research	R03 CA184578-02	93.393	—	3,491
Cancer Cause and Prevention Research	2U10EY013272-11A1	93.393	—	(52,913)
Cancer Cause and Prevention Research	3R01CA168925-03S1 REV	93.393	—	(2,012)
Cancer Cause and Prevention Research	3R01CA178999-03S1	93.393	—	(2,631)
Cancer Cause and Prevention Research	5R01CA105116-11	93.393	—	14
Cancer Cause and Prevention Research	5R01CA106826-09 REV	93.393	—	1,908
Cancer Cause and Prevention Research	5U01CA154282-05	93.393	87,923	445,839
Pass-through Boston University	4500001596/AMND003	93.393	—	85,680
Pass-through Dartmouth College	R755	93.393	—	185,349
Pass-through Harvard University	114952-5060413/AMND	93.393	—	30,680
Pass-through Mayo Clinic	3U01CA195568-02	93.393	—	16,109
Pass-through Mayo Clinic	3U01CA195568-02S1	93.393	—	45,332
Pass-through Mayo Clinic	EMO-202539-03	93.393	—	342,241
Pass-through Univ of Texas Health Sciences Ctr	0011696A Am 6	93.393	—	82,883
Pass-through University of California San Francisco	93735C	93.393	—	11,667
Pass-through University of Michigan	300413324	93.393	—	153,597
Pass-through University of Michigan	3004170880	93.393	—	98,191
Pass-through University of North Carolina Chapel Hill	5033529 Am 2	93.393	—	(2,632)
Pass-through University of North Carolina Chapel Hill	5-33530	93.393	—	5,309
Pass-through Wake Forest University	WFUHS 553087/AMEND #	93.393	—	9,919
Total CFDA No. 93.393			<u>306,649</u>	<u>3,290,091</u>
Cancer Detection and Diagnosis Research	1R01CA204254-01A1	93.394	—	125,913
Cancer Detection and Diagnosis Research	4R01CA156775-06	93.394	—	129,852
Cancer Detection and Diagnosis Research	4R01CA169188-05	93.394	—	332,129
Cancer Detection and Diagnosis Research	4U01CA168449-05	93.394	—	593,033
Cancer Detection and Diagnosis Research	5R01CA154846-05 REV	93.394	—	110,230
Cancer Detection and Diagnosis Research	5R01CA169188-04	93.394	—	(5,059)
Cancer Detection and Diagnosis Research	5R01CA169937-05 REVI	93.394	—	364,415
Cancer Detection and Diagnosis Research	5R01CA176659-03	93.394	—	(148)
Cancer Detection and Diagnosis Research	5R01CA176659-05	93.394	174,314	286,418
Cancer Detection and Diagnosis Research	5R01CA202846-02 REVI	93.394	65,211	478,123
Cancer Detection and Diagnosis Research	5R21CA176684-02	93.394	—	147,841
Cancer Detection and Diagnosis Research	5R21CA182661-02	93.394	—	53,566
Cancer Detection and Diagnosis Research	5R21CA206508-02 REVI	93.394	—	167,981
Cancer Detection and Diagnosis Research	5U01CA113913-10REV	93.394	—	(2,054)
Cancer Detection and Diagnosis Research	5U01CA113913-12 RevI	93.394	120,147	823,340
Cancer Detection and Diagnosis Research	5U01CA151802-05	93.394	—	2,130
Cancer Detection and Diagnosis Research	5U01CA172027-03 REVI	93.394	12,788	10,005
Cancer Detection and Diagnosis Research	5U01CA172027-05	93.394	148,116	549,449
Cancer Detection and Diagnosis Research	5U01CA198913-03S1	93.394	20,726	669,035
Cancer Detection and Diagnosis Research	5U01CA207821-02	93.394	129,200	640,254
Cancer Detection and Diagnosis Research	5U24CA194362-03 RevI	93.394	354,058	692,746
Cancer Detection and Diagnosis Research	5R01CA121320-06	93.394	—	22
Cancer Detection and Diagnosis Research	5R01CA156775-05REVIS	93.394	—	(236)
Cancer Detection and Diagnosis Research	5U01CA151810-05 REVI	93.394	—	(17,237)
Cancer Detection and Diagnosis Research	5U01CA168449-04	93.394	—	(428)
Pass-through Beth Israel Deaconess Medical Center	1028380	93.394	—	32,993
Pass-through Beth Israel Deaconess Medical Center	01029053-Amend 1	93.394	—	166,347
Pass-through Dartmouth College	R219	93.394	—	279,231
Pass-through State University of New York Stony Brook	75819-1134614-2	93.394	—	134,885
Pass-through Univ of Arkansas for Medical Services	PO-G170120339	93.394	—	328,468
Pass-through University of California Los Angeles	1900 G TA672	93.394	—	39,603
Pass-through Van Andel Institute	EMORY-BH-1-0-40234-1	93.394	—	55,453
Pass-through Washington University	WU-15-76 POW#2922479Y	93.394	—	179
Total CFDA No. 93.394			<u>1,024,560</u>	<u>7,188,479</u>
Cancer Treatment Research	1R01CA203928-01A1	93.395	—	94,289
Cancer Treatment Research	1R01CA207768-01A1	93.395	—	72,484
Cancer Treatment Research	1R01CA208328-01A1	93.395	—	95,706
Cancer Treatment Research	1R01CA214557-01	93.395	—	42,370
Cancer Treatment Research	1R13CA203283-01	93.395	—	22,310
Cancer Treatment Research	3R01CA202763-02S1	93.395	146,819	508,149
Cancer Treatment Research	4R01CA157754-05 REVI	93.395	—	237,330
Cancer Treatment Research	4R01CA160522-05	93.395	—	192,568
Cancer Treatment Research	4R01CA165306-05	93.395	25,883	223,123
Cancer Treatment Research	5 R01 CA176001-04	93.395	—	294,207
Cancer Treatment Research	5R01CA118450-10	93.395	—	93,742
Cancer Treatment Research	5R01CA136534-07 REVI	93.395	—	385,583
Cancer Treatment Research	5R01CA160522-02 RevI	93.395	—	88
Cancer Treatment Research	5R01CA180805-03	93.395	86,622	239,487
Cancer Treatment Research	5R01CA186129-04 RevI	93.395	—	347,509
Cancer Treatment Research	5R01CA186918-03	93.395	—	321,970
Cancer Treatment Research	5R01CA188523-04 REVI	93.395	—	219,606
Cancer Treatment Research	5R01CA193828-03	93.395	—	378,967
Cancer Treatment Research	5R01CA194027-02 REVI	93.395	—	521,702
Cancer Treatment Research	5R21CA185882-02REVIS	93.395	—	126,463
Cancer Treatment Research	5U10CA180864-04	93.395	—	537,154
Cancer Treatment Research	5U10CA180950-04	93.395	582,945	664,873
Cancer Treatment Research	7R01CA172385-05	93.395	—	64,870
Cancer Treatment Research	1R01CA200905-01A1	93.395	—	249,402
Cancer Treatment Research	5R01CA143107-06	93.395	—	32,109
Cancer Treatment Research	5R01CA154129-05	93.395	—	1,789
Pass-through Childrens Healthcare of Atlanta	657004-0219-01	93.395	—	18,746
Pass-through Childrens Healthcare of Atlanta	U01CA180886	93.395	—	822
Pass-through Childrens Hospital of Los Angeles	NANT 2004-05	93.395	1,324	1,604
Pass-through Ecog-Acrin Medical Research Foundation	1UG1CA189828-01-EMRY	93.395	—	27,942
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820-01-EMRY1	93.395	—	14,966
Pass-through Fred Hutchinson Cancer Research Center	804235	93.395	—	20
Pass-through Fred Hutchinson Cancer Research Center	824190	93.395	—	84
Pass-through Georgia Institute of Technology	FRG983-G1	93.395	—	83,676
Pass-through Georgia State University	SP00011812-01 AMND 3	93.395	—	146,249
Pass-through Johns Hopkins University	2002934120	93.395	—	44,421
Pass-through Medical College of Wisconsin	PO# 1541088	93.395	—	21,093

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Nrg Oncology Foundation, Inc.	009-NRG-16	93.395	\$ —	33,094
Pass-through Nrg Oncology Foundation, Inc.	5U10CA180868-04 REVI	93.395	—	134,646
Pass-through Nrg Oncology Foundation, Inc.	Emory-Yr.4	93.395	—	48,412
Pass-through Nrg Oncology Foundation, Inc.	Emory/Bruner-NCOR-03	93.395	—	143,474
Pass-through Stanford University	61251749-118307	93.395	—	240,083
Pass-through University of Alabama Birmingham	000508488-004/A02	93.395	637	5,775
Pass-through University of Arizona	225828	93.395	—	81,106
Pass-through University of California Los Angeles	1568 G TA558	93.395	—	171,905
Pass-through University of Florida	UFDSP00011464	93.395	—	15,064
Pass-through University of North Carolina Chapel Hill	5104715	93.395	2,880	18,239
Pass-through University of Southern California	78370131	93.395	—	91,181
Pass-through University of Tennessee Hlth Science Ctr	CA193609 Emory/AMND	93.395	—	40,331
Pass-through University of Utah	10039113-01	93.395	—	146,172
Total CFDA No. 93.395			847,110	7,496,755
Cancer Biology Research	3P30CA138292-09S2	93.396	—	964,915
Cancer Biology Research	3R01CA163722-05S1REV	93.396	—	396,607
Cancer Biology Research	3R01CA201340-02S1	93.396	—	391,993
Cancer Biology Research	5R01CA123490-10 REVI	93.396	—	161,325
Cancer Biology Research	5R01CA140515-08	93.396	12,451	470,799
Cancer Biology Research	5R01CA171189-03	93.396	—	(14)
Cancer Biology Research	5R01CA171189-05	93.396	—	326,597
Cancer Biology Research	5R01CA172392-05 REVI	93.396	—	318,844
Cancer Biology Research	5R01CA174786-03	93.396	1,675	322,113
Cancer Biology Research	5R01CA175316-04 REVI	93.396	—	368,593
Cancer Biology Research	5R01CA183594-04 REVI	93.396	1,952	286,851
Cancer Biology Research	5R01CA192844-02 REV	93.396	47,431	350,468
Cancer Biology Research	5R21CA181754-02	93.396	—	66,729
Cancer Biology Research	5R21CA201744-02 REV	93.396	—	124,446
Cancer Biology Research	5U01CA160882-05	93.396	318,949	583,886
Cancer Biology Research	5R01CA123368-10	93.396	—	64,067
Cancer Biology Research	5R01CA140571-05 REVI	93.396	—	164,017
Cancer Biology Research	5R01CA142858-05	93.396	—	1,277
Pass-through University Of Arizona	293328	93.396	—	56,349
Total CFDA No. 93.396			382,458	5,419,462
Cancer Centers Support Grants	4P30CA138292-08 REVI	93.397	—	1,377,559
Cancer Centers Support Grants	5P20CA210298-02	93.397	9,745	113,079
Pass-through Childrens Healthcare of Atlanta	962101 - RSUB	93.397	—	7,497
Pass-through Johns Hopkins University	2003334008 Am 4	93.397	—	5,526
Pass-through University of California San Francisco	9015sc	93.397	—	1,958
Pass-through Yale University	C17A12610(A10781)	93.397	—	50,772
Total CFDA No. 93.397			9,745	1,556,391
Cancer Research Manpower	1F31CA221002-01	93.398	—	3,028
Cancer Research Manpower	4F31CA180319-03	93.398	—	1,568
Cancer Research Manpower	4T32CA160040-04	93.398	—	229,220
Cancer Research Manpower	5 F32CA189633-02	93.398	—	(2,341)
Cancer Research Manpower	5F30CA206291-02 REVI	93.398	—	49,247
Cancer Research Manpower	5F31CA180319-02	93.398	—	(1,568)
Cancer Research Manpower	5F31CA180511-03	93.398	—	13,927
Cancer Research Manpower	5F31CA186511-03	93.398	—	44,999
Cancer Research Manpower	5F31CA186676-03	93.398	—	35,077
Cancer Research Manpower	5F31CA189672-03REVIS	93.398	—	26,416
Cancer Research Manpower	5F31CA189772-03 REVI	93.398	—	31,021
Cancer Research Manpower	5F31CA196183 REVISED	93.398	—	32,154
Cancer Research Manpower	5F31CA200383-02	93.398	—	11,530
Cancer Research Manpower	5F31CA210601-02	93.398	—	32,253
Cancer Research Manpower	5F32CA199834-02	93.398	—	56,371
Cancer Research Manpower	5K08CA194162-03	93.398	—	197,281
Cancer Research Manpower	5K23CA164015-05	93.398	—	29
Cancer Research Manpower	5K24CA208132-02	93.398	—	188,566
Cancer Research Manpower	5K25CA181503-04	93.398	—	111,964
Cancer Research Manpower	5K99CA197804-02	93.398	—	101,464
Cancer Research Manpower	5T32CA160040	93.398	—	(42)
Pass-through Health Research Roswell Park	116-01	93.398	—	40,806
Total CFDA No. 93.398			—	1,203,070
Cancer Control	5P50CA128301-05REVIS	93.399	—	(2,673)
Total CFDA No. 93.399			—	(2,673)
ACL National Institute on Disability, Independent Living, and Rehabilitation Research:				
Pass-through Georgia Institute Of Technology	RF543-G1	93.433	—	26,940
Total CFDA No. 93.433			—	26,940
Strengthening Public Health Infrastructure for Improved Health Outcomes	200-2016-91596	93.507	60,506	116,305
Strengthening Public Health Infrastructure for Improved Health Outcomes	200-2016-91600	93.507	191,650	299,057
Total CFDA No. 93.583			252,156	415,362
Health Careers Opportunity Program	6 D18HP290340301	93.822	—	669,454
Total CFDA No. 93.822			—	669,454
Ebola Support: Transmission and Prevention Control, Public Health Preparedness, Vaccine Development	1U54CK000453-01REV	93.823	206,437	506,631
Total CFDA No. 93.823			206,437	506,631
National Ebola Training and Education Center	5 U3REP150549-03-00	93.825	208,782	1,164,532
Total CFDA No. 93.825			208,782	1,164,532
Section 223 Demonstration Programs to Improve Community Mental Health Services	1R56HL131059-01	93.829	4,768	198,256
Total CFDA No. 93.829			4,768	198,256
Cardiovascular Diseases Research	1F31HL136184-01 REVI	93.837	—	4,996
Cardiovascular Diseases Research	1K08HL136873-01	93.837	—	74,414
Cardiovascular Diseases Research	1K22HL126922-01A1	93.837	—	92,116
Cardiovascular Diseases Research	1K23HL128795-01A1REV	93.837	—	189,163
Cardiovascular Diseases Research	1P20HL113451-05	93.837	—	307,796
Cardiovascular Diseases Research	1R01HL127236-01A1	93.837	130,401	559,052
Cardiovascular Diseases Research	1R01HL130915-01	93.837	97,500	423,553
Cardiovascular Diseases Research	1R01HL133618-01 REVI	93.837	—	15,700
Cardiovascular Diseases Research	1R01HL136205-01 REVI	93.837	—	236,997
Cardiovascular Diseases Research	1UG1HL135682-01	93.837	—	47,835
Cardiovascular Diseases Research	3R01HL130471-02S2	93.837	10,457	712,540

EMORY UNIVERSITY
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cardiovascular Diseases Research	4R01HL109413-04	93.837	\$ —	327,602
Cardiovascular Diseases Research	4U54HL112309-05	93.837	179,368	1,746,569
Cardiovascular Diseases Research	5F30HL118954-03	93.837	—	37,501
Cardiovascular Diseases Research	5F30HL122065-04	93.837	—	33,251
Cardiovascular Diseases Research	5F32HL124974-03	93.837	—	59,932
Cardiovascular Diseases Research	5F32HL134290-02	93.837	—	56,282
Cardiovascular Diseases Research	5K08HL119592-04	93.837	—	181,533
Cardiovascular Diseases Research	5K08HL124292-03	93.837	—	173,605
Cardiovascular Diseases Research	5K23HL105787-04	93.837	—	110,454
Cardiovascular Diseases Research	5K23HL124287-03	93.837	—	155,601
Cardiovascular Diseases Research	5K23HL127251-02	93.837	—	228,193
Cardiovascular Diseases Research	5P01HL095070-08	93.837	32,171	1,805,256
Cardiovascular Diseases Research	5R00HL119567-05	93.837	—	221,326
Cardiovascular Diseases Research	5R01HL111646-05	93.837	8,618	381,704
Cardiovascular Diseases Research	5R01HL113167-05	93.837	—	347,924
Cardiovascular Diseases Research	5R01HL119291-05	93.837	67,913	329,598
Cardiovascular Diseases Research	5R01HL119798-05	93.837	227,343	511,109
Cardiovascular Diseases Research	5R01HL122200-02	93.837	73,192	271,586
Cardiovascular Diseases Research	5R01HL122392-05	93.837	125,713	251,166
Cardiovascular Diseases Research	5R01HL125442-03	93.837	46,933	325,026
Cardiovascular Diseases Research	5R01HL127726-02	93.837	—	336,193
Cardiovascular Diseases Research	5R01HL127759-03	93.837	17,976	366,677
Cardiovascular Diseases Research	5R01HL129511-02	93.837	—	367,825
Cardiovascular Diseases Research	5R25HL131507-02	93.837	—	145,682
Cardiovascular Diseases Research	5R34HL122557-03	93.837	74,145	166,914
Cardiovascular Diseases Research	5T32HL007745-24	93.837	—	447,830
Cardiovascular Diseases Research	5T32HL130025-02 REVI	93.837	—	201,497
Cardiovascular Diseases Research	5U01HL105561-06	93.837	830,356	1,135,367
Cardiovascular Diseases Research	5U01HL117721-03	93.837	23,938	17,394
Cardiovascular Diseases Research	5U01HL128566-03	93.837	303,795	868,614
Cardiovascular Diseases Research	5U10HL110302-06	93.837	—	333,384
Cardiovascular Diseases Research	5U54HL112309-04	93.837	—	(1,235)
Cardiovascular Diseases Research	7R01HL125761-03	93.837	—	41,440
Cardiovascular Diseases Research	2T32HL00774511	93.837	—	(84,948)
Cardiovascular Diseases Research	5K23HL098744-05	93.837	—	5,700
Cardiovascular Diseases Research	5K23HL103842-05	93.837	—	40,206
Cardiovascular Diseases Research	5K24HL077506-10	93.837	—	3,989
Cardiovascular Diseases Research	5P01HL101939-05 Revi	93.837	—	200,984
Cardiovascular Diseases Research	5P20HL113451-04	93.837	—	(723)
Cardiovascular Diseases Research	5R01HL125246-03	93.837	92,577	1,117,195
Cardiovascular Diseases Research	5R37HL038206-29	93.837	—	22,618
Cardiovascular Diseases Research	5T32HL007745-20	93.837	—	84,948
Cardiovascular Diseases Research	5U10HL109781-05	93.837	308,908	357,253
Cardiovascular Diseases Research	GENFD0001172417	93.837	—	12,000
Pass-through Boston Children's Hospital	109317	93.837	1,187	1,650
Pass-through Childrens Hospital Medical Center	16091605-03	93.837	—	26,269
Pass-through Cornell University	R01HL105448	93.837	—	15,113
Pass-through Duke Clinical Research Institute	ATHENA	93.837	—	3,020
Pass-through Duke University	WBSE2035543/SPS21934	93.837	—	17,717
Pass-through Johns Hopkins University	2001185488	93.837	—	59,388
Pass-through Massachusetts General Hospital	5U01HL23336-02	93.837	—	2,849
Pass-through Medical College of Wisconsin	5R01HL119747-04	93.837	—	2,449
Pass-through Medical University of South Carolina	MUSC14-066 Am 2	93.837	55,518	69,654
Pass-through Morehouse School of Medicine	004-Emory-350086-04	93.837	—	31,436
Pass-through Mount Sinai School of Medicine	0255-1521-4609	93.837	—	6,349
Pass-through Mount Sinai School of Medicine	0255-9038-4609/Amnd#	93.837	—	60,000
Pass-through Mount Sinai School of Medicine	ISMMS 0255-3107-4605	93.837	—	12,808
Pass-through New England Research Institutes	U01HL107407	93.837	—	160
Pass-through New England Research Institutes	U01HL68270	93.837	12,211	15,605
Pass-through New York University	U01HL105907	93.837	—	136
Pass-through NIH Natl Institute of Health	1R01HL135575-01	93.837	—	214,848
Pass-through St. Jude Childrens Research Hospital	112141020-7770157	93.837	2,244	22,505
Pass-through University of California Davis	201401440-01	93.837	—	373,335
Pass-through University of California San Francisco	80435C	93.837	—	35,717
Pass-through University of Florida	UFDSP00011601	93.837	—	61,090
Pass-through University of Georgia	RR211-510/S001246/AM	93.837	—	59,569
Pass-through University of Georgia	RR376-352/4945936	93.837	—	16,204
Pass-through University of Minnesota	N004944406	93.837	—	17,448
Pass-through University of Minnesota	P004720401	93.837	—	35,853
Pass-through University of Pittsburgh	0046317 (126441-3)	93.837	3,677	4,437
Pass-through University of Rochester	416745	93.837	—	20,440
Pass-through University of Virginia	GB10336 152588	93.837	—	154,149
Pass-through Virginia Commonwealth University	PT107848-SC104184	93.837	—	(380)
Pass-through Wake Forest University	WFULHS 114146/AMND 8	93.837	9,603	95,707
Pass-through Wake Forest University	WFULHS 114870/AMND1	93.837	—	32,077
Pass-through Washington University	5U54HL112303-04	93.837	—	142
Pass-through Washington University	PO2928764A WU-16-179	93.837	—	3,104
Pass-through Weill Cornell Medical College	170851-03	93.837	—	42,686
Pass-through Yale University	nih nhlibi	93.837	—	4,371
Total CFDA No. 93.837			2,735,744	17,924,189
Lung Diseases Research	1F31HL136101-01A1 R	93.838	—	7,948
Lung Diseases Research	1F32HL132493-01 REVI	93.838	—	47,105
Lung Diseases Research	1R01HL133053-01A1	93.838	—	92,265
Lung Diseases Research	1R01HL138508-01	93.838	—	140,300
Lung Diseases Research	4R01HL113548-05	93.838	11,815	262,640
Lung Diseases Research	4R01HL116959-04	93.838	—	170,597
Lung Diseases Research	5R01 HL116959-03	93.838	—	(1,585)
Lung Diseases Research	5R01HL102167-07	93.838	—	337,929
Lung Diseases Research	5R01HL113548-04	93.838	—	(1,134)
Lung Diseases Research	5R01HL125042-04	93.838	—	714,923
Lung Diseases Research	5R01HL126603-03	93.838	73,315	543,268
Lung Diseases Research	5T32HL116271-03	93.838	—	(19,682)
Lung Diseases Research	5T32HL116271-05 REVI	93.838	—	288,245
Lung Diseases Research	5UM1HL134590-02 REVI	93.838	1,102,601	2,529,513
Lung Diseases Research	5R01HL122559-03	93.838	—	361,309
Pass-through Georgia Institute of Technology	RH328-G1	93.838	—	24,623
Pass-through Morehouse School of Medicine	COPDgene/R01HL089897	93.838	—	1,323
Pass-through Seattle Children's Research Institute	11028SUB	93.838	1,000	12,724
Pass-through University of Arizona	328533	93.838	—	170,136
Pass-through University of California San Francisco	7746sc	93.838	573	732

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Vanderbilt University	VUMC 40923 Am 4	93.838	\$ —	(561)
Pass-through Wake Forest University	WFUHS 115917	93.838	—	104,580
Total CFDA No. 93.838			1,189,304	5,787,198
Blood Diseases and Resources Research	1K01HL131333-01REVIS	93.839	—	114,453
Blood Diseases and Resources Research	1K23HL136900-01	93.839	—	35,902
Blood Diseases and Resources Research	1R21HL133584-01	93.839	—	182,276
Blood Diseases and Resources Research	5F31HL134241-02	93.839	—	31,814
Blood Diseases and Resources Research	5K23HL128942-02	93.839	—	170,196
Blood Diseases and Resources Research	5K23HL133446-02	93.839	—	157,889
Blood Diseases and Resources Research	5P01HL086773-08	93.839	468,659	1,699,725
Blood Diseases and Resources Research	5R01HL082808-12	93.839	84,048	410,417
Blood Diseases and Resources Research	5R01HL095479-08	93.839	480,951	821,593
Blood Diseases and Resources Research	5R01HL117081-06	93.839	—	282,410
Blood Diseases and Resources Research	5R01HL123984-03	93.839	—	412,576
Blood Diseases and Resources Research	5R01HL130995-02	93.839	—	260,371
Blood Diseases and Resources Research	5R01HL131414-02	93.839	—	489,464
Blood Diseases and Resources Research	5U01HL117721-05	93.839	1,076,497	1,833,229
Blood Diseases and Resources Research	5F31HL131428-02	93.839	—	33,315
Blood Diseases and Resources Research	5R01HL121264-03REVIS	93.839	13,250	446,326
Blood Diseases and Resources Research	5T32HL069769-14 REVI	93.839	—	108,171
Pass-through Bloodcenter of Wisconsin	0115-81148	93.839	—	4,083
Pass-through Bloodcenter of Wisconsin	0263-81148	93.839	—	8,998
Pass-through New England Research Institutes	U01HL072268	93.839	—	(149)
Pass-through Scripps Research Institute	5-53354	93.839	—	52,919
Pass-through University of Iowa	100168003	93.839	—	33,552
Pass-through University of North Carolina Chapel Hill	5103509	93.839	—	48,967
Pass-through Washington University	WU-17-255 PO# 29284	93.839	—	7,080
Total CFDA No. 93.839			2,123,405	7,645,577
Arthritis, Musculoskeletal and Skin Diseases Research	1F31 AR066476-01A1	93.846	—	33,160
Arthritis, Musculoskeletal and Skin Diseases Research	1F32AR068207-01A1	93.846	—	56,814
Arthritis, Musculoskeletal and Skin Diseases Research	1R01AR070898-01	93.846	—	462,347
Arthritis, Musculoskeletal and Skin Diseases Research	2R01AR050501-13A1	93.846	—	4,680
Arthritis, Musculoskeletal and Skin Diseases Research	2R1AR048615-16A1	93.846	—	57
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR048615-15	93.846	—	295,750
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR054625-10	93.846	—	394,213
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR060268-05	93.846	—	150,855
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR061267-05	93.846	—	295,564
Arthritis, Musculoskeletal and Skin Diseases Research	4R01AR062483-05	93.846	—	289,446
Arthritis, Musculoskeletal and Skin Diseases Research	5F31AR067645-03	93.846	—	33,223
Arthritis, Musculoskeletal and Skin Diseases Research	5F31AR069994-02	93.846	—	32,247
Arthritis, Musculoskeletal and Skin Diseases Research	5K01AR061453-04	93.846	—	(14)
Arthritis, Musculoskeletal and Skin Diseases Research	5K01AR065481-04	93.846	—	136,619
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR047901-14	93.846	—	377,890
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR048266-14	93.846	—	492,305
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR054625-09	93.846	—	893
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR062483-04	93.846	—	(1,456)
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR064307-04	93.846	72,156	371,566
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR067786-03	93.846	—	273,297
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR068157-03	93.846	—	641,170
Arthritis, Musculoskeletal and Skin Diseases Research	5R21AR066920-02	93.846	—	86,479
Arthritis, Musculoskeletal and Skin Diseases Research	5U01AR067169-03 REVI	93.846	11,397	285,673
Arthritis, Musculoskeletal and Skin Diseases Research	1R01AR070091-01A1REV	93.846	—	409,635
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR050501-12	93.846	—	75,834
Arthritis, Musculoskeletal and Skin Diseases Research	5R01AR060893-04	93.846	—	622
Pass-through Auburn University	16-HDFS-201305-EU	93.846	—	242,833
Pass-through Childrens Hospital Medical Center	134737	93.846	—	(79)
Pass-through Cincinnati Childrens Hospital	131796	93.846	—	455
Pass-through Georgia Institute of Technology	RF880-G1	93.846	—	18,894
Pass-through Georgia Institute of Technology	RG710-G1	93.846	—	45,826
Pass-through NIH Natl Institute of Health	5R01AR061987-05REVIS	93.846	—	81,485
Pass-through University of Georgia	RR093-401/4708851	93.846	—	82,131
Pass-through University of Maryland	20395-Z0579001	93.846	—	7,416
Pass-through University of North Carolina Chapel Hill	5103371	93.846	—	25,075
Total CFDA No. 93.846			83,553	5,702,905
Diabetes, Digestive, and Kidney Diseases Extramural Research	1DP3DK094346-01 REV	93.847	—	(8,733)
Diabetes, Digestive, and Kidney Diseases Extramural Research	1K01DK109025-01A1	93.847	—	38,529
Diabetes, Digestive, and Kidney Diseases Extramural Research	1K01DK110264-01A1	93.847	—	3,385
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R01DK111678-01	93.847	—	47,150
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R01DK115213-01	93.847	—	62,732
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R13DK115222-01	93.847	—	1,154
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R21DK112108-01A1	93.847	—	22,606
Diabetes, Digestive, and Kidney Diseases Extramural Research	2R56DK054154-15REV	93.847	—	(686)
Diabetes, Digestive, and Kidney Diseases Extramural Research	3DP3DK108245-01S1	93.847	73,799	695,039
Diabetes, Digestive, and Kidney Diseases Extramural Research	3P30DK111024-02S1	93.847	—	271,182
Diabetes, Digestive, and Kidney Diseases Extramural Research	3T32DK007656-27	93.847	—	169,954
Diabetes, Digestive, and Kidney Diseases Extramural Research	4F30DK100097-04 REVI	93.847	—	20,969
Diabetes, Digestive, and Kidney Diseases Extramural Research	4K08DK091506-05	93.847	—	166,761
Diabetes, Digestive, and Kidney Diseases Extramural Research	4K24DK096574-10	93.847	—	168,508
Diabetes, Digestive, and Kidney Diseases Extramural Research	4R01DK062092-13	93.847	—	238,940
Diabetes, Digestive, and Kidney Diseases Extramural Research	4R01DK079713-10	93.847	—	140,360
Diabetes, Digestive, and Kidney Diseases Extramural Research	4T32DK007734-20	93.847	—	176,242
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F30DK100097-03	93.847	—	714
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F30DK109665-02 REVI	93.847	—	42,161
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F31DK107229-02REVIS	93.847	—	19,047
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F31DK111171-02	93.847	—	32,146
Diabetes, Digestive, and Kidney Diseases Extramural Research	5F32DK107191-02	93.847	—	55,912
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K01DK102851-04	93.847	—	135,588
Diabetes, Digestive, and Kidney Diseases Extramural Research	5K08DK091506-04	93.847	—	(412)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK041707-22	93.847	—	296,566
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK044234-25	93.847	—	383,141
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK054514-16 REVI	93.847	—	277,954
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK056239-16	93.847	—	512,358
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK059380-15 REVI	93.847	—	315,718
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK061418-13	93.847	—	99,264
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK071597-09	93.847	—	66,435
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK074731-06	93.847	—	266,195
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK079713-09	93.847	—	(69)

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

<u>Program title/federal grantor/pass-through entity</u>	<u>Award number</u>	<u>Federal CFDA number</u>	<u>Passed through to subrecipients</u>	<u>Federal expenditures</u>
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK080684-08	93.847	\$ 84,605	289,229
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK087694-07	93.847	66,741	578,229
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK092722-06	93.847	—	264,000
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK095610-04	93.847	—	39,828
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK095750-04	93.847	—	(392)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK096983-03	93.847	—	38,711
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098231-05	93.847	—	345,712
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK100582-04	93.847	—	412,923
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK104125-03	93.847	—	446,263
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK107719-02	93.847	—	395,079
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK107900-02 REV	93.847	152,176	465,290
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK108070-02	93.847	76,057	250,980
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK108842-02 REVI	93.847	—	384,311
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R03DK096157-02	93.847	—	(11)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK098558-02	93.847	36,355	62,648
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK099716-02	93.847	—	106,575
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R21DK105891-02 REVI	93.847	52,169	225,050
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R25DK101390-04	93.847	—	85,789
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37 DK038842-27	93.847	—	(957)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37DK038842-29	93.847	—	410,646
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R37DK057665-19 REVI	93.847	—	324,187
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32 DK108735-02	93.847	—	142,341
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007734-19	93.847	—	15,000
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007771-15	93.847	—	17,349
Diabetes, Digestive, and Kidney Diseases Extramural Research	5U01DK106934-04 REVI	93.847	—	350,485
Diabetes, Digestive, and Kidney Diseases Extramural Research	6R01DK061498-15	93.847	—	354,825
Diabetes, Digestive, and Kidney Diseases Extramural Research	4R01DK095750-05	93.847	—	262,873
Diabetes, Digestive, and Kidney Diseases Extramural Research	1K01DK114391-01	93.847	—	6,161
Diabetes, Digestive, and Kidney Diseases Extramural Research	1R13DK107243-01	93.847	20,000	20,000
Diabetes, Digestive, and Kidney Diseases Extramural Research	3R01DK085097-05S1	93.847	—	(202)
Diabetes, Digestive, and Kidney Diseases Extramural Research	3R01DK087694-04S1	93.847	151,643	260,856
Diabetes, Digestive, and Kidney Diseases Extramural Research	3U01DK062470-14S1	93.847	193,110	465,036
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK047987-24	93.847	—	307,421
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK056239-14	93.847	—	2,626
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK087838-05	93.847	—	42,369
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK089828-04	93.847	—	(89)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098231-03	93.847	82,152	124,692
Diabetes, Digestive, and Kidney Diseases Extramural Research	5R01DK098391-04 REVI	93.847	—	371,990
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007298-35 REVI	93.847	—	(7,493)
Diabetes, Digestive, and Kidney Diseases Extramural Research	5T32DK007656-25S1	93.847	—	1,510
Pass-through Brigham and Womens Hospital	111977	93.847	—	(6,189)
Pass-through Brigham and Womens Hospital	112659	93.847	—	6,380
Pass-through Children's Hospital of Philadelphia	3200370521/PO#962243	93.847	—	20,092
Pass-through Connecticut Childrens Medical Center	17-179296-02	93.847	—	282,427
Pass-through Medical University of South Carolina	MUSC15-032/AMND 2	93.847	—	64,814
Pass-through Nat'l Jewish Health	20108201	93.847	—	17,408
Pass-through Northern California Inst of Res and Edu	TIE1980-02	93.847	—	558
Pass-through Ohio State University	60056849	93.847	—	10,415
Pass-through Research Institute At Nationwide Childre	952616	93.847	—	48,705
Pass-through Research Institute At Nationwide Childre	25UM1DK100966-02	93.847	—	3,796
Pass-through University of California Los Angeles	1652 G TA 103	93.847	—	2,323
Pass-through University of Chicago	FP05642102-PR	93.847	—	2,817
Pass-through University of Chicago	FP060692	93.847	—	24,633
Pass-through University of Colorado Denver	FY16.220.009	93.847	521	668
Pass-through University of Florida	UFDSP00011230	93.847	—	50,605
Pass-through University of Iowa	1001493763	93.847	—	11,139
Pass-through University of Michigan	3001819808	93.847	—	(1,022)
Pass-through University of Michigan	3003756238	93.847	—	406,313
Pass-through University of Michigan	2U54DK083912-06	93.847	(2,054)	551
Pass-through University of Michigan	SUBK00003798	93.847	1,824	5,084
Pass-through University of Pennsylvania	565161	93.847	—	10,593
Pass-through University of Pittsburgh	0019927 (124926-B)/A	93.847	4,321	67,646
Pass-through Virginia Commonwealth University	PD30355674 SC105312/AM	93.847	5,916	139,505
Pass-through Weill Cornell Medical College	17091470	93.847	—	39,126
Pass-through Weill Cornell Medical College	17040480-02	93.847	—	91,713
Total CFDA No. 93.847			<u>999,335</u>	<u>13,898,750</u>
Kidney Diseases, Urology and Hematology Research	5T32DK00765620	93.849	—	(21,024)
Kidney Diseases, Urology and Hematology Research	5U01DK06240804	93.849	—	(6,197)
Total CFDA No. 93.849			<u>—</u>	<u>(27,221)</u>
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS071518-05	93.853	—	10,323
Extramural Research Programs in the Neurosciences and Neurological Disorders	1 R03 NS091699-02	93.853	—	77,676
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS098764-01A1REV	93.853	—	10,905
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS101932-01REVIS	93.853	—	9,935
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS103595-01REVIS	93.853	—	5,938
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS091585-02 REVI	93.853	—	172,476
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS100967-01	93.853	—	70,249
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS101701-01	93.853	—	177,786
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS102306-01	93.853	—	31,378
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS102871-01	93.853	—	67,616
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS100419-01A1	93.853	—	21,566
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS102913-01	93.853	—	8,112
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R56NS102980-01	93.853	—	46,704
Extramural Research Programs in the Neurosciences and Neurological Disorders	1U24NS100673-01	93.853	—	12,106
Extramural Research Programs in the Neurosciences and Neurological Disorders	1UG3NS100559-01REVIS	93.853	—	310,198
Extramural Research Programs in the Neurosciences and Neurological Disorders	2R01NS036232-18A1	93.853	—	125,880
Extramural Research Programs in the Neurosciences and Neurological Disorders	3R01NS092122-03S1	93.853	5,483	419,674
Extramural Research Programs in the Neurosciences and Neurological Disorders	3U01NS038455-15S1	93.853	1,669,951	2,069,533
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS036232-17REVIS	93.853	—	39,988
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS057190-10	93.853	—	272,212
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS061070-11	93.853	—	292,638
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS078095-05	93.853	—	281,497
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS079625-05	93.853	28,382	356,896
Extramural Research Programs in the Neurosciences and Neurological Disorders	4R01NS085006-04	93.853	—	232,598
Extramural Research Programs in the Neurosciences and Neurological Disorders	4U10NS0593032-10	93.853	—	263,543
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS086370-03	93.853	—	219
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS087713-03	93.853	—	24,632
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS089242-03	93.853	—	26,646

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS089406-02REVIS	93.853	\$ —	5,151
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS092437-03REVIS	93.853	—	30,521
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS093859-02REVIS	93.853	—	32,041
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS095528-02REVIS	93.853	—	32,120
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098648-02	93.853	—	27,350
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098673-02	93.853	—	32,256
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F31NS098736-02	93.853	—	32,738
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS070572-03REVIS	93.853	—	1,208
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS087915-03	93.853	—	44,371
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS092342-02	93.853	—	41,862
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS098615-02	93.853	—	54,394
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K08NS099474-02	93.853	—	195,780
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS083748-04	93.853	—	177,874
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K23NS097576-02	93.853	—	166,079
Extramural Research Programs in the Neurosciences and Neurological Disorders	5P30NS050577-08	93.853	—	686,230
Extramural Research Programs in the Neurosciences and Neurological Disorders	5P50NS098685-02	93.853	—	1,409,629
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R00NS065974-05	93.853	—	26,870
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS036654-19	93.853	—	479,428
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS037112-17	93.853	37,939	347,088
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS047357-13REVIS	93.853	—	346,305
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS061070-10	93.853	—	(372)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065371-09	93.853	—	371,851
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065992-06 REVI	93.853	—	351,276
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS073994-05	93.853	20,330	122,383
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS073994-05	93.853	—	20,004
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS077982-04	93.853	36,393	377,870
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS078095-04	93.853	8,107	8,663
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079268-04	93.853	—	22,568
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079331-05 REVI	93.853	—	332,017
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079625-04	93.853	6,863	6,863
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS079858-05REVIS	93.853	—	223,312
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS083386-05	93.853	—	297,531
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS084744-04	93.853	—	259,160
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS084844-05 REVI	93.853	—	338,930
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085006-03	93.853	—	(14)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085568-04	93.853	—	218,617
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS087142-03REVIS	93.853	—	483,549
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088413-04REVIS	93.853	—	402,428
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088528-03S2	93.853	44,367	262,139
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS088748-04 REVI	93.853	292,024	775,799
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS089694-04	93.853	—	292,588
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS089719-02	93.853	—	672,562
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090319-03	93.853	309,602	528,969
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS090677-03	93.853	159,664	554,556
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091201-03	93.853	—	388,195
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS091749-02REVIS	93.853	—	253,025
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS092343-03	93.853	—	288,932
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS093016-03	93.853	—	261,005
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS093362-03	93.853	—	262,385
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095064-02 REVI	93.853	—	514,315
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095181-03	93.853	—	226,516
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095269-02 REVI	93.853	—	371,166
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS095279-03	93.853	—	278,252
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS096236-02	93.853	—	308,155
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS097776-02REVIS	93.853	—	521,934
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS081606-02	93.853	—	8,432
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084358-02	93.853	—	14,654
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS085553-02	93.853	—	1,242
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS088503-02	93.853	—	(924)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS089080-02REV	93.853	—	3,222
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS091038-02	93.853	—	6,341
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS091630-02REVIS	93.853	2,346	24,400
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS091986-02	93.853	—	135,084
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS092385-02	93.853	—	149,952
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS093446-02 REVI	93.853	—	254,577
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS093550-02	93.853	—	99,055
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS096455-02 REVI	93.853	—	303,126
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS098776-02	93.853	—	154,397
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R24NS092989-02	93.853	—	239,668
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R25NS065739-09	93.853	—	4,792
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R31NS086174-03	93.853	—	3,272
Extramural Research Programs in the Neurosciences and Neurological Disorders	5T32NS007480-17	93.853	3,604	250,975
Extramural Research Programs in the Neurosciences and Neurological Disorders	5T32NS090600-22	93.853	—	240,097
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS038455-14REVIS	93.853	474,101	497,391
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS094302-03	93.853	378,960	708,113
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS077866-07	93.853	—	293,595
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS086607-03	93.853	—	2,193
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS086607-05	93.853	—	370,914
Extramural Research Programs in the Neurosciences and Neurological Disorders	7K08NS083626-03	93.853	—	94,633
Extramural Research Programs in the Neurosciences and Neurological Disorders	7R01NS073768-06REVIS	93.853	4,834	143,126
Extramural Research Programs in the Neurosciences and Neurological Disorders	1F31NS098663-01A1	93.853	—	1,987
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R01NS099375-01A1	93.853	—	131,800
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R03NS100355-01	93.853	—	2,995
Extramural Research Programs in the Neurosciences and Neurological Disorders	1R21NS10244-01A1	93.853	—	36,052
Extramural Research Programs in the Neurosciences and Neurological Disorders	5F32NS087775-02	93.853	—	44,981
Extramural Research Programs in the Neurosciences and Neurological Disorders	5K08NS087121-04	93.853	—	190,346
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS051630-12REVIS	93.853	—	549,839
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS062073-06 REV	93.853	—	(639)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS064162-04	93.853	—	13,517
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065371-07	93.853	—	(1,920)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS065949-05 REV	93.853	—	83
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS070526-05 REVI	93.853	—	106,725
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS071867-05 REVI	93.853	57,263	120,719
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS072221-04	93.853	—	(169)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R01NS085387-04	93.853	—	316,127
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084163-02	93.853	—	159
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS084647-02REV	93.853	1,165	42,373
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS087488-02	93.853	—	177,976
Extramural Research Programs in the Neurosciences and Neurological Disorders	5R21NS094136-02	93.853	—	60,166
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS058153-10REVIS	93.853	—	(962)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U01NS062778-05REV	93.853	71,886	292,241
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U10NS053379-07	93.853	—	(380)
Extramural Research Programs in the Neurosciences and Neurological Disorders	5U54NS065701-05 REVI	93.853	—	38
Pass-through Case Western Reserve University	RES510707/AMND#1	93.853	—	52,125

EMORY UNIVERSITY
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Cleveland Clinic Foundation	681-SUB	93.853	\$ —	8,439
Pass-through Duke University	16-NIH-1038/AMND#1	93.853	—	6,389
Pass-through George Washington University	15-S27/ MOD #1	93.853	—	85,920
Pass-through Georgia Institute of Technology	RC836-G1	93.853	—	(591)
Pass-through Georgia Institute of Technology	RG321-G1	93.853	—	62,896
Pass-through Georgia Institute of Technology	RG574-G1	93.853	—	213,457
Pass-through Georgia Institute of Technology	RH057-G2	93.853	—	44,400
Pass-through Johns Hopkins University	2003237738	93.853	—	261,993
Pass-through Johns Hopkins University	2003138853 AMEN 3	93.853	—	44,412
Pass-through Massachusetts General Hospital	U01NS077366-01	93.853	—	2,363
Pass-through Mayo Clinic	EMO-187276-04	93.853	—	3,173
Pass-through Mercer University	420210-FU	93.853	—	44,285
Pass-through Northwestern University	60036745EU	93.853	—	10,201
Pass-through Northwestern University	60040984 EU	93.853	—	32,870
Pass-through Optima Neurosciences	OPT-004-EMORY	93.853	—	40,617
Pass-through University of California San Francisco	9952sc	93.853	—	2,462
Pass-through University of Miami	669246	93.853	—	100,810
Pass-through University of Michigan	3002268352	93.853	—	15,412
Pass-through University of Michigan	111993-SHN	93.853	—	57,797
Pass-through University of Michigan	30002672030-ISPOT	93.853	—	1,039
Pass-through University of Michigan	3001413083-PNT	93.853	—	16,345
Pass-through University of Michigan	SUBK00004094-ESETT	93.853	—	30,045
Pass-through University of North Carolina	5100029	93.853	—	(218)
Pass-through University of North Carolina	5102005	93.853	—	216,694
Pass-through University of Southern California	6577278	93.853	—	1,723
Pass-through University of Wisconsin-Madison	613K476 Am 1	93.853	—	23,104
Pass-through University of Wisconsin-Madison	652K330	93.853	—	9,155
Total CFDA No. 93.853			3,613,264	27,679,046
Allergy, Immunology and Transplantation Research	1F31A1122973-01A1	93.855	—	17,367
Allergy, Immunology and Transplantation Research	1F31A1133950-01 REVI	93.855	—	3,974
Allergy, Immunology and Transplantation Research	1K08A1132747-01	93.855	—	22,556
Allergy, Immunology and Transplantation Research	1K23A1108335-03	93.855	—	(27)
Allergy, Immunology and Transplantation Research	1R01A1116835-01 REVI	93.855	—	(16,428)
Allergy, Immunology and Transplantation Research	1R01A1123733-01	93.855	—	344,227
Allergy, Immunology and Transplantation Research	1R01A1127799-01	93.855	51,214	290,942
Allergy, Immunology and Transplantation Research	1R01A1128799-01	93.855	—	236,044
Allergy, Immunology and Transplantation Research	1R01A1128857-01	93.855	—	33,841
Allergy, Immunology and Transplantation Research	1R01A112982-01A1	93.855	—	138,877
Allergy, Immunology and Transplantation Research	1R01A1132833-01	93.855	—	88,911
Allergy, Immunology and Transplantation Research	1R01A1134244-01	93.855	—	18,674
Allergy, Immunology and Transplantation Research	1R13A1134407-01 REVI	93.855	—	75
Allergy, Immunology and Transplantation Research	1R21A1122192-01A1	93.855	—	84,071
Allergy, Immunology and Transplantation Research	1R21A1128313-01	93.855	—	98,807
Allergy, Immunology and Transplantation Research	1R21A1129607-01	93.855	—	143,209
Allergy, Immunology and Transplantation Research	1R21A1130918-01	93.855	—	46,621
Allergy, Immunology and Transplantation Research	1R56A1110516-01	93.855	—	158,760
Allergy, Immunology and Transplantation Research	1R56A1117851-01	93.855	—	390,937
Allergy, Immunology and Transplantation Research	1U01A1131566-01 REVI	93.855	—	119,274
Allergy, Immunology and Transplantation Research	1U01A1132904-01	93.855	—	20,990
Allergy, Immunology and Transplantation Research	1UJ2A1132345-01	93.855	—	2,061
Allergy, Immunology and Transplantation Research	1UM1A1124436-01	93.855	538,867	7,184,317
Allergy, Immunology and Transplantation Research	2P30A1050409-19 REVI	93.855	402,926	3,291,926
Allergy, Immunology and Transplantation Research	2R01A1020211-30A1	93.855	—	397,036
Allergy, Immunology and Transplantation Research	2R01A1073707-06	93.855	—	242,887
Allergy, Immunology and Transplantation Research	2R56A1083366-06A1	93.855	13,443	377,635
Allergy, Immunology and Transplantation Research	2U19A1051731-16	93.855	—	196,938
Allergy, Immunology and Transplantation Research	3R01A1104699-03	93.855	—	(33)
Allergy, Immunology and Transplantation Research	3R01A1110482-03S1	93.855	569,109	896,696
Allergy, Immunology and Transplantation Research	4R01A1028731-26	93.855	—	442,643
Allergy, Immunology and Transplantation Research	4R01A1058057-12	93.855	—	257,297
Allergy, Immunology and Transplantation Research	4R01A1058706-14	93.855	103,029	789,913
Allergy, Immunology and Transplantation Research	4R01A1064462-10	93.855	—	286,713
Allergy, Immunology and Transplantation Research	4R01A1070101-10	93.855	—	104,876
Allergy, Immunology and Transplantation Research	4R01A1072435-11	93.855	—	136,828
Allergy, Immunology and Transplantation Research	4R01A1093881-05 REVI	93.855	—	(436)
Allergy, Immunology and Transplantation Research	4R01A1096879-05	93.855	—	424,734
Allergy, Immunology and Transplantation Research	4R01A1098628-05	93.855	25,702	954,672
Allergy, Immunology and Transplantation Research	4R01A1099000-05	93.855	—	290,231
Allergy, Immunology and Transplantation Research	4R01A1100110-05	93.855	—	530,509
Allergy, Immunology and Transplantation Research	4R37A1040519-20 REVI	93.855	—	235,239
Allergy, Immunology and Transplantation Research	4R37A1066998-13	93.855	—	953,394
Allergy, Immunology and Transplantation Research	4T32A1070081-10 REVI	93.855	—	140,510
Allergy, Immunology and Transplantation Research	4U19A1051731-15	93.855	1,621,016	2,634,526
Allergy, Immunology and Transplantation Research	5 R21 A1116200-02	93.855	—	(3,114)
Allergy, Immunology and Transplantation Research	5 R37 A1049638-17	93.855	—	335,008
Allergy, Immunology and Transplantation Research	5F30A1124568-02	93.855	—	30,301
Allergy, Immunology and Transplantation Research	5F31A1112261-03REVIS	93.855	—	253
Allergy, Immunology and Transplantation Research	5F31A1114250-03	93.855	—	30,728
Allergy, Immunology and Transplantation Research	5F31A1122926-02 REVI	93.855	—	36,012
Allergy, Immunology and Transplantation Research	5F31A1124611-02REVIS	93.855	—	28,813
Allergy, Immunology and Transplantation Research	5K01A1103544-05	93.855	—	119,073
Allergy, Immunology and Transplantation Research	5K08A1110528-05	93.855	—	211,680
Allergy, Immunology and Transplantation Research	5K08A1119448-02	93.855	—	162,257
Allergy, Immunology and Transplantation Research	5K23A1103044-05	93.855	—	159,251
Allergy, Immunology and Transplantation Research	5K23A1108335-05	93.855	—	214,938
Allergy, Immunology and Transplantation Research	5K23A1114407-04	93.855	—	190,846
Allergy, Immunology and Transplantation Research	5K23A1116388-03 REVI	93.855	—	4,385
Allergy, Immunology and Transplantation Research	5K23A1124913-02	93.855	—	167,968
Allergy, Immunology and Transplantation Research	5P01A1125180-02	93.855	440,568	1,944,646
Allergy, Immunology and Transplantation Research	5P30A1050409-17REVIS	93.855	72,342	149,235
Allergy, Immunology and Transplantation Research	5R01A1030048-24	93.855	—	43,629
Allergy, Immunology and Transplantation Research	5R01A1049781-14	93.855	—	289,541
Allergy, Immunology and Transplantation Research	5R01A1053668-15	93.855	—	(2,347)
Allergy, Immunology and Transplantation Research	5R01A1053668-17	93.855	—	423,395
Allergy, Immunology and Transplantation Research	5R01A1058706-13	93.855	—	(18)
Allergy, Immunology and Transplantation Research	5R01A1058828-10	93.855	—	1,422
Allergy, Immunology and Transplantation Research	5R01A1064060-13	93.855	768,083	1,619,003
Allergy, Immunology and Transplantation Research	5R01A1064462-09	93.855	—	13,814
Allergy, Immunology and Transplantation Research	5R01A1065429-13	93.855	—	613,515
Allergy, Immunology and Transplantation Research	5R01A1087465-05	93.855	101,183	193,229
Allergy, Immunology and Transplantation Research	5R01A1088025-08	93.855	8,886	419,356
Allergy, Immunology and Transplantation Research	5R01A1089349-06 REV	93.855	122,217	179,221

EMORY UNIVERSITY
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Alergy, Immunology and Transplantation Research	5R01AI093406-05	93.855	\$ 403,905	607,987
Alergy, Immunology and Transplantation Research	5R01AI094575-04 REVI	93.855	82,269	214,292
Alergy, Immunology and Transplantation Research	5R01AI100110-04 REVI	93.855	—	901
Alergy, Immunology and Transplantation Research	5R01AI101047-04	93.855	—	(2,810)
Alergy, Immunology and Transplantation Research	5R01AI104699-05	93.855	—	351,614
Alergy, Immunology and Transplantation Research	5R01AI106715-03	93.855	—	54,843
Alergy, Immunology and Transplantation Research	5R01AI107960-04	93.855	220,765	714,524
Alergy, Immunology and Transplantation Research	5R01AI110113-03	93.855	—	215,474
Alergy, Immunology and Transplantation Research	5R01AI110334-03	93.855	21,901	97,873
Alergy, Immunology and Transplantation Research	5R01AI110334-05	93.855	159,759	673,386
Alergy, Immunology and Transplantation Research	5R01AI110474-03	93.855	—	214,788
Alergy, Immunology and Transplantation Research	5R01AI110680-03	93.855	198,386	759,979
Alergy, Immunology and Transplantation Research	5R01AI110701-04	93.855	—	660,595
Alergy, Immunology and Transplantation Research	5R01AI110720-04	93.855	145,734	311,779
Alergy, Immunology and Transplantation Research	5R01AI111557-04	93.855	180,272	821,222
Alergy, Immunology and Transplantation Research	5R01AI111851-04	93.855	150,783	469,508
Alergy, Immunology and Transplantation Research	5R01AI111863-03 REVI	93.855	51,549	35,878
Alergy, Immunology and Transplantation Research	5R01AI111948-04	93.855	166,779	891,796
Alergy, Immunology and Transplantation Research	5R01AI112723-03	93.855	21,717	1,129,421
Alergy, Immunology and Transplantation Research	5R01AI113021-04	93.855	—	292,270
Alergy, Immunology and Transplantation Research	5R01AI113883-02	93.855	—	814
Alergy, Immunology and Transplantation Research	5R01AI116379-02	93.855	—	1,061,638
Alergy, Immunology and Transplantation Research	5R01AI116933-03	93.855	—	438,756
Alergy, Immunology and Transplantation Research	5R01AI118853-03	93.855	—	422,510
Alergy, Immunology and Transplantation Research	5R01AI121252-02	93.855	—	454,775
Alergy, Immunology and Transplantation Research	5R01AI123126-02	93.855	—	203,110
Alergy, Immunology and Transplantation Research	5R01AI124680-02	93.855	106,072	428,481
Alergy, Immunology and Transplantation Research	5R01AI125064-02	93.855	—	822,157
Alergy, Immunology and Transplantation Research	5R01AI125268-02	93.855	—	315,120
Alergy, Immunology and Transplantation Research	5R01AI125405-02	93.855	171,246	398,075
Alergy, Immunology and Transplantation Research	5R01AI126322-02	93.855	154,078	860,189
Alergy, Immunology and Transplantation Research	5R03AI111396-02	93.855	5,699	13,073
Alergy, Immunology and Transplantation Research	5R21AI103270-02	93.855	—	1,268
Alergy, Immunology and Transplantation Research	5R21AI103651-02	93.855	—	139,835
Alergy, Immunology and Transplantation Research	5R21AI106386-02	93.855	17,090	17,591
Alergy, Immunology and Transplantation Research	5R21AI112768-02	93.855	—	202,149
Alergy, Immunology and Transplantation Research	5R21AI113385-02 REVI	93.855	61,834	102,700
Alergy, Immunology and Transplantation Research	5R21AI113485-02	93.855	29,013	146,940
Alergy, Immunology and Transplantation Research	5R21AI115018-02	93.855	—	21,891
Alergy, Immunology and Transplantation Research	5R21AI115183-02	93.855	—	76,277
Alergy, Immunology and Transplantation Research	5R21AI117162-02	93.855	34,322	178,876
Alergy, Immunology and Transplantation Research	5R21AI117459-02	93.855	75,632	324,454
Alergy, Immunology and Transplantation Research	5R21AI118542-02	93.855	81,568	236,014
Alergy, Immunology and Transplantation Research	5R21AI121684-02	93.855	108,540	215,093
Alergy, Immunology and Transplantation Research	5R21AI121860-02	93.855	—	161,500
Alergy, Immunology and Transplantation Research	5R33AI098800-05	93.855	—	365,697
Alergy, Immunology and Transplantation Research	5R33AI102197-05	93.855	—	356,994
Alergy, Immunology and Transplantation Research	5R33AI104278-05	93.855	—	230,704
Alergy, Immunology and Transplantation Research	5R37AI021150-32	93.855	93,464	416,602
Alergy, Immunology and Transplantation Research	5R37AI049660-14	93.855	—	319,905
Alergy, Immunology and Transplantation Research	5R37AI051231-16	93.855	94,900	957,595
Alergy, Immunology and Transplantation Research	5R37AI112787-04	93.855	111,597	648,669
Alergy, Immunology and Transplantation Research	5T32AI070081-09	93.855	—	8,757
Alergy, Immunology and Transplantation Research	5T32AI074492-09	93.855	—	317,705
Alergy, Immunology and Transplantation Research	5T32AI106699-04	93.855	—	141,099
Alergy, Immunology and Transplantation Research	5U01AI084150-05 REVI	93.855	848,055	535,649
Alergy, Immunology and Transplantation Research	5U01AI103408-03 REV	93.855	27,656	33,793
Alergy, Immunology and Transplantation Research	5U01AI115651-03	93.855	252,036	692,507
Alergy, Immunology and Transplantation Research	5U19AI051731-14REVIS	93.855	734,049	494,649
Alergy, Immunology and Transplantation Research	5U19AI057266-14	93.855	1,215,279	2,811,319
Alergy, Immunology and Transplantation Research	5U19AI090233-05	93.855	51,376	51,102
Alergy, Immunology and Transplantation Research	5U19AI090233-08	93.855	809,767	2,247,681
Alergy, Immunology and Transplantation Research	5U19AI109633-04	93.855	66,090	2,037,868
Alergy, Immunology and Transplantation Research	5U19AI110483-04	93.855	—	461,575
Alergy, Immunology and Transplantation Research	5U19AI111211-04REVIS	93.855	1,297,062	2,705,717
Alergy, Immunology and Transplantation Research	5U19AI117891-03	93.855	566,065	1,586,988
Alergy, Immunology and Transplantation Research	5U24AI120134-03	93.855	—	362,607
Alergy, Immunology and Transplantation Research	5UH2AI122320-02	93.855	548,599	650,337
Alergy, Immunology and Transplantation Research	5UM1AI069418-11REVIS	93.855	536,305	2,053,854
Alergy, Immunology and Transplantation Research	1R21AI122001-01	93.855	99,483	161,269
Alergy, Immunology and Transplantation Research	4R01HD067359-05	93.855	—	169,189
Alergy, Immunology and Transplantation Research	5F31AI115968-02 REVI	93.855	—	11,902
Alergy, Immunology and Transplantation Research	5K01AI106961-03	93.855	—	140,120
Alergy, Immunology and Transplantation Research	5R01AI083366-05 REVI	93.855	—	76
Alergy, Immunology and Transplantation Research	5R01AI098879-04	93.855	—	(723)
Alergy, Immunology and Transplantation Research	5R01AI098000-04	93.855	—	828
Alergy, Immunology and Transplantation Research	5R21AI126816-02	93.855	—	201,427
Alergy, Immunology and Transplantation Research	5R37AI051231-14	93.855	—	(12,260)
Alergy, Immunology and Transplantation Research	5U01AI103408-05 REVI	93.855	87,989	2,002,229
Alergy, Immunology and Transplantation Research	5U19AI096187-05 REVI	93.855	253,555	405,723
Alergy, Immunology and Transplantation Research	P01AI078907	93.855	44,273	40,746
Pass-through Albert Einstein College of Medicine	310842 Amend #6	93.855	—	9,590
Pass-through Benaroya Research Institute At Virginia	FY15ITN117	93.855	—	15,995
Pass-through Benaroya Research Institute At Virginia	FY15ITN153	93.855	—	74,950
Pass-through Benaroya Research Institute At Virginia	FY16ITN215	93.855	—	8,272
Pass-through Benaroya Research Institute At Virginia	FY17ITN236	93.855	—	13,593
Pass-through Benaroya Research Institute At Virginia	FY17ITN236 Amen 1	93.855	—	49,733
Pass-through Beth Israel Deaconess Medical Center	FY17ITN242	93.855	—	17,949
Pass-through Beth Israel Deaconess Medical Center	1024717	93.855	—	283,331
Pass-through Beth Israel Deaconess Medical Center	1028933	93.855	—	237,616
Pass-through Boston Children's Hospital	GENFD0001301584/1306	93.855	—	90,857
Pass-through Boston University	4500002016	93.855	—	(52)
Pass-through Brandeis University	401862	93.855	29,848	65,610
Pass-through Brigham and Womens Hospital	110007	93.855	—	174
Pass-through Brigham and Womens Hospital	110009	93.855	—	17,728
Pass-through Brigham and Womens Hospital	110229	93.855	—	18,917
Pass-through Brigham and Womens Hospital	111406	93.855	—	71,853
Pass-through Brigham and Womens Hospital	113298	93.855	—	30,741
Pass-through Brigham and Womens Hospital	114727	93.855	—	44,696
Pass-through Brigham and Womens Hospital	2UM1A06936-08	93.855	—	5,321
Pass-through Brigham and Womens Hospital	5UM1A068636-11	93.855	—	154,980
Pass-through Case Western Reserve University	RES509044	93.855	—	73,370

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Case Western Reserve University	RES509540 Amen 1	93.855	\$ —	1,527
Pass-through Case Western Reserve University	RES511329	93.855	—	142,856
Pass-through Case Western Reserve University	RES511346-02	93.855	—	342,893
Pass-through Centre for The Aids Program of Res. In S	1R21AI115978	93.855	—	20,937
Pass-through Childrens Hospital Oakland	12.7845_Eemory_5	93.855	—	215,568
Pass-through Childrens Hospital of Boston	5R0AI084011-04	93.855	3,500	4,428
Pass-through Duke University	2033045	93.855	—	(899)
Pass-through Duke University	2038471	93.855	—	17,678
Pass-through Duke University	189925/218470	93.855	—	63
Pass-through Family Health International	PO15004277	93.855	209,814	638,321
Pass-through Fred Hutchinson Cancer Research Center	852867	93.855	—	88,087
Pass-through Fred Hutchinson Cancer Research Center	853370	93.855	—	222,898
Pass-through Fred Hutchinson Cancer Research Center	866272	93.855	—	19,789
Pass-through Fred Hutchinson Cancer Research Center	888347	93.855	—	19,304
Pass-through Fred Hutchinson Cancer Research Center	888692	93.855	—	419,894
Pass-through Fred Hutchinson Cancer Research Center	893339	93.855	—	308,728
Pass-through Fred Hutchinson Cancer Research Center	893628	93.855	—	138,461
Pass-through Fred Hutchinson Cancer Research Center	906010	93.855	—	514,328
Pass-through Georgia Institute of Technology	RE606-G2 Am.2	93.855	—	66,641
Pass-through Georgia Institute of Technology	RG532-G3	93.855	—	23,502
Pass-through Georgia Institute of Technology	RG673-G1/AMEND #1	93.855	—	290,877
Pass-through Georgia State University	SP00011272-02	93.855	—	110,760
Pass-through Georgia State University	SP00011671-03	93.855	—	79,613
Pass-through Georgia State University	SP00012035-01	93.855	—	9,888
Pass-through Georgia State University	SP00012035-02	93.855	—	9,234
Pass-through Georgia State University	SP00012249-01/AMND1	93.855	—	93,817
Pass-through Georgia State University	SP00012355-02	93.855	—	47,645
Pass-through Harvard University	152382.5087277.1106	93.855	—	334,703
Pass-through Henry M Jackson Foundation	307419-3.01-64461/PO	93.855	—	119,772
Pass-through Johns Hopkins University	2002658448	93.855	—	72,924
Pass-through Johns Hopkins University	5U19AI113127-03	93.855	—	39,422
Pass-through Johns Hopkins University	LDR 01 MOD 01	93.855	—	17,415
Pass-through Johns Hopkins University	PO# 2001007978	93.855	—	20,557
Pass-through La Jolla Institute for Allergy	22496-60-382	93.855	—	377,237
Pass-through Massachusetts General Hospital	223544	93.855	—	19,416
Pass-through Massachusetts General Hospital	228429	93.855	—	4,995
Pass-through Mayo Clinic	63484620	93.855	—	479,486
Pass-through Mayo Clinic Rochester	PO6520032	93.855	—	1,101
Pass-through Md Anderson	PO- 3000920012	93.855	—	40,186
Pass-through Mount Sinai School of Medicine	25580714609	93.855	—	134,004
Pass-through Mount Sinai School of Medicine	U19AI118610	93.855	—	107,790
Pass-through Mount Sinai School of Medicine	0254-3193-4609	93.855	—	358,380
Pass-through Mount Sinai School of Medicine	0255-1368-4609	93.855	—	106,254
Pass-through Mount Sinai School of Medicine	0255-8640-4609/SC783	93.855	—	185,568
Pass-through Ohio State University	60051430	93.855	—	32,862
Pass-through Public Health Foundation of India	HHSN268200900026C	93.855	—	(175,087)
Pass-through Regents of The University of California	9477	93.855	—	24,953
Pass-through Regents of The University of California	9862SC Amendment #1	93.855	—	10,271
Pass-through Research Institute At Nationwide Childre	763416	93.855	—	60,676
Pass-through Research Institute At Nationwide Childre	82154216	93.855	—	316,876
Pass-through Scripps Research Institute	5-52755	93.855	—	91,755
Pass-through Scripps Research Institute	5-53265	93.855	—	70,712
Pass-through Seattle Childrens Hospital	11330SUB	93.855	—	3,779
Pass-through Seattle Childrens Hospital	11578SUB	93.855	—	23,708
Pass-through Stanford University	61019079-117727	93.855	—	28,041
Pass-through Stanford University	61212672-28291	93.855	—	165,892
Pass-through Stanford University	61537964-28291	93.855	—	13,313
Pass-through Tulane University	TUL-HSC-553582-16/17	93.855	—	529,213
Pass-through University of Alabama Birmingham	000502889-SP007-001	93.855	—	295,865
Pass-through University of Alabama Birmingham	000505362-001	93.855	—	122,436
Pass-through University of California Davis	201303042-07	93.855	—	257,649
Pass-through University of California San Diego	66085916	93.855	—	72,747
Pass-through University of California San Diego	82056849/PO# 5900157	93.855	—	62,099
Pass-through University of California San Francisco	726asc	93.855	—	22,859
Pass-through University of California San Francisco	8820sc/AMEND#2	93.855	—	47,962
Pass-through University of California San Francisco	9255sc AM. 1	93.855	—	54,158
Pass-through University of California San Francisco	943asc	93.855	—	433,557
Pass-through University of Georgia	RR374-101/4708622	93.855	—	89,068
Pass-through University of Georgia	RR374-126/S001205	93.855	—	58,627
Pass-through University of Houston	R-16-0075/AMND 1	93.855	—	126,130
Pass-through University of Illinois	2015-01658-01 Am. 1	93.855	—	9,339
Pass-through University of Louisiana At Lafayettete	87100-02	93.855	—	21,238
Pass-through University of Louisiana At Lafayettete	8799-01	93.855	—	(12,536)
Pass-through University of Maryland	10018314-742	93.855	—	297,398
Pass-through University of Miami	667686	93.855	—	274,404
Pass-through University of Minnesota	N002877305	93.855	—	10,623
Pass-through University of Nebraska	34-5160-2084-001	93.855	—	34,840
Pass-through University of Nebraska	34-5160-2108-001	93.855	—	274,619
Pass-through University of Nebraska	Subaward 34-5160-208	93.855	—	9,029
Pass-through University of Nevada	UNR-16-45	93.855	—	72,273
Pass-through University of North Carolina	5105563	93.855	—	371,308
Pass-through University of North Carolina	5U54AI057157-11	93.855	—	(99,406)
Pass-through University of North Carolina Chapel Hill	5101375	93.855	—	40,093
Pass-through University of North Carolina Chapel Hill	5103944	93.855	—	27,152
Pass-through University of North Carolina Chapel Hill	5107082	93.855	—	68,142
Pass-through University of Notre Dame	202980EU	93.855	—	24,398
Pass-through University of Pennsylvania	562140	93.855	—	90
Pass-through University of Pennsylvania	566103	93.855	—	(157)
Pass-through University of Pennsylvania	PO# 3826995	93.855	—	35,034
Pass-through University of Texas Southwestern	GMO150402/PO#RGC0000	93.855	—	134,643
Pass-through University of Washington Seattle	UWSC6143	93.855	—	481,208
Pass-through University of Wisconsin-Madison	298K012 / 581K523	93.855	—	237,748
Pass-through Vanderbilt University	PO 4016078156	93.855	—	(1,678)
Pass-through Vanderbilt University	VUMC 38503	93.855	—	(127,502)
Pass-through Vanderbilt University	VUMC57217	93.855	—	154,519
Pass-through Vanderbilt University	VUMC59385	93.855	—	308,663
Pass-through Vanderbilt University Medical Center	VUMC38503	93.855	—	158,676
Pass-through Vanderbilt University Medical Center	VUMC40875/AMND 1	93.855	—	2,190
Pass-through Vanderbilt University Medical Center	VUMC59252	93.855	—	15,160
Pass-through Washington University	WU-16-326	93.855	—	14,814

EMORY UNIVERSITY
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Wistar Institute	25131-04-374	93.855	\$ —	607,836
Pass-through Yale University	M16A12520 (A10202)	93.855	—	8,411
Total CFDA No. 93.855			15,468,620	83,800,717
Microbiology and Infectious Diseases Research		93.856	—	—
Pass-through Baylor College of Medicine	7000000342	93.856	—	66,194
Pass-through University of Florida	UFDSP00011683	93.856	—	15,461
Total CFDA No. 93.856			—	81,655
Biomedical Research and Research Training	1F31GM123750-01 REVI	93.859	—	10,296
Biomedical Research and Research Training	1F32GM117895-01 REVI	93.859	—	(123)
Biomedical Research and Research Training	1F32GM121071-01	93.859	—	53,865
Biomedical Research and Research Training	1R01GM117946-01	93.859	63,654	234,713
Biomedical Research and Research Training	2R01GM051173-32	93.859	—	273,109
Biomedical Research and Research Training	2R01GM100151-05	93.859	—	302,490
Biomedical Research and Research Training	2T32GM008169-31S1	93.859	—	3,382
Biomedical Research and Research Training	3R25GM099644-03S1REV	93.859	—	70,082
Biomedical Research and Research Training	3T32GM008169-30S1	93.859	—	954,582
Biomedical Research and Research Training	4R01GM035463-29	93.859	—	304,708
Biomedical Research and Research Training	4R01GM051173-31REV	93.859	—	129,706
Biomedical Research and Research Training	4R01GM058728-16	93.859	—	247,844
Biomedical Research and Research Training	4R01GM077569-08	93.859	—	101,733
Biomedical Research and Research Training	4R01GM097399-05	93.859	—	382
Biomedical Research and Research Training	4R01GM101040-04	93.859	—	113,802
Biomedical Research and Research Training	4R01GM103613-04	93.859	—	256,734
Biomedical Research and Research Training	4R01GM104323-04	93.859	—	286,599
Biomedical Research and Research Training	4R01GM105113-04	93.859	109,133	216,539
Biomedical Research and Research Training	4R01GM111027-20 REVI	93.859	—	17,793
Biomedical Research and Research Training	4R25GM102789-05	93.859	71,773	179,840
Biomedical Research and Research Training	4T32GM008602-20	93.859	—	172,480
Biomedical Research and Research Training	5F31GM111047-03 REVI	93.859	—	9,527
Biomedical Research and Research Training	5F31GM112418-03	93.859	—	32,324
Biomedical Research and Research Training	5F31GM113397-03	93.859	—	30,760
Biomedical Research and Research Training	5F31GM113631-02	93.859	—	31,038
Biomedical Research and Research Training	5F31GM115178-02 REVI	93.859	—	31,326
Biomedical Research and Research Training	5F31GM116556-02 REVI	93.859	—	33,212
Biomedical Research and Research Training	5F32GM112517-02	93.859	—	4,727
Biomedical Research and Research Training	5F32GM113570-03	93.859	—	52,200
Biomedical Research and Research Training	5K12GM000690-18	93.859	138,088	1,515,659
Biomedical Research and Research Training	5R01GM047310-19 REV	93.859	—	25,289
Biomedical Research and Research Training	5R01GM049245-23REVIS	93.859	—	242,161
Biomedical Research and Research Training	5R01GM054787-22	93.859	—	58,088
Biomedical Research and Research Training	5R01GM054787-24	93.859	25,035	482,568
Biomedical Research and Research Training	5R01GM072808-13	93.859	—	287,557
Biomedical Research and Research Training	5R01GM083889-18	93.859	—	80,245
Biomedical Research and Research Training	5R01GM084070-09	93.859	—	427,136
Biomedical Research and Research Training	5R01GM090158-07REVIS	93.859	62,149	355,924
Biomedical Research and Research Training	5R01GM093278-07 REVI	93.859	98,032	394,799
Biomedical Research and Research Training	5R01GM093294-04	93.859	—	2,208
Biomedical Research and Research Training	5R01GM099142-07	93.859	—	488,265
Biomedical Research and Research Training	5R01GM104198-05	93.859	—	72
Biomedical Research and Research Training	5R01GM104198-07	93.859	—	390,711
Biomedical Research and Research Training	5R01GM104323-03	93.859	—	(312)
Biomedical Research and Research Training	5R01GM104540-05 REVI	93.859	38,010	300,212
Biomedical Research and Research Training	5R01GM105813-03	93.859	—	156,245
Biomedical Research and Research Training	5R01GM106565-04 REVI	93.859	—	256,216
Biomedical Research and Research Training	5R01GM108838-03 REVI	93.859	—	251,648
Biomedical Research and Research Training	5R01GM109501-05	93.859	184,249	338,487
Biomedical Research and Research Training	5R01GM109779-04 REVI	93.859	—	281,669
Biomedical Research and Research Training	5R01GM110000-04REVIS	93.859	—	197,021
Biomedical Research and Research Training	5R01GM110663-04	93.859	—	480,696
Biomedical Research and Research Training	5R01GM111027-19	93.859	2,036	70,552
Biomedical Research and Research Training	5R01GM113228-03 REVI	93.859	—	364,353
Biomedical Research and Research Training	5R01GM114306-03	93.859	53,518	204,458
Biomedical Research and Research Training	5R01GM114561-02 REVI	93.859	155,048	434,856
Biomedical Research and Research Training	5R01GM114612-03 REVI	93.859	29,879	174,342
Biomedical Research and Research Training	5R01GM116065-03	93.859	36,218	216,946
Biomedical Research and Research Training	5R01GM120271-02	93.859	—	300,697
Biomedical Research and Research Training	5R01GM122083-02	93.859	157,478	244,533
Biomedical Research and Research Training	5R25GM099644-03REVIS	93.859	—	329,500
Biomedical Research and Research Training	5T32GM008367-28	93.859	—	236,100
Biomedical Research and Research Training	5T32GM008490-25REVIS	93.859	—	307,593
Biomedical Research and Research Training	5T32GM095442-07	93.859	—	288,984
Biomedical Research and Research Training	7R01GM116991-02	93.859	—	3,844
Biomedical Research and Research Training	1R01GM124472-01	93.859	—	51,710
Biomedical Research and Research Training	1R35GM122591-01	93.859	—	125,257
Biomedical Research and Research Training	2R01GM035463-30	93.859	—	133,613
Biomedical Research and Research Training	5R01GM053640-21	93.859	—	387,861
Biomedical Research and Research Training	5R01GM069971-12 REVI	93.859	—	380,083
Biomedical Research and Research Training	5R01GM084070-05 REV	93.859	—	(119)
Biomedical Research and Research Training	5R01GM091875-17	93.859	—	320,576
Biomedical Research and Research Training	5R01GM097331-04 REV	93.859	—	86,772
Biomedical Research and Research Training	5R01GM100151-04 REV	93.859	—	24
Biomedical Research and Research Training	5R01GM108480-03	93.859	—	507
Biomedical Research and Research Training	5R01GM109501-03	93.859	4,202	4,204
Biomedical Research and Research Training	5T32GM095442-05	93.859	—	293
Biomedical Research and Research Training	7R35GM119426-02	93.859	—	238,211
Pass-through Albert Einstein College of Medicine	311119/AMND 2	93.859	—	31,351
Pass-through Albert Einstein College of Medicine	PO0605243	93.859	—	597,736
Pass-through Duke University	13-NIH-1020	93.859	—	105,629
Pass-through Fred Hutchinson Cancer Research Center	215918	93.859	—	128,689
Pass-through Fred Hutchinson Cancer Research Center	905064	93.859	—	19,748
Pass-through Georgia Institute of Technology	RA927-G2	93.859	—	(1,595)
Pass-through Ohio State University	6Q044032-001	93.859	—	29,623
Pass-through University of California San Diego	83805795	93.859	—	6,630
Pass-through University of Georgia	RR166-500/S000883	93.859	—	9,635
Pass-through University of Georgia	RR166-500/S001097	93.859	—	24,371
Pass-through University of Georgia	RR166-501/4708616	93.859	—	297,012
Pass-through University of Georgia	RR166-501/4708617	93.859	—	170,805
Pass-through University of Georgia	RR549-343/4785766	93.859	—	24,765

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through University of Minnesota	P003397401/AMND4	93.859	\$ —	94,478
Pass-through University of Texas Medical Branch	16-052 PO#UOSPC-1418	93.859	—	97,021
Total CFDA No. 93.859			1,228,502	17,710,182
Child Health and Human Development Extramural Research	1R01HD092033-01	93.865	—	109,778
Child Health and Human Development Extramural Research	1R21HD087760-01A1	93.865	—	46,620
Child Health and Human Development Extramural Research	1R21HD089160-01A1	93.865	—	11,098
Child Health and Human Development Extramural Research	3K12HD072245-05S1	93.865	—	290,112
Child Health and Human Development Extramural Research	3K12HD085850-03S1	93.865	—	277,495
Child Health and Human Development Extramural Research	3R21HD092785-01S1	93.865	—	51
Child Health and Human Development Extramural Research	4R01HD072659-05	93.865	182,333	264,767
Child Health and Human Development Extramural Research	5F31HD080404-02	93.865	—	12,123
Child Health and Human Development Extramural Research	5F31HD086964-02	93.865	—	28,989
Child Health and Human Development Extramural Research	5F31HD088043-02REVIS	93.865	—	30,214
Child Health and Human Development Extramural Research	5K01HD074726-05	93.865	—	121,658
Child Health and Human Development Extramural Research	5K01HD079584-04	93.865	—	113,139
Child Health and Human Development Extramural Research	5K01HD080722-03	93.865	—	119,088
Child Health and Human Development Extramural Research	5K23HD078153-04	93.865	—	140,262
Child Health and Human Development Extramural Research	5K23HD080837-03	93.865	—	133,211
Child Health and Human Development Extramural Research	5K25HD086276-02	93.865	—	110,853
Child Health and Human Development Extramural Research	5R01HD071982-05	93.865	17,679	400,042
Child Health and Human Development Extramural Research	5R01HD074486-05	93.865	—	359,834
Child Health and Human Development Extramural Research	5R01HD077623-05	93.865	—	631,882
Child Health and Human Development Extramural Research	5R01HD081274-04	93.865	108,211	395,345
Child Health and Human Development Extramural Research	5R01HD082373-03REVIS	93.865	—	232,150
Child Health and Human Development Extramural Research	5R01HD085877-03 REVI	93.865	44,498	376,330
Child Health and Human Development Extramural Research	5R01HD090642-02	93.865	73,716	222,250
Child Health and Human Development Extramural Research	5R03HD074724-02	93.865	—	29
Child Health and Human Development Extramural Research	5R03HD081438-02	93.865	11,472	78,533
Child Health and Human Development Extramural Research	5R03HD083727-02 REVI	93.865	—	7,437
Child Health and Human Development Extramural Research	5R21HD075612-02 REV	93.865	—	66,516
Child Health and Human Development Extramural Research	5R21HD078077-02	93.865	—	2,056
Child Health and Human Development Extramural Research	5R21HD078121-02	93.865	—	151,526
Child Health and Human Development Extramural Research	5R21HD078778-02	93.865	1,488	63,221
Child Health and Human Development Extramural Research	5R21HD079969-02 REVI	93.865	—	237,160
Child Health and Human Development Extramural Research	5R21HD080107-02	93.865	—	75,977
Child Health and Human Development Extramural Research	5R21HD080429-02	93.865	—	59,209
Child Health and Human Development Extramural Research	5R21HD084114-02	93.865	61,290	137,650
Child Health and Human Development Extramural Research	5R21HD086491-02	93.865	47,051	77,096
Child Health and Human Development Extramural Research	5R21HD089056-02	93.865	2,800	149,085
Child Health and Human Development Extramural Research	5R25HD079102-04 REVI	93.865	—	86,256
Child Health and Human Development Extramural Research	5T32HD071845-05 REVI	93.865	—	233,304
Child Health and Human Development Extramural Research	5U01HD066439-04	93.865	—	(145)
Child Health and Human Development Extramural Research	5UG1HD027851-27	93.865	—	246,815
Child Health and Human Development Extramural Research	5U54NS091859-03	93.865	—	286,544
Child Health and Human Development Extramural Research	1R01HD090925-01A1	93.865	—	27,517
Child Health and Human Development Extramural Research	3P01HD032571-19S1	93.865	—	(271)
Child Health and Human Development Extramural Research	4P01HD032571-20	93.865	452,614	784,746
Child Health and Human Development Extramural Research	5K12HD072245-04REVIS	93.865	—	(395)
Child Health and Human Development Extramural Research	5R01HD075784-04 REVI	93.865	187,837	454,052
Child Health and Human Development Extramural Research	5R01HD077623-03	93.865	—	7,503
Child Health and Human Development Extramural Research	5R03HD082436-02	93.865	40,480	52,008
Child Health and Human Development Extramural Research	5R03HD083729-02 REVI	93.865	22,701	69,667
Child Health and Human Development Extramural Research	5R21HD086762-02 REVI	93.865	65,443	191,610
Child Health and Human Development Extramural Research	5T32HD052460-10	93.865	—	35,145
Pass-through Georgia State University	R01HD079327	93.865	—	142,463
Pass-through Georgia State University	SP00011537-1 AMD 4	93.865	—	102,658
Pass-through Mclean Hospital	401286	93.865	—	34,849
Pass-through New York University	14-A0-00-002901-01	93.865	—	21,303
Pass-through Seattle Children's Research Institute	11536SUB	93.865	—	47,176
Pass-through Tulane University	TUL-HSC-554721-16/17	93.865	—	16,384
Pass-through Univ of Massachusetts Medical School	W000441545-0SP201700	93.865	—	412,487
Pass-through University of California, Santa Barbara	KK1601 Amend 1	93.865	—	25,420
Pass-through University of California Davis	201224693-01/AMND4	93.865	—	92,727
Pass-through University of California San Francisco	9547sc	93.865	—	114,512
Pass-through University of Cape Town	1RMA25268	93.865	—	49,980
Pass-through University of Georgia	RR376-416/S000739	93.865	—	7,757
Pass-through University of Michigan	3003518660	93.865	—	142,679
Pass-through University of Michigan	PO# 3003539487	93.865	—	8,524
Pass-through University of Nevada	UNR-17-19	93.865	—	35,988
Pass-through University of North Carolina Chapel Hill	5105608	93.865	—	387,747
Pass-through University of North Carolina Chapel Hill	5107006	93.865	—	38,276
Pass-through University of North Carolina Chapel Hill	5107706	93.865	—	9,780
Pass-through University of Pennsylvania	569643/ PO #3770643	93.865	—	5,829
Pass-through Washington University	WU-13-134-MOD 5	93.865	60,935	119,755
Pass-through Washington University	WU-16-106	93.865	—	6,873
Pass-through Washington University	WU-17-140	93.865	—	129,569
Total CFDA No. 93.865			1,380,548	9,944,792
Aging Research	1R21AG054903-01A1	93.866	—	4,410
Aging Research	5R21AG043885-02	93.866	—	255
Aging Research	1R01AG055634-01 REVI	93.866	—	49,562
Aging Research	1R03AG055810-01	93.866	—	17,910
Aging Research	1R03AG056448-01	93.866	—	9,259
Aging Research	1R21AG054206-01A1	93.866	—	77,342
Aging Research	1R21AG055995-01	93.866	—	14,235
Aging Research	1RF1AG047667-01	93.866	—	256,823
Aging Research	1RF1AG051538-01A1	93.866	—	782,423
Aging Research	3P50AG025688-13S1	93.866	63,065	1,807,682
Aging Research	3R01AG023236-08S1	93.866	—	(756)
Aging Research	3RF1AG051514-01S1	93.866	10,473	815,746
Aging Research	3RF1AG051633-01S2	93.866	185,231	1,476,144
Aging Research	3U01AG046161-04S1 RE	93.866	511,987	1,888,234
Aging Research	4R01AG019206-15	93.866	—	258,210
Aging Research	5F31AG051310-03	93.866	—	32,453
Aging Research	5K01AG042498-06	93.866	—	76,989
Aging Research	5K23AG042856-05	93.866	—	191,558
Aging Research	5R01AG023695-10	93.866	—	196,953
Aging Research	5R01AG038746-05rev	93.866	44,673	39,240
Aging Research	5R01AG040013-05	93.866	—	219,909
Aging Research	5R01AG042127-06 REVI	93.866	—	810,067
Aging Research	5R01AG047408-03	93.866	40,464	327,593
Aging Research	5R01AG049752-02 REV	93.866	—	556,609

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Aging Research	5R01AG054046-02	93.866	\$ —	482,447
Aging Research	5R01AG054079-02S1	93.866	12,456	469,015
Aging Research	5R03AG050930-02 REVI	93.866	—	86,781
Aging Research	5R13AG047064-03	93.866	—	14,927
Aging Research	5R21AG050793-03 Revi	93.866	—	169,205
Aging Research	5U01AG052460-02	93.866	—	546,212
Pass-through Baylor College of Medicine	7000000211	93.866	—	120,657
Pass-through Boston University	4500002111	93.866	—	119,200
Pass-through Georgia State University	SP00011514-01	93.866	—	56,788
Pass-through Georgia State University	SP00012468-01	93.866	—	98,327
Pass-through Johns Hopkins University	2002710289 Am 1	93.866	—	37,121
Pass-through Medical University of South Carolina	MUSC14-075	93.866	—	35,750
Pass-through Northwestern University	60041739EU	93.866	—	28,484
Pass-through Northwestern University	60043310 EU	93.866	—	15,229
Pass-through Rush University Medical Center	09031002-SUB01	93.866	—	37,443
Pass-through University of Alabama Birmingham	000410331-003	93.866	—	45,778
Pass-through University of Minnesota	N005175201	93.866	—	29,326
Pass-through University of Pennsylvania	563249	93.866	—	(2,928)
Pass-through University of Southern California	79635055	93.866	—	24,621
Pass-through University of Washington	UWSC7721	93.866	—	26,271
Pass-through Wake Forest University	WFUHS 110918 Neigh	93.866	—	5,905
Total CFDA No. 93.866			<u>868,349</u>	<u>12,355,409</u>
Vision Research	1R01EY027711-01	93.867	66,028	142,270
Vision Research	2R01EY004964-30A1	93.867	—	(1,910)
Vision Research	4R01EY021592-04	93.867	(71)	501,966
Vision Research	5F30EY025154-03 REVI	93.867	—	32,399
Vision Research	5K23EY021760-05 REVI	93.867	—	835
Vision Research	5P30EY006360-32	93.867	—	791,732
Vision Research	5R01EY016400-10	93.867	—	94,924
Vision Research	5R01EY016470-09	93.867	35,588	31,676
Vision Research	5R01EY017841-08	93.867	34,146	341,655
Vision Research	5R01EY025978-03	93.867	—	143,531
Vision Research	5T32EY007092-31 REVI	93.867	50,616	188,572
Vision Research	5UG1EY013272-14	93.867	—	20,641
Vision Research	5UG1EY013287-14	93.867	—	193,511
Vision Research	5UG1EY025553-02	93.867	91,334	225,041
Vision Research	5P30EY006360-30	93.867	—	(353)
Vision Research	5R01EY000484-34	93.867	—	501,295
Vision Research	5R01EY014026-10	93.867	14,269	88,422
Vision Research	5R01EY014852-13	93.867	—	526,013
Vision Research	5T32EY007092-28Revis	93.867	—	(453)
Pass-through Cambium Medical Technologies	1R41EY026353-01	93.867	—	19,240
Pass-through Georgia Institute of Technology	RG181-G1	93.867	—	111,587
Pass-through Jaeb Center for Health Research	Protocol V	93.867	—	749
Pass-through Johns Hopkins University	2002484216	93.867	—	29,003
Pass-through Johns Hopkins University	2003162709	93.867	—	31,631
Pass-through Massachusetts Eye and Ear	PO# 142925	93.867	—	58,595
Pass-through Morehouse School of Medicine	1R01EY022216-12	93.867	—	8,066
Pass-through Morehouse School of Medicine	SA1701AMND 2	93.867	—	77,815
Pass-through New England College of Optometry	3708-01-01-16EU	93.867	—	44,048
Pass-through Pennsylvania State University	EMJUEY023533	93.867	—	39
Pass-through University of Colorado	FY14.558.003_AMD4	93.867	—	62,946
Pass-through University of Florida	UFDSP00010865	93.867	—	15,595
Pass-through University of Pennsylvania	560624 PO# 3387224	93.867	40,302	88,436
Pass-through University of Texas Medical Branch	12-090AMD2	93.867	—	10,824
Pass-through Vanderbilt University	VUMC 41809	93.867	—	74,078
Pass-through Vanderbilt University Medical Center	VUMC 41809	93.867	—	69,209
Pass-through Washington University	WU -116 -110- MOD -1	93.867	—	45,166
Total CFDA No. 93.867			<u>332,212</u>	<u>4,568,794</u>
Medical Library Assistance	5R01LM012372-02	93.879	—	236,155
Pass-through State University Of New York Stony Brook	67542-116467-2	93.879	—	(453)
Total CFDA No. 93.879			<u>—</u>	<u>235,702</u>
Grants for Training in Primary Care Medicine and Dentistry	5D55HP232050500	93.884	—	44,371
Grants for Training in Primary Care Medicine and Dentistry	6 TOBHP28571-03-01	93.884	—	246,417
Pass-through Grady Memorial Hospital	S201622	93.884	—	250,000
Total CFDA No. 93.884			<u>—</u>	<u>540,788</u>
HIV Emergency Relief Project Grants:				
Pass-through Fulton County	VS0000014448/PO 1181	93.914	—	487,751
Pass-through Fulton County	VS14448/PO11817S1085	93.914	—	238,459
Total CFDA No. 93.914			<u>—</u>	<u>726,210</u>
Special Projects of National Significance	U90HA07632	93.928	—	10,171
Total CFDA No. 93.928			<u>—</u>	<u>10,171</u>
HIV Demonstration, Research, Public and Professional Education Projects	1U01PS005112-01 REVI	93.941	8,916	255,036
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS003322-04 REVI	93.941	3,792	43,619
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS003322-04REV	93.941	—	28,717
HIV Demonstration, Research, Public and Professional Education Projects	5U01PS004977-03	93.941	237,380	515,346
Total CFDA No. 93.941			<u>250,088</u>	<u>842,718</u>
Block Grants for Prevention and Treatment of Substance Abuse:				
Pass-through Georgia Department of Behavioral Health	MSACD 44100-906-0000	93.959	—	5,858
Total CFDA No. 93.959			<u>—</u>	<u>5,858</u>
Geriatric Education Centers	6 UB4HP19215-05-02	93.969	—	(54)
Total CFDA No. 93.969			<u>—</u>	<u>(54)</u>
Family Planning Service Delivery Improvement Research Grants	5 FPRPA006056-03-00	93.974	—	217
Total CFDA No. 93.974			<u>—</u>	<u>217</u>
International Research and Research Training	4D43TW009127-04	93.989	23,197	224,790
International Research and Research Training	4D43TW009135-05	93.989	28,716	117,343
International Research and Research Training	4K01TW000964-04	93.989	27,000	162,928
International Research and Research Training	5D43TW007124-13	93.989	—	173,100
International Research and Research Training	5K01TW000964-03	93.989	5,613	5,426
International Research and Research Training	5U2RTW010114-03 REVI	93.989	166,495	255,603

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Addis Ababa University	1D43TW010143-01	93.989	\$ —	115,948
Pass-through Aga Khan University	2D43TW007585	93.989	—	(3,848)
Pass-through Vanderbilt University	VUMC 64584	93.989	—	14,911
Pass-through Vanderbilt University	VUMC 58633	93.989	—	31,727
Pass-through Vanderbilt University	VUMC 58634	93.989	—	22,472
Pass-through Vanderbilt University	VUMC 58635	93.989	—	32,599
Pass-through Vanderbilt University	VUMC 58636	93.989	—	47,545
Pass-through Vanderbilt University	VUMC 58638	93.989	—	6,564
Pass-through Vanderbilt University	VUMC 61636	93.989	—	11,547
Total CFDA No. 93.989			251,021	1,218,656
Contract	U3REP170552-01-00	93.RD	63,459	257,398
Contract	200-2011-41278	93.RD	—	508,383
Contract	200-2012-51279	93.RD	—	43,263
Contract	200-2016-91940	93.RD	—	53,037
Contract	200-2016-M_8579	93.RD	—	17,248
Contract	200-2017-92309	93.RD	—	76,136
Contract	HHSN2610006 Mod 5	93.RD	22,875	2,314,838
Contract	HHSN261201300015/HH	93.RD	—	48,393
Contract	HHSN272200800005C	93.RD	—	990,078
Contract	HHSN272201200031C	93.RD	774,318	4,957,498
Contract	HHSN272201300006C	93.RD	—	2,511,980
Contract	HHSN2722013000018	93.RD	—	407,599
Contract	HHSN2722013000181	93.RD	—	9,395
Contract	HHSN2722013000181/HH	93.RD	—	389,300
Contract	HHSN2722013000181	93.RD	—	3,069,773
Contract	HHSN27220130001844	93.RD	—	1,042,211
Contract	HHSN272201400004C	93.RD	1,198,226	4,104,746
Contract	HHSN272201500008C	93.RD	370,529	1,141,239
Contract	HHSN2752014000001I	93.RD	—	9,855
Contract	HHSN275201400017C	93.RD	—	290,230
Contract	HHSN2752015000001I	93.RD	—	391,115
Contract	HHSN261201500402P	93.RD	—	7,184
Contract	VA268-16-C-0032	93.RD	—	21,343
Pass-through Assoc of Schools & Pgms of Public Health	S5033	93.RD	1,622,108	2,054,647
Pass-through Brigham and Womens Hospital	114663	93.RD	—	11,905
Pass-through Childrens Healthcare of Atlanta	657004-0217-02	93.RD	—	14,933
Pass-through Childrens Healthcare of Atlanta	657004-1120-01	93.RD	—	1,974
Pass-through Childrens Healthcare of Atlanta	657004-1120-02	93.RD	—	3,749
Pass-through Childrens Healthcare of Atlanta	U01CA180886	93.RD	—	44,998
Pass-through Childrens Hospital of Los Angeles	Study 2014-01	93.RD	1,400	1,789
Pass-through Childrens Mercy Hospital	13-0027	93.RD	6,774	9,744
Pass-through Dana Farber Cancer Institute	1280901	93.RD	—	8,997
Pass-through Duke University	Pro 00045657	93.RD	—	110
Pass-through Dystonia Medical Research Foundation	1R21NS096455	93.RD	—	4,211
Pass-through Georgia Institute of Technology	RH-269G1	93.RD	—	3,190
Pass-through Georgia Institute of Technology	RH466-S1	93.RD	—	21,517
Pass-through H Lee Moffitt Cancer Center and Res Inst	10-14398-99-01	93.RD	—	(145)
Pass-through H Lee Moffitt Cancer Center and Res Inst	10143989901EMORY1543	93.RD	—	(17)
Pass-through H Lee Moffitt Cancer Center and Res Inst	10-16385-99-01-01	93.RD	—	(1,090)
Pass-through H Lee Moffitt Cancer Center and Res Inst	HHSN261200622008C	93.RD	—	33
Pass-through Harvard Pilgrim Health Care Institute	HHSF23230091006/HHF	93.RD	—	11,625
Pass-through Human Sciences Research Council	GH000258	93.RD	—	70,532
Pass-through Intl Aids Vaccine Initiative	06-646-9933	93.RD	—	651,723
Pass-through Leidos Biomedical Research	14X138	93.RD	20,577	181,813
Pass-through Leidos Biomedical Research	29XS132	93.RD	—	178,251
Pass-through Massachusetts General Hospital	Subcontract # 225532	93.RD	—	18,878
Pass-through Minneapolis Medical Research Foundation	HHSN250201500009C	93.RD	—	17,726
Pass-through Natl Marrow Donor Program	BMT CTN 0801	93.RD	—	1,404
Pass-through New England Research Institutes	HHSN268201200001I	93.RD	—	10,074
Pass-through Norc At The University of Chicago	HHSP233201500023I	93.RD	—	47,405
Pass-through Ocean Nanotech	Quantum dot FRET imm	93.RD	—	75,758
Pass-through Pennsylvania State University	EMUJ 109086	93.RD	1,075	3,335
Pass-through Research Support Services Inc	200-2013-5734_1 Task	93.RD	—	115,981
Pass-through Research Support Services Inc	200-2013-57341 Order	93.RD	—	5,868
Pass-through Research Triangle Institute	HD036790	93.RD	—	327
Pass-through Scripps Research Institute	5-52756	93.RD	—	469,805
Pass-through Scripps Research Institute	5-52903	93.RD	—	1,283,572
Pass-through State University of New York Stony Brook	1137965-2-77417	93.RD	—	7,327
Pass-through Univ of Arkansas for Medical Services	5109- POG170120309	93.RD	—	44,561
Pass-through Univ of Arkansas for Medical Services	51095 POG160101318	93.RD	—	808
Pass-through Univ of Arkansas for Medical Services	51097 POG170120310	93.RD	—	24,737
Pass-through University of Alabama Birmingham	41610	93.RD	—	2,637
Pass-through University of Alabama Birmingham	000406257-013/AMD#3	93.RD	—	(8,755)
Pass-through University of Alabama Birmingham	000406291-010/AMEND	93.RD	—	63,225
Pass-through University of Alabama Birmingham	000406291-010/AMEND	93.RD	—	3,032
Pass-through University of Alabama Birmingham	000500918-T013-005	93.RD	—	7,112
Pass-through University of Miami	666578	93.RD	—	5,134
Pass-through University of Minnesota	A005062101	93.RD	—	110,191
Pass-through University of Minnesota	P005498902	93.RD	—	7,973
Pass-through University of Minnesota	P005639702	93.RD	—	23,344
Pass-through University of Pittsburgh	0024031-1	93.RD	—	222,005
Pass-through University of South Florida	TrialNet Clinic Agmt	93.RD	54	10,868
Pass-through University of Southern California	75860854	93.RD	—	21,088
Pass-through University of Texas Southwestern	GMO 120703/AMEND #7	93.RD	22,940	40,441
Pass-through Wake Forest University	WFUHS330220	93.RD	—	69,153
Pass-through Weill Cornell Medical College	15060932	93.RD	57,445	196,970
Total CFDA No. 93.RD			4,161,780	28,838,515
U.S. Department of Health and Human Services Total			50,096,784	359,594,850
U.S. Agency for International Development: USAID Foreign Assistance for Programs Overseas	AID-GH-F-15-00008	98.001	63,217	172,331
Pass-through Intl Aids Vaccine Initiative	06-646-9933	98.001	—	1,032,444
Pass-through Intl Aids Vaccine Initiative	Annual SOW 2166	98.001	—	(28,659)
Pass-through Intl Aids Vaccine Initiative	Annual SOW 2175	98.001	—	(54)
Pass-through University of California San Diego	45032328	98.001	—	11,338
Total CFDA No. 98.001			63,217	1,187,400

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Cooperative Development Program (CDP):				
Pass-through Georgia Institute of Technology	RF409-G1	98.002	\$ —	19,577
Total CFDA No. 98.002			—	19,577
Contract:				
Pass-through Queensland Institute of Medical Research	AID-OAA-F-16-00094	98.RD	—	2,128
Total CFDA No. 98.002			—	2,128
U.S. Agency for International Development Total			63,217	1,209,105
Total Research and Development Cluster			58,749,691	398,320,753
Student Financial Assistance Cluster (notes 3 and 4):				
U.S. Department of Education:				
Federal Work Study Program		84.033	—	2,040,269
Federal Supplemental Education Opportunity Grant Program		84.007	—	1,210,195
Federal Pell Grant Program		84.063	—	6,710,658
Federal Direct Stafford Loan Program		84.268	—	79,082,447
Federal Direct PLUS Loan Program		84.268	—	45,405,723
Federal Perkins Loan Program		84.038	—	13,482,545
Total U.S. Department of Education			—	147,931,837
Total Student Financial Assistance Cluster			—	147,931,837
U.S. Department of Agriculture:				
Special Supplemental Nutrition Program for Women, Infants, and Children:				
Pass-through Georgia Dept of Public Health	40500-041-16161820	10.557	—	22,267
Pass-through Georgia Dept of Public Health	40500-041-17161820	10.557	—	60,865
Total CFDA No. 10.557			—	83,132
U.S. Department of Agriculture Total			—	83,132
U.S. Department of Defense:				
Contract:				
Pass-through Cherokee Nation Technology Solutions	0115700-0010	12.CTR	—	55,000
Total CFDA No. 12.CTR			—	55,000
U.S. Department of Defense Total			—	55,000
U.S. Department of State:				
Academic Exchange Programs – Humphrey Fellowship Program:				
Pass-through Institute of International Education	3067_EU_10.1.15	19.010	—	27,017
Total CFDA No. 19.010			—	27,017
U.S. Department of State Total			—	27,017
National Endowment for The Arts and Humanities:				
Promotion of the Humanities_Professional Development	FV-230920-15	45.163	—	1,271
Total CFDA No. 45.163			—	1,271
Promotion of the Humanities_ Office of Digital Humanities	HK-230986-15	45.169	—	153,896
Total CFDA No. 45.169			—	153,896
National Endowment for The Arts and Humanities Total			—	155,167
U.S. Department of Health and Human Services:				
Global AIDS	5 NU2GGH001443-04-00	93.067	618,912	1,397,933
Global AIDS	5NU2GGH001815-03-00	93.067	323,928	644,677
Total CFDA No. 93.067			942,840	2,042,610
Birth Defects and Developmental Disabilities – Prevention and Surveillance	5NU5DD004932-03-00	93.073	—	458,295
Total CFDA No. 93.073			—	458,295
Prevention of Disease, Disability, and Death by Infectious Diseases	5 NU38PS004646-04-00	93.084	400,816	1,303,782
Total CFDA No. 93.084			400,816	1,303,782
Maternal and Child Health Federal Consolidated Programs	4 H46MC24090-05-02	93.110	165,315	445,040
Maternal and Child Health Federal Consolidated Programs	6 H46MC240900301	93.110	(43,298)	(459,918)
Maternal and Child Health Federal Consolidated Programs	UH7MC30772-01-00	93.110	—	191,617
Total CFDA No. 93.110			122,017	176,739
Project Grants and Cooperative Agreements for Tuberculosis Control Programs				
Pass-through Georgia Dept of Public Health	40500-046-15151505	93.116	—	22,334
Pass-through Georgia Dept of Public Health	40500-046-17151505	93.116	—	23,931
Total CFDA No. 93.116			—	46,265
Community Programs to Improve Minority Health Grant Program:				
Pass-through Amer College of Rheumatology	1CPIMP141065-01-00	93.137	—	25,000
Total CFDA No. 93.137			—	25,000
Health Program for Toxic Substances and Disease Registry:				
Pass-through Amer Academy of Pediatrics	771102-EUSM/AMND3	93.161	56,547	200,165
Total CFDA No. 93.161			56,547	200,165
Disabilities Prevention:				
Pass-through Georgia State University	SP00011716-01 AMEN 2	93.184	—	128,859
Total CFDA No. 93.184			—	128,859
Substance Abuse and Mental Health Services_Projects of Regional and National Significance:				
Pass-through Childrens Healthcare of Atlanta	1U79SM061214-01	93.243	—	3,676
Pass-through Highland Rivers Community Service Board	1H79SM061070-01	93.243	—	4,729
Total CFDA No. 93.243			—	8,405
Rapid Expansion of Antiretroviral Therapy Programs for HIV-Infected Persons in Selected Countries in:				
Africa and the Caribbean Under the President's Emergency Plan for AIDS Relief:				
Pass-through Columbia University	5U92HA12772-08-00	93.266	—	2,777
Total CFDA No. 93.266			—	2,777
Adult Viral Hepatitis Prevention and Control	1U51PS003909-01S1	93.270	—	79,284
Total CFDA No. 93.270			—	79,284
Centers for Disease Control and Prevention_Investigations and Technical Assistance	200-2016-91959	93.283	—	127,860
Centers for Disease Control and Prevention_Investigations and Technical Assistance	5U01DP005119-04 REV1	93.283	—	11,538
Pass-through Amer Thrombosis and Hemostasis Netwo	ATHN2015-ATHN1	93.283	—	85
Pass-through Assoc of Schools & Pgms of Public Health	U36 OE00002	93.283	—	687,853

EMORY UNIVERSITY
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2017

Program title/federal grantor/pass-through entity	Award number	Federal CFDA number	Passed through to subrecipients	Federal expenditures
Pass-through Association of American Medical Colleges	GT-32001-02-2	93.283	\$ 6,117	8,989
Pass-through Atlanta Research and Education Fdtn	AREF MOU M16005	93.283	23,348	58,389
Pass-through Atlanta Research and Education Fdtn	M15007	93.283	—	(327)
Total CFDA No. 93.283			<u>29,465</u>	<u>894,387</u>
Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems,	NU19GH001583-03-01	93.318	—	444,459
Total CFDA No. 93.318			<u>—</u>	<u>444,459</u>
NON-ACA/PPHF—Building Capacity of the Public Health System to Improve Population Health through	63-10723 Req. No. 652	93.424	—	17,479
Pass-through Assoc State Territorial Health Official			—	17,479
Total CFDA No. 93.424			<u>—</u>	<u>17,479</u>
Children's Justice Grants to States:				
Pass-through Georgia Department of Human Services	42700-040-0000029413	93.643	—	1,430
Pass-through Georgia Department of Human Services	42700-040-0000056774	93.643	—	98,982
Total CFDA No. 93.643			<u>—</u>	<u>100,412</u>
Social Services Block Grant:				
Pass-through Georgia DHS/Division of Aging Services	42700-373-0000047896	93.667	—	5,259
Total CFDA No. 93.667			<u>—</u>	<u>5,259</u>
Prevention Public Health Fund: Viral Hepatitis Prevention	1U51PS003909-01REV	93.736	—	(79,284)
Total CFDA No. 93.736			<u>—</u>	<u>(79,284)</u>
Diabetes Prevention – State and Local Public Health Actions to Prevent Obesity, Diabetes, and Heart				
Pass-through Maryland Department of Health and Mental	M00B7400233	93.757	—	24,183
Pass-through South Carolina Dept of Hlth and Env Ctr	N. CY-5-626	93.757	—	86,443
Pass-through South Dakota Department of Health	no 17SC090715	93.757	—	90,000
Total CFDA No. 93.757			<u>—</u>	<u>200,626</u>
Medical Assistance Program				
Pass-through Georgia Department of Behavioral Health	44100-906-0000062709	93.778	—	17,905
Pass-through Georgia Department of Behavioral Health	44100-907-0000070367	93.778	—	11,322
Pass-through Georgia Department of Behavioral Health	co44100-907-0000087	93.778	—	236,367
Total CFDA No. 93.778			<u>—</u>	<u>265,594</u>
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities				
Pass-through Georgia Dept of Public Health	40500-033-161809	93.817	409,344	1,430,699
Total CFDA No. 93.817			<u>409,344</u>	<u>1,430,699</u>
Grants to Provide Outpatient Early Intervention Services with Respect to HIV Disease	5H76HA07848--11--01	93.918	—	636,455
Total CFDA No. 93.918			<u>—</u>	<u>636,455</u>
Assistance Programs for Chronic Disease Prevention and Control				
Pass-through Tennessee Department of Health	34352-06215	93.945	—	8,431
Total CFDA No. 93.945			<u>—</u>	<u>8,431</u>
Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	5 U01 DP003894-05	93.946	142,590	640,955
Total CFDA No. 93.946			<u>142,590</u>	<u>640,955</u>
Block Grants for Prevention and Treatment of Substance Abuse				
Pass-through Georgia Dept of Behavioral Health	44100-906-0000073706	93.959	—	63,870
Pass-through Georgia Dept of Behavioral Health	44100-906-0000086519	93.959	—	454,848
Total CFDA No. 93.959			<u>—</u>	<u>518,718</u>
Preventive Health Services_Sexually Transmitted Diseases Control Grants	6NH25PS004311-04-01	93.977	—	92,358
Total CFDA No. 93.977			<u>—</u>	<u>92,358</u>
Contract	00HCUHC1-2013-54173	93.CTR	—	6,983
Contract	200-2007-19630/0004	93.CTR	—	2,453
Contract	200-2012-51332	93.CTR	—	29,706
Contract	200-2014-M-58528	93.CTR	—	(72)
Contract	200-2014-M-61117	93.CTR	—	(35)
Contract	200-2015-87862 00004	93.CTR	—	1,327,131
Contract	200-2015-M-62909	93.CTR	—	81,229
Contract	200-2016-M-91197	93.CTR	—	74,292
Contract	200-2016-M-92385	93.CTR	—	27,180
Contract	HSH258201300008C	93.CTR	—	45,339
Pass-through Amer Thrombosis and Hemostasis Netwo	NHPCC-1-01	93.CTR	—	715
Pass-through Assoc of State & Territorial Denta	ASTDD072215	93.CTR	—	7,552
Pass-through Eastern Virginia Medical School	S2050211-2	93.CTR	1,320	1,692
Pass-through Georgia Department of Community Health	2017001	93.CTR	—	252,288
Pass-through Georgia Dept of Public Health	40500-036-18161798	93.CTR	—	15,880
Pass-through Norc At The University of Chicago	7843.Emory.01	93.CTR	—	35,804
Pass-through Northwestern University	SP0035018 60041567EU	93.CTR	—	2,209
Pass-through Tennessee Department of Health	34347-61317	93.CTR	—	14,974
Total CFDA No. 93.CTR			<u>1,320</u>	<u>1,925,320</u>
U.S. Department of Health And Human Services Total			<u>2,104,939</u>	<u>11,574,049</u>
U.S. Department of Homeland Security				
Assistance to Firefighters Grant				
Pass-through Columbia University	COLUM-0000066367	97.044	—	1,412
Total CFDA No. 97.044			<u>—</u>	<u>1,412</u>
U.S. Department of Homeland Security Total			<u>—</u>	<u>1,412</u>
U.S. Agency for International Development				
Cooperative Development Program (CDP)				
Pass-through Aspen Institute	AID-00AA-A-15-0038	98.002	—	239,595
Pass-through Aspen Institute	AID-OAA-A-15-0038	98.002	—	60,000
Total CFDA No. 98.002			<u>—</u>	<u>299,595</u>
U.S. Agency for International Development Total			<u>—</u>	<u>299,595</u>
Total Expenditures of Federal Awards			<u>\$ 60,854,630</u>	<u>558,447,962</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND
EXPENDITURES OF STATE OF GEORGIA AWARDS**

EMORY UNIVERSITY

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2017

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
00004234	GEORGIA DEPT OF PUBLIC HEALTH	Contract #40500-046-17151505: Henry Blumberg 2017	\$ 19,463	23,931
00004299	GEORGIA DEPARTMENT OF HUMAN SERVICES	2017 Summer Child Advocacy Program	12,762	98,982
2017001	GEORGIA DEPARTMENT OF COMMUNITY HEALTH	Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Pro	350,924	252,288
40500-033-161809	GEORGIA DEPT OF PUBLIC HEALTH	HPP Ebola Preparedness and Response Activities	—	1,430,699
40500-036-16161891	GEORGIA DEPT OF PUBLIC HEALTH	Statistical Support for Syndromic Surveillance	33,357	21,619
40500-036-18161798	GEORGIA DEPT OF PUBLIC HEALTH	Operation of the Statewide Georgia Comprehensive Cancer Registry	1,286,269	700,084
40500-041-17161820	GEORGIA DEPT OF PUBLIC HEALTH	Medical Foods For WIC Participants With Positive Inborn Errors of Metabolic Disord	62,977	60,865
40500-041-18161820	GEORGIA DEPT OF PUBLIC HEALTH	Medical Foods For WIC Participants With Positive Inborn Errors of Metabolic Disord	148,421	22,267
40500-046-15151505	GEORGIA DEPT OF PUBLIC HEALTH	2016 – Contract #40500-046-15151505	26,961	22,334
42700-040-0000029413	GEORGIA DEPARTMENT OF HUMAN SERVICES	2015 Summer Child Advocacy Program	84,723	1,430
42700-373-0000047896	GEORGIA DHS/DIVISION OF AGING SERVICES	2016 Georgia Department of Aging Services Contract	16,666	5,259
44100-906-0000062709	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Improving Community-Based Infrastructure	364,763	17,905
44100-906-0000073706	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Maternal Substance Abuse and Child Development Project	83,323	63,870
44100-906-0000086519	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Fetal Alcohol and Drug Screening project: MASCD	416,660	454,848
44100-907-0000070367	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Emory Neuro Developmental Exposure Clinic (ENEC)	95,000	11,322
col44100-907-0000087293	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Neuro Developmental Exposure Clinic (ENEC)	285,001	236,367
MSACD 44100-906-0000	GEORGIA DEPARTMENT OF BEHAVIORAL HEALTH	Fetal Alcohol and Drug Screening Project: Maternal Substance Abuse	42,937	5,858
			\$ 3,330,207	3,429,928

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

EMORY UNIVERSITY

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2017

(1) Summary of Significant Accounting Policies

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University (the University) and is presented on the accrual basis of accounting. The Schedule presents all federal assistance received directly from the federal government and awards passed through to the University from non-federal organizations pursuant to federal grants, contracts and similar agreements. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred (i.e., on an accrual basis) by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

(2) Pass-Through Funding

The University passes through certain federal awards to non-federal subrecipient organizations. Such subrecipients are responsible for compliance with the applicable provisions of the grants and contracts governing the underlying federal awards. Federal awards passed through to subrecipients by the University during fiscal 2017 are presented by individual award on the Schedule and are summarized as follows:

<u>Federal program</u>	<u>Number</u>	<u>Amount</u>
Research and Development Cluster	Various	\$ 58,749,691
Other federally funded programs	Various	<u>2,104,939</u>
Total		\$ <u><u>60,854,630</u></u>

(3) Noncash Federal Assistance

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the Federal Direct Student Loan Program (FDSLPL) and revolving loan programs, such as the Federal Perkins Loan Program.

EMORY UNIVERSITY

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2017

The loans advanced and related expenditures are as follows for the various student loan programs:

	<u>CFDA number</u>		<u>Amount</u>
Federal Direct Student Loan Programs:			
Student loans advanced:			
Subsidized Stafford Loan Program	84.268	\$	8,858,556
Unsubsidized Stafford Loan Program	84.268		<u>70,223,891</u>
Total Direct Stafford Loan Program			79,082,447
Federal Direct PLUS Loan Program			<u>45,405,723</u>
Total Direct Student Loan Programs		\$	<u><u>124,488,170</u></u>
Federal Perkins Loan Program	84.038	\$	974,731

The Federal Perkins Loan Program is administered directly by the University and balances and transactions relating to this program are included in the University's consolidated financial statements. Federal Perkins loans outstanding at August 31, 2017 totaled \$10,871,292.

The University is responsible for the performance of certain administrative duties with respect to the FDSLPL loan program. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2017. These loans are not included in the University's consolidated financial statements.

(4) Matching

Under the Federal Supplemental Educational Opportunity Grant (FSEOG) program, the University matched \$302,549 in funds awarded to students for the year ended August 31, 2017 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study (FWS) program, the University matched \$616,535 in total compensation to students for the year ended August 31, 2017 in addition to the federal share of expenditures included in the Schedule.

(5) Indirect Cost

For the year ended August 31, 2017, the University did not elect to use the 10% de minimis Indirect Cost Rate permitted by the Uniform Guidance.

UNIFORM GUIDANCE REPORTS



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards

The Board of Trustees
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the consolidated financial statements of Emory University (the University), which comprise the consolidated statement of financial position as of August 31, 2017, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 19, 2017.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia
December 19, 2017



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Compliance for Each Major Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

The Board of Trustees
Emory University:

Report on Compliance for Each Major Federal Program

We have audited Emory University's compliance with the types of compliance requirements described in the *OMB Compliance Supplement* that could have a direct and material effect on each of Emory University's major federal programs for the year ended August 31, 2017. Emory University's major federal programs are identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

Management Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditors' Responsibility

Our responsibility is to express an opinion on compliance for each of Emory University's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and audit requirements of the Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Emory University's compliance with those requirements and performing such other procedures as we consider necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Emory University's compliance.

Opinion on Each Major Federal Program

In our opinion, Emory University complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended August 31, 2017.



Report on Internal Control Over Compliance

Management of Emory University is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Emory University's internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Emory University's internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



Report on Supplementary Schedule of Expenditures of Federal Awards Required by the Uniform Guidance and Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

We have audited the consolidated financial statements of Emory University and subsidiaries as of and for the year ended August 31, 2017, and have issued our report thereon dated December 19, 2017, which contained an unmodified opinion on those consolidated financial statements. Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying supplementary schedule of expenditures of federal awards and supplementary schedule of cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and the State of Georgia, respectively, and are not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplementary schedule of expenditures of federal awards and supplementary schedule of cash receipts and expenditures of State of Georgia awards are fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

KPMG LLP

February 20, 2018

EMORY UNIVERSITY
Schedule of Findings and Questioned Costs
Year ended August 31, 2017

(1) Summary of Auditors' Results

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the financial statements:
 - Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (c) Noncompliance which is material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major programs disclosed by the audit:
 - Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (e) The type of auditors' report issued on compliance for major programs: **Unmodified**
- (f) Any audit findings which are required to be reported under 2 CFR 200.516(a): **None reported**
- (g) Major programs: **Student Financial Assistance Cluster (various CFDA numbers);
Global AIDS (CFDA 93.067)**
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,000,000**
- (i) Auditee qualified as a low-risk auditee: **Yes**

**(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with
Government Auditing Standards**

None.

(3) Findings and Questioned Costs Relating to Federal Awards

None.